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1.1 Clinical aspects of psoriasis
Psoriasis is a chronic inflammatory skin disease characterized by remissions and 
exacerbations, with a prevalence of approximately 2% measured within the 
Caucasion population.1 Males and females are equally affected.2 One third of the 
patients develops psoriasis during childhood.3 There is a peak onset of psoriasis 
between 16-22 years of age and between 57 and 60 years of age.4
Psoriasis has a number of clinical presentations; psoriasis vulgaris, guttate psoriasis, 
erythrodermic psoriasis and various forms of pustular psoriasis.1 It is highly discussed 
whether generalized pustular psoriasis5 and palmoplantar pustulosis (PPP)6-8 are 
variants of psoriasis, or whether they should be considered as a special disease 
entity. Psoriasis vulgaris or chronic plaque psoriasis, on which we will focus in this 
thesis, is the most common variant of psoriasis, accounting for 90% of all cases.9,10 It 
is characterized by sharply demarcated, raised, erythematosquamous plaques that 
can range from a few millimetres to several centimetres in diameter (Fig. 1). Sites of 
predilection are the extensor aspects of elbows and knees, scalp, the umbilical and 
the sacral region. 
While skin manifestations are the most characteristic findings of psoriasis, important 
extracutaneous manifestations of the disease involve the nails and the joints. Nail 
psoriasis is observed in 10-81% of all cases11 and is characterized by nail matrix 
and nail bed features, such as pitting, subungual hyperkeratosis and onycholysis.12 
Psoriatic arthritis is a seronegative inflammatory arthritis with a prevalence that 
may be as high as 30%.13,14 Furthermore, psoriasis is increasingly recognized as a 
skin disease with potential systemic effects due to chronic inflammation.15-17 Patients 
are at a higher risk of developing associated conditions,18 such as cardiovascular 
disease19,20 and metabolic syndrome.21,22 
Very important, but often underreported, are remarkably diminished quality of life 
scores in patients with psoriasis.23 Patients are embarrassed about their skin. And 
like patients with other major diseases, they have reduced levels of employment and 
income.24
1.2 Histology 
Normal skin structure and function
The skin consists of a stratified cellular epidermis and an underlying dermis made of 
connective tissue. The boundary between these two compartments is established by 
a specialized layer called the basement membrane. Keratinocytes are the main cell 
type (90-95%) of the epidermis. They continuously divide and undergo programmed 
differentiation to allow for constant renewal of the skin. They are organized in 
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continuous layers (from bottom to surface): the stratum basale, the stratum 
spinosum, the stratum granulosum and the stratum corneum (Fig. 2).25 The latter 
layer consists of dead keratinocytes, called corneocytes. In addition to keratinocytes, 
the epidermis is host to melanocytes and immune cells such as Langerhans cells and 
T lymphocytes.
The dermis is composed of structural components, like collagen and elastic fibers, 
that provide strength and elasticity. Furthermore, it gives rise to hair follicles, sweat 
glands, sebaceous glands, nerve fibers and blood vessels. Many immune cells, such 
as dendritic cells (DCs), αß T cells, natural killer (NK) cells, mast cells, macrophages 
and γδ T cells, reside within the dermis. 
Psoriasis
Psoriasis is characterized by epidermal as well as dermal morphological changes. 
Hyperproliferation of the epidermis together with premature maturation of 
keratinocytes results in incomplete cornification with retention of nuclei in the 
stratum corneum. Histologically this can be seen as thickening of the epidermis 
(acanthosis) with elongated rete ridges and parakeratosis (retention of nuclei in 
the stratum corneum) (Fig. 3).10,26 Accumulation of neutrophils within a spongiotic 
pustule is referred to as “spongiform pustule of Kogoj”. Accumulation of neutrophil 
remnants within parakeratotic areas of the stratum corneum is formally known as 
“microabscess of Munro”. These microabscesses are one of the most characteristic 
histological features of active lesions. 
In the dermis, a mixed perivascular infiltrate is present, consisting of lymphocytes, 
DCs, neutrophils, NK cells, mast cells and macrophages. Furthermore, there is 
increased vascularity of the dermis with tortuous appearance of the capillaries that 
can be observed as prominent ascending blood vessels within the dermal papillae.27 
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Figure 1. Clinical pictures of psoriasis vulgaris or chronic plaque psoriasis: sharply 
demarcated erythematosquamous plaques. Figure is adapted from Griffiths CE, Barker JN. 
Lancet 2007; 370: 263-71.
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1.3 Skin immunology 
The skin serves as a first line of defense, as it is constantly exposed to potential 
hazards from the environment. It is a multitasking organ, not only serving as a 
physical and biochemical barrier but also as an immune-protective organ. In case 
of a potential threat, there is cross-talk between keratinocytes, antigen presenting 
cells (APCs) and dermal immune cells. During inflammation a plethora of resident as 
well as infiltrating leukocytes can be found. An excessive immune response against 
pathogens can lead to chronic inflammation and autoimmunity. Both active defense 
mechanisms and tolerogenic pathways are necessary in order to achieve immune 
homeostasis.28,29
Epidermis
In the epidermis, Langerhans cells are the main DC subset. They reside in the 
suprabasal layers where they are regularly spaced among keratinocytes. Langerhans 
cells are among the first DCs to come in contact with microbial agents and present 
antigens to effector T (Teff) cells.30 The epidermis contains αß T cells - mainly memory 
CD8+ cytotoxic T lymphocytes -, that often lie in close proximity with Langerhans 
cells.31
Figure 2. Normal skin morphology. The epidermis of normal skin consists of several strata or 
sublayers in which the keratinocytes are in different stages of differentiation. Furthermore, it 
gives rise to specialized cells such as melanocytes, CD8+ T lymphocytes, and Langerhans cells. 
The dermis is build out of structural components and contains many different immune cells. 
Bar = 50 µm. Figure is adapted from Nestle FO, Di Meglio P, Qin JZ et al. Nat Rev Immunol 
2009: 9(10):679-691.
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Dermis
In the dermis, a diverse range of DCs has been identified. Dermal DCs (DDCs) are the 
only subtype to be present in healthy skin. They are involved in antigen presentation 
in the lymph nodes and possess phagocytosing capacities.32,33 There are 2 important 
inflammatory DCs; inflammatory dendritic skin cells (IDSCs) and plasmacytoid DCs 
(pDCs). Amongst other functions, IDSCs have the capacity to produce proinflammatory 
cytokines such as tumor necrosis factor (TNF) α, while pDCs are known for their 
robust production of type I interferons (IFNs).34 
Normal human skin contains twice as many T cells as the human blood.35 The 
dermis contains CD4+ as well as CD8+ T cells, that preferentially cluster around the 
postcapillary venules just beneath the dermal epidermal junction. The majority of 
the T cells are memory-type T cells expressing cutaneous lymphocyte-associated 
antigen (CLA).36 T cells in the human skin consist of tissue-resident memory T 
cells and recirculating Teff memory cells.37,38 Dependent on the type of infection/
inflammation, subpopulations of CD4+ T cells can be found; T helper (Th) 1, Th2, Th17 
and Th22 cells.34 T helper subtypes that are relevant for the understanding of this 
thesis, will be discussed extensively in paragraph 1.5. Ten percent of the skin CD4+ 
T cell population is represented by regulatory T cells (Treg), a subtype of T helper 
cells with anti-inflammatory capacities.39 They play an important role in maintaining 
immune homeostasis.40  
Several innate immune cells can be found in the healthy dermis where they serve as 
first line of defense. NK cells, also referred to as class 1 innate lymphoid cells (ILC), 
can recognize and kill altered cells when they are transformed or infected by using 
effector mechanisms such as the release of cytotoxic granules.37,41,42 Mast cells are 
most famous for their role in IgE mediated hypersensitivity reactions. However, they 
also play an essential role in host defense against parasites, bacteria and viruses, by 
priming the innate as well as the effector phase of an adaptive immune response.43 
Macrophages in the skin eliminate pathogens via phagocytosis. γδ T cells represent 
a small subset of T cells that, as opposed to the much more common αß T cells, 
possess a distinct T cell receptor (TCR) on their surface. In human skin, unlike murine 
skin, γδ T cells are only present in the dermis.37 γδ T cells are the first immune 
cells found in the fetus and provide immunity to newborns, prior the activation of 
other adaptive immune cells. They are present at epithelial sites, and function in 
clearance of infections, for example through antigen presentation and by promoting 
recruitment of Teff cells to the site of inflammation.44 
Neutrophils are absent in normal skin, but are one of the earliest phagocytotic cells 
to appear during inflammation. The process of phagocytosis is accompanied by the 
release of antimicrobial enzymes (myeloperoxidase and elastase) and large amounts 
of cytokines (interleukin(IL)-1, IL-6, TNFα, IL-8, IL-12 and IL-19).34
Chapter 1
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1.4 Pathogenesis of psoriasis
Genetic reconstitution and environmental factors 
Psoriasis results from a combination of genetic predisposition and environmental 
triggers.26 Although psoriasis has a strong genetic component, the inheritance 
pattern is still unclear. Population studies have shown that there is a higher risk of 
psoriasis among first-degree and second-degree relatives of patients as compared 
to the general population.2,45 Genome-wide association scans (GWAS) identified 
36 susceptibility loci linked to psoriasis.46,47 PSORS1 has been shown to have the 
strongest association with psoriasis and harbours HLA-C*06,48 the most likely 
susceptibility gene of PSORS1.49 Given the role of human leukocyte antigen (HLA) 
in antigen presentation, the association with HLA-C*06 points towards a role of the 
adaptive immune system in psoriasis.50 The PSORS1 region accounts for less than 
50% of the heredity of the disease,51 indicating that other loci must contribute to 
the pathogenesis of psoriasis. Deletion of the late cornified envelope (LCE) genes, 
LCE3B and LCE3C, has recently been identified as another risk factor for psoriasis. 
LCE3 genes encode for proteins that are involved in barrier repair following injury or 
inflammation.52 Other widely replicated genetic risk factors that are of importance 
for the understanding of the data presented in this thesis, include the gene encoding 
for the IL-23 receptor (IL23R)53 and IL12B encoding for the p40 subunit of IL-12/IL-
23.53,54
Figure 3. Morphological changes is psoriasis. The psoriatic epidermis is characterized by 
acanthosis, elongated rete ridges and a parakeratotic stratum corneum. In the stratum 
corneum, accumulated neutrophils can be identified as microabscesses of Munro. In the 
dermis a mixed perivascular infiltrate and ascending tortuous capillaries are observed. Bar 
= 200 µm.
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Environmental influences that may trigger or worsen psoriasis in genetically 
predisposed individuals include certain drugs (such as lithium, beta-blockers, 
antimalarials, IFN, NSAIDs and rapid tapering or high dose of corticosteroids),55 
trauma (Koebner phenomenon),56 psychogenic stress,57 and viral (HIV)58 or bacterial 
infections (especially streptococcal throat infections).59-61
Interplay between keratinocytes and immune cells
While in the past psoriasis was considered to be solely a hyperproliferative disease of 
the keratinocytes, it was discovered that the immune system also plays an important 
role. However, whether the disease is of epithelial or immunological origin, is still a 
matter of debate as genetic risk factors were discovered in both compartments. At 
this moment it is known that at least three main biological pathways are involved; 
adaptive immunity, innate immunity and skin barrier function.50 Interaction between 
these 3 pathways is necessary to establish and maintain chronicity of the disease. 
Genetic reconstitution of the host in combination with environmental triggers leads 
to stressed keratinocytes. There is activation of pDCs via the formation of DNA-
LL-37 complexes.62 It was shown that pDCs are increased and activated in early 
psoriatic lesions and produce IFNα, that plays an important role in the induction 
of psoriatic lesions.63,64 IFNα in combination with IL-1ß, IL-6 and TNFα derived from 
keratinocytes and T cells, causes activation of myeloid DCs. Myeloid DCs migrate into 
the draining lymph nodes and secrete mediators such as IL-12 and IL-23, leading to 
differentiation of naïve T cells into Th1, Th17 and Th22 cells, respectively.26 Th1 cells 
produce cytokines like IFNγ and TNFα, whereas Th17 cells produce IL-17 and IL-21. 
Th22 cells solely secrete IL-22.65 These cytokines then act on keratinocytes, leading to 
activation, proliferation, and production of antimicrobial peptides (LL-37 cathelicidin 
and ß-defensins), proinflammatory cytokines (TNFα, IL-1ß and IL-6), chemokines 
(CXLC1 and CCL20) and S100 proteins.26,66,67 Neutrophils are attracted to the scene 
by CXCL8, CCL20 and IL-17A.29 Soluble factors feed back into the proinflammatory 
disease cycle. Figure 4 provides a schematic overview of the interplay between the 
different effectors that shape the psoriatic inflammatory process. 
1.5 IL-23/IL-17 signaling in psoriasis
IL-17 is a proinflammatory cytokine that plays a key role in clearing extracellular 
pathogens, but is also known to be involved in various autoimmune and inflammatory 
conditions, such as psoriasis.68-72 IL-17 production is dependent on IL-23. The IL-17 
family has six family members (IL-17A to F), of which IL-17A, IL-17C and IL-17F mRNA as 
well as protein expression levels are elevated in lesional psoriatic skin.73,74 IL-17A and 
IL-17F can be secreted as both homodimeric and heterodimeric (IL-17A/F) proteins 
General introduction
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with different potencies (from IL-17A being the most potent isoform, followed by IL-
17A/F and IL-17F).72 The afore mentioned cytokines exert their function in the skin 
by directly stimulating the keratinocytes to produce psoriasis-associated molecules, 
such as cytokines, ß-defensins, antimicrobial peptides (AMPs), and neutrophil-, 
macrophage- and lymphocyte-attracting chemokines.75-78 
Evidence to support an important role for IL-23/IL-17 signaling in the pathogenesis of 
psoriasis, was derived from GWAS and candidate gene approaches.73 Ustekinumab a 
monoclonal antibody (mAb) targeting the shared p40 subunit of IL-12 and IL-23 is a 
well established, frequently used and effective drug in the treatment of psoriasis.79-81 
Moreover, recent developed mAbs directly targeting IL-17 or the IL-17 receptor show 
very promising results in the treatment of psoriasis.82-84
At this moment, T cells are considered the main producers of IL-17 in the human skin. 
However, multiple other cell types are associated with production of IL-17, including 
neutrophils, mast cells, γδ T cells and class 3 ILCs.
Th17 cells
Th17 cells represent a distinct lineage of CD4+ T helper cells that require RORγt 
as a key transcription factor for their differentiation.85 In humans, these cells 
Figure 4. Interplay between cells from the innate and adaptive immune system in psoriasis. 
Figure from Nestle FO, Kaplan DH and Barker J. N Engl J Med 2009; 361:496-509.
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secrete predominantly IL-17A, but also other mediators like IL-17F and IL-21. Their 
development is dependent on transforming growth factor (TGF)-ß, IL-6, IL-21, IL-
1ß and especially IL-23.68 Th17 cells coexpress IL-23R, CCR6 and CCR4 on their 
surface86 and play an critical role in the clearance of extracellular pathogens, such 
as Candida and Klebsiella. However, under certain circumstances they are associated 
with the pathogenesis of several autoimmune and inflammatory conditions, such 
as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), multiple sclerosis 
(MS), inflammatory bowel disease (IBD) and psoriasis.68-71 
Regulatory T cells 
Treg are a subtype of CD4+ T helper cells with anti-inflammatory properties. Treg 
derived from the thymus are referred to as naturally occurring Treg (nTreg),40 while Treg 
that are induced de novo from naïve CD4+ T cells are referred to as iTreg.87-89 nTreg and 
iTreg have many phenotypical characteristics in resemblance. The key transcription 
factor of Treg is forkhead box P3 (Foxp3). Identification of Treg is complicated due to 
the fact that activated conventional T cells (Tconv) may express similar expression 
markers. In general, nTreg are defined as CD4+CD25highCD127lowFoxp3+ cells.90,91 Treg 
play an important role in controlling autoimmunity and inflammation by regulating the 
effector arm of the immune system through the production of immunosuppressive 
cytokines like IL-10,87 TGF-ß88 and IL-35.89 Impaired Treg functioning is considered 
in the context of several autoimmune and inflammatory diseases such as type I 
diabetes, MS, SLE, RA, IBD and recently psoriasis.90,92,93
Interestingly, recent insights reveal that the Treg phenotype is not as stable as 
previously considered. Under proinflammatory conditions Treg may convert into a 
more inflammatory cell type.91 In psoriasis, it was found that Treg of patients indeed 
had impaired suppressive capacity and could easily differentiate into IL-17-producing 
cells upon loss of Foxp3 expression. This Treg to Th17 conversion was enhanced by 
IL-23.94,95
1.6 Targeted treatment options
Mild-to-moderate psoriasis is usually treated with topical agents, such as 
corticosteroids, vitamin D analogues, topical retinoids, calcineurin inhibitors, or 
a combination of these agents.96,97 For patients with moderate to severe psoriasis 
systemic agents, such as methotrexate, cyclosporine, oral retinoids and fumaric 
acid esters, are available. These drugs are often used in combination with ongoing 
topical treatments. Furthermore, phototherapy represents a safe and very effective 
treatment option for moderate to severe forms of psoriasis vulgaris.98
As of 2004, new treatment options became available for moderate to severe 
Chapter 1
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psoriasis, the so-called biologics. Biologic therapies utilize molecules designed to 
block specific molecular steps that are important in the pathogenesis of psoriasis and 
have a favorable safety profile. Adalimumab and infliximab are both monoclonal Abs 
specifically targeting TNF, whereas etanercept is a genetic engineered fusion protein 
specifically developed to bind to the TNF receptor.98,99 
Intervening in the IL-17/IL-23 pathway
In the last years, several therapeutical advances have been made, by intervening in 
the IL-23/IL-17 pathway. Ustekinumab, is a fully human mAb that is directed towards 
the p40 subunit of IL-12 and IL-23. It thus prevents IL-12 and IL-23 from binding to 
its receptor (IL-12Rß1) on the surface of immune cells. Thereby differentiation of 
naïve T cells into Th1 and Th17 effector cells is (partially) blocked. Ustekinumab is a 
well-established, frequently used and effective drug in the treatment of psoriasis.79-81 
Currently, three agents neutralizing IL-17 (i.e. secukinumab and ixekizumab ) or 
antagonizing its receptor (i.e. brodalumab), are being tested in phase III clinical trials. 
Phase II clinical trials already showed marked improvement of the disease severity, 
as measured by the Psoriasis Area and Severity Index (PASI) score. Whereas reaching 
a PASI improvement of 75% (PASI75) at week 12 of treatment was used as primary 
end point, a considerable amount of patients on these new agents even reached a 
PASI90.82 The results of these new agents once again emphasize the importance of 
IL-17 in the pathogenesis of psoriasis.
1.7 Models of psoriasis 
In this thesis we used several dynamic skin models that provided a unique opportunity 
to study skin immune cells in time. Dynamic skin models in mice as well as in human, 
in healthy skin as well as in psoriatic skin, were used. 
Murine models of psoriasis
Psoriasis does not exist as a naturally occurring disease in mice. However, there are 
several approaches to mimic psoriasis-like skin inflammation in mice. Immunological 
reconstitution approaches and xenotransplantation models have shed light on the 
immunopathogenesis of psoriasis.100 Lately, many studies used the application of 
imiquimod (IMQ) on mouse back skin as a model to study psoriasis, as IMQ induced 
skin inflammation is mediated via the IL-23/IL-17 axis.101-103 In this thesis we used 
human peripheral blood lymphocyte reconstituted severe combined immunodeficient 
(SCID) mouse human skin allograft model (huPBL-SCID-huSkin model) to study skin 
inflammation.104,105 In this model human skin is transplanted onto immunodeficient 
mice. Upon healing of the skin, allogeneic human peripheral blood mononuclear 
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cells (PBMCs) are infused intra peritoneally. Although this model was initially used 
as a model to study local skin inflammation in vivo, it could potentially be used as 
a model to study psoriasis, as the skin phenotype resembles human plaque-type 
psoriasis at multiple levels. 
Human models of psoriasis
In this thesis we used two models to study skin inflammation in vivo in human; the 
application of leukotriene B4 (LTB4) and tape-stripping. Histologically, these models 
have similarities with psoriasis. Moreover, each model induces skin inflammation via 
a different pathway known to be involved in psoriasis. The application of LTB4 is a 
potent chemoattractant for innate and adaptive immune cells, while tape- stripping 
causes an impaired barrier function. It is important to bear in mind that these models 
are an approach to reality, and that they do not fully mimic psoriasis. 
Leukotrienes are lipid mediators generated in a variety of inflammatory and allergic 
reactions in the skin.106 Of particular significance is the 5-lipoxygenase product LTB4, 
of which high levels were found in lesional psoriatic skin.107,108 LTB4 is produced by 
the metabolism of arachidonic acid through the 5-lipoxygenase pathway109 and is 
rapidly generated from activated innate immune cells.110,111 Ligation of BLT1 (LTB4 
receptor-1) by LTB4 causes activation and recruitment of inflammatory cells. LTB4 
is a potent chemoattractant for neutrophils, eosinophils, monocytes, macrophages, 
mast cells, dendritic cells, and Teff cells.110,112 In vitro LTB4 stimulates epidermal 
growth.113 Topical application of LTB4 causes epidermal proliferation, influx of 
polymorphonuclear (PMN) cells in the epidermis (where they accumulate and form 
small abscesses) and dermis followed by a mononuclear cell infiltrate. Clinically, the 
application of LTB4 causes mild erythema and edema at the site of application. 
Tape-stripping involves repeated application and removal of cellophane tape on 
the skin, resulting in absence of the stratum corneum. An impaired barrier function 
through tape-stripping causes epidermal proliferation, keratinization,114,115 and an 
immune response.116 (Partial) Removal of the stratum corneum by tape-stripping is 
clinically observed as an abrasive lesion.
Apart from these two models to study the dynamics of immune cell influx in healthy 
volunteers, we studied the different phases of plaque formation in psoriatic patients. 
Therefore, we used the transition from symptomless to lesional psoriatic skin.117-119 
It is commonly accepted that the symptomless skin of psoriatic patients should not 
be considered as healthy skin.120 Furthermore, the symptomless skin adjacent to the 
rim of the lesion harbors phenomena of early lesion development. Lesional skin at 
the margin of the lesion represents an intermediate phase and central lesional skin 
represents a more chronic phase.
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1.8 Aims and outline of this thesis
Accumulating evidence points towards an important role for IL-17 in the pathogenesis 
of psoriasis. Th17 cells have long been considered the main source of IL-17 in psoriasis 
and were widely studied. However, more recent data, including data from our centre, 
revealed that in psoriasis IL-17 is not exclusively produced by Th17 cells.91,121,122 It 
was shown that peripheral blood derived Treg from severe psoriatic patients have 
reduced suppressive capacity and have an enhanced propensity to differentiate into 
an IL-17-producing phenotype, especially upon stimulation with IL-23. Furthermore, 
the occurrence of IL-17-producing Treg was confirmed in lesional psoriatic skin.95 
Demonstration of both Treg and Th17 characteristics by the same cell, inspired us 
to further study this conversion in vivo by using different dynamic approaches. Our 
goal was to study Treg and Treg to Th17 conversion by using models for induced skin 
inflammation in healthy volunteers. Moreover, we looked at these cells in patients 
during the different phases of psoriatic plaque development and during topical 
as well as systemic treatment. Finally, we addressed whether this phenomenon 
exclusively occurred in psoriasis, or also in other chronic inflammatory diseases such 
as atopic dermatitis. 
Indeed, we observed substantial expression of IL-17 present in the skin of both mice 
and human. Unlike mice, this IL-17 expression could only sporadically be linked to 
T cells in humans. Only few IL-17+ Treg were found. Considering the importance of 
IL-17 in psoriasis, we looked at other cell types that may be associated with this 
abundant IL-17 expression. Based on the existing literature, we redirected our focus 
on innate immune cells, and especially on IL-17-expressing mast cells and neutrophils 
by using the same dynamic approaches as described in the above. We addressed this 
new concept, eventually working towards a paradigm shift on the cellular sources of 
IL-17.
Chapter 1 provides a short introduction to several aspects of psoriasis, especially 
focusing on the immune pathogenesis of psoriasis. Furthermore, this chapter 
gives an overview of the different immune cell subsets that are relevant for the 
understanding of this thesis. 
In chapter 2, we analyzed biopsies derived from different locations in and around a 
psoriatic plaque for the presence of Treg and T helper cells. The different locations 
represented the different phases of plaque formation. Our goal was to assess the 
balance of anti-inflammatory versus proinflammatory T cells in the different phases 
of plaque development by means of the Foxp3/CD4 ratio. Furthermore, this study 
provides the first hints that not only T cells are associated with the expression of 
IL-17. In continuation of chapter 2, chapter 3 assesses the Foxp3/CD4 ratio during 
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anti-psoriatic treatment with topical agent calcipotriol-betamethasone dipropionate 
(CBD) and systemic treatment with adalimumab. 
It was previously found that Treg in peripheral blood from patients with psoriasis had 
an instable phenotype and were able to produce IL-17 under certain circumstances. 
In chapter 4 we looked whether this phenomenon specifically occurs in psoriasis, 
or whether this can also be observed in atopic dermatitis, another common chronic 
inflammatory disease.
In chapter 5 we examined the additional advances of the previously described 
huPBL-SCID-huSkin allograft model as a powerful tool to study human skin immune 
pathology in vivo. Furthermore, it was assessed whether this model could also serve 
as a model to study the pathogenesis of psoriasis at the level of skin and immune 
biology.
The application of LTB4 and tape-stripping are 2 frequently used models to study 
skin inflammation in vivo. Chapter 6 and 7 provide an update on the morphological 
changes induced by LTB4 and tape-stripping. In chapter 8 we use these models to 
study the presence of different IL-17-expressing adaptive and innate immune cells 
in time. Additional experiments were performed to further characterize these IL-17-
expressing cells.
Chapter 9 serves as a critical viewpoint addressing the current literature on the 
cellular sources of IL-17 in psoriasis and other inflammatory diseases, thereby placing 
the results of this thesis in a wider context. 
Furthermore, the data presented in this thesis are summarized and discussed in 
chapter 10.
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Abstract
Background In the pathogenesis of psoriasis, proinflammatory T cells are strongly 
involved in the inflammatory process, where regulatory T cell (Treg) function is 
impaired.
Objectives As effective Treg function is associated with a numerical balance between 
Treg and effector T cells, we wondered whether Treg/T helper cell ratios may be 
associated with certain stages of the inflammatory process. We opted for the margin 
zone model as a dynamic approach.
Methods From nine patients with chronic plaque psoriasis, 3-mm punch biopsies 
were obtained from the centre and margin of the lesion, perilesional skin and distant 
uninvolved skin. Skin biopsies of 10 healthy volunteers were included as a control. 
Samples were analysed by immunohistochemistry and immunofluorescence. 
Results In the transition from symptomless to lesional skin, a significant increase 
of CD3+, CD4+, and Foxp3+ cells was found. In seven of nine patients the ratio 
Treg (Foxp3+) vs. CD4+ T cells was higher in the distant uninvolved skin than in 
the perilesional and lesional skin. Interestingly, the Foxp3/CD4 ratio in the distant 
uninvolved skin was even higher than in the skin of healthy controls. Notably, we 
found that most of the interleukin (IL)-17 expression was not related to CD4+ cells, 
but to mast cells. 
Conclusions The relatively high Foxp3/CD4 ratio in symptomless skin of patients 
with psoriasis suggests an active immune controlling mechanism distant from the 
psoriatic plaque. In the margin and center of the plaque the ratio appears skewed 
towards effector cells associated with inflammation. IL-17, an important driver of 
the psoriatic process, is mostly related to mast cells, and only sporadically to T cells.
Chapter 2
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Introduction
Psoriasis is an autoimmune-related chronic inflammatory skin disease, strongly 
associated with proinflammatory T cell subsets. T helper (Th) 1 cells play an important 
role in this disease and recent interest has focused on Th17 cells in the pathogenesis 
of psoriasis. In addition to their function in antimicrobial immunity, these Th17 cells 
are implicated in various autoimmune and inflammatory pathologies.1-3 Human Th17 
cells may originate from naive or memory CD4+ T cells or even regulatory T cells (Treg) 
and this differentiation process is highly facilitated by cytokines such as interleukin 
(IL)-1β, IL-21 and IL-23.4-6 Human Th17 cells are characterized by the expression 
of transcription factor retinoid-related orphan receptor-γt. In addition to their key 
effector cytokine IL-17A (IL-17), they also produce IL-17F, IL-21 and IL-22.6,7 Supporting 
evidence that IL-23 signalling and Th17 cell lineages play an important role in the 
pathogenesis of psoriasis was obtained from recent genome-wide association scans.8 
Treatment with human monoclonal antibodies (Abs) against the p40 subunit of IL-12 
and IL-23 has proven to be successful in the treatment of psoriasis.9,10 Moreover, 
phase-II clinical trials with human Abs against IL-17 or the IL-17 receptor (ixekizumab, 
secukinumab and brodalumab) in patients with psoriasis showed promising results, 
supporting a role for Th17 cells in the pathophysiology of psoriasis.11-13 Notably, T 
cells are not the sole producers of IL-17; mast cells and neutrophils also express IL-
17.14,15 To maintain immune tolerance and prevent autoimmunity, effective control 
mechanisms are required. Treg are essential for immune homeostasis by virtue of 
their capacity to modulate immune responses, inflammation, and tissue destruction 
by suppressing the functions of different T cell types including T and B cells and 
antigen presenting cells. In humans, Treg comprise approximately 2% of all CD4+ T 
cells in the peripheral blood, they are suppressive by nature and characterized by high 
expression of CD25 and the transcription factor forkhead box P3 (Foxp3), combined 
with low CD127 expression.16,17 An aberrant function of Treg has been demonstrated 
in several human chronic (auto)inflammatory diseases, such as rheumatoid arthritis, 
type 1 diabetes, multiple sclerosis, myasthenia gravis, and psoriasis18 (reviewed19). 
Recent insights reveal that the Treg phenotype is not as stable as previously 
considered and that conversion of Treg into an IL-17-producing phenotype may 
occur under proinflammatory conditions.17 Recently, we found that not only was the 
Treg suppressor function of patients hampered,20 but found that these dysfunctional 
Treg lost Foxp3 expression and indeed revealed an increased propensity to produce 
IL-17. The occurrence of this type of IL-17-producing Treg in psoriatic plaques 
was confirmed by immunohistochemical staining on lesional skin of patients with 
psoriasis. Coexpression as well as single expression of Foxp3 and IL-17 was observed 
especially in the papillary dermis. 
Effective Treg function has been associated with the numerical balance between Treg 
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and effector T cells; sufficient numbers of functional Treg are required.21 Interestingly, 
in the previous study by Bovenschen et al.,20 interindividual heterogeneity was 
noticed with respect to the number of Foxp3- and IL-17-expressing cells. We therefore 
wondered whether Treg vs. T effector cell numbers may be associated with a certain 
stage of the inflammatory process and may indicate severity of dysregulation. 
As previously reported,22-24 the margin zone of a psoriatic lesion presents an 
interesting approach to describe the different phases in the outgrowth of a psoriatic 
plaque. Using immunohistochemistry (IHC) and immunofluorescence (IF) we studied 
cellular infiltrates in the transition from symptomless to lesional skin. In particular, 
we studied the balance of Treg vs. CD4+ Th cells in the different skin locations. In 
addition, we questioned whether symptomless skin at a distance from the psoriatic 
plaque would resemble skin of healthy volunteers, or rather would display heightened 
regulatory features.
Methods
Patients and healthy volunteers
Ten patients with mild-to-moderate chronic plaque psoriasis (Psoriasis Area and 
Severity Index (PASI) score < 15) were recruited according to the Declaration of 
Helsinki principles and after approval by the medical ethics committee of Radboud 
University Nijmegen Medical Centre. All patients gave informed consent. One patient 
was excluded from participation based on the histology, which was not conclusive 
for psoriasis. Eventually, nine patients, seven men and two women (median age 61, 
range 31-74), were included. The patients had a median PASI score of 5.6 (range 2.4-
10). A wash-out period of 2 weeks for topical treatment, 4 weeks for photo (chemo) 
therapy, 4 weeks for systemic therapy and 12 weeks for biologics, was taken into 
account. As a control we obtained normal skin from 10 healthy subjects.
Tissue specimens
After infiltrating the selected target lesions with local anaesthesia (xylocaine/
adrenaline 1:200.000), we obtained four 3-mm punch biopsies per patient; one from 
the centre of the psoriatic plaque, one from the clinically involved margin of the 
psoriatic plaque, one from the symptomless perilesional skin and one from distant 
uninvolved skin (at least 2 cm from the target lesion) (Fig. 1). Histology of the different 
biopsy locations is shown in the same figure. The target lesions had a diameter of at 
least 2 cm and were located on the extremities or the trunk.
Immunohistochemistry
Tissue sections of 4 μm were generated after embedding the skin biopsies in paraffin. 
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Figure 1. Biopsy locations. Upper panel, picture showing the different biopsy locations on the 
skin; lower panels, haematoxylin and eosin (H&E) stainings of the different biopsy locations. 
C, centre of the psoriatic plaque; M, margin of the psoriatic plaque; Pls, perilesional skin; D, 
distant uninvolved skin. 
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Figure 2. Immunohistochemistry and quantification of several markers. Left panel, (a) 
CD3, (b) CD4, (c) Foxp3 and (d) IL-17 expression is shown in psoriatic skin at an objective 
magnification of 10x and 40x. Right panel, the corresponding numbers of positively stained 
cells per mm⁻2 dermis are depicted per biopsy location (n=9) (see Fig. 1). As a control, normal 
skin (NS) of healthy volunteers is added to the graphs (n=10).
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Immunostainings were conducted using the following antihuman primary antibodies: 
CD3 (general T cell marker) (F7.2.38; Abcam, Cambridge, UK), CD4 (Th cell marker) 
(BC/1F6; SantaCruz Biotechnology, Santa Cruz, CA), Foxp3 (PCH101; eBioscience, 
San Diego, CA) and IL-17 polyclonal goat IgG (R&D-Systems, Minneapolis, MN). 
After deparaffination and rehydration, heat- induced antigen retrieval with Tris/
ethylenediaminetetraacetic acid (EDTA) (50 mM/L Tris + 2 mM/L EDTA, pH 9.0 for 
Foxp3 and IL-17) or EDTA/Tween (EDTA pH 8.0 + 0.5% Tween for CD3 and CD4) was 
performed for 10 minutes. After washing, sections were incubated with 1% bovine 
serum albumin (BSA; Dako, Glostrup, Denmark). Antibodies were applied (CD3 
1:500, CD4 1:100, Foxp3 1:100 and IL-17 1:500) dissolved in 1% BSA, and sections 
were incubated overnight. The sections were sequentially washed and incubated 
with horseradish peroxidase (HRP) labelled polymer (Envision; Dako for CD3 and 
CD4) or avidin-biotin complex–HRP solution (1:50) (Vectastain ABC-elite kit; Vector-
Laboratories, Burlingame, CA for Foxp3 and IL-17) depending on the species used. 
HRP was visualized with 3,3’-diaminobenzidine tetrahydrochloride solution (Sigma-
Aldrich, St. Louis, MO). After counterstaining with Mayer’s Hematoxylin (Sigma-
Aldrich) for 90 seconds, the sections were washed in tap water, dehydrated and 
mounted using Permount® (Fisher Scientific, Whitby, ON).
Immunofluorescence 
To detect co-staining of IL-17 in T cells, mast cells and neutrophils, anti-IL-17 polyclonal 
goat IgG (1:500; R&D-Systems) was used in combination with CD4 (SantaCruz 
Biotechnology), neutrophil elastase (NP57; Dako) and mast cell tryptase (AA1; Dako). 
Sections of 4 µm were deparaffinized and rehydrated. Antigen retrieval took place 
by boiling the sections for 1 minute in Tris/EDTA buffer for the combination of IL-
17 with neutrophil elastase or with mast cell tryptase and for 10 minutes in EDTA/
Tween buffer for the combination of IL-17 with CD4. The sections were sequentially 
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washed and incubated overnight at room temperature with the primary Abs (IL-
17, 1:500; CD4, 1:100; neutrophil elastase, 1:3000; and mast cell tryptase, 1:1000). 
Following on, the sections were incubated with a mix of matched secondary Abs 
during 6 hours at room temperature. CD4, elastase and tryptase were labeled with 
IgG Alexa Fluor 488 (1:200; Invitrogen, Carlsbad, CA). IL-17 was labelled with Alexa 
Fluor 594 (1:400; Invitrogen). The slides were counterstained with 4’,6-Diamidino-2-
phenylindole (DAPI) (1:3; Vector Laboaratories) and mounted using Fluoromount-G 
(Southern Biotech, Birmingham, Al).
Co-staining of CD39 (1:1000) (ab127167; Abcam) with Foxp3 (1:100) (PCH101; 
eBioscience) was performed likewise, labeling Foxp3 with IgG Alexa Fluor 488 (1:200; 
Invitrogen) and CD39 with Alexa Fluor 594 (1:200; Invitrogen). Epitope retrieval was 
performed by boiling the sections for 1 minute in Tris/EDTA buffer and subsequently 
for 10 minutes in 0.01 mol/L citrate buffer, pH 6.0. 
We used the Olympus FV1000 confocal laser scanning microscope (Olympus, Tokyo, 
Japan) to make captures at an oil objective of 60x1.2 numerial aperture. Conventional 
immunofluorescent pictures were taken with the Axioskop2 MOT (Zeiss, Oberkochen, 
Germany).
Quantification of cells
The immunohistochemical stained sections were visualized and photographed using 
a microscope (Axioskop2 MOT; Zeiss) and digital camera (Axiocam MRc5; Zeiss). 
The photographs were automatically analysed for stained cells using image analysis 
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Figure 3. Representative immunofluorescent double-staining for Foxp3 and CD39 in the 
dermis of a patient with psoriasis. White arrows, Foxp3+CD39+ cell; grey arrow, Foxp3+CD39- 
cell; open arrow, Foxp3-CD39+ cell; DAPI, 4’,6-Diamidino-2-phenylindole.
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software (ImageJ software, National Institutes of Health; http://rsbweb.nih.gov/
ij/). Using the mentioned software we were able to look specifically at the dermis 
within a depth of 350 µm. For each section we took three overlapping photographs 
at a magnification of 10x, thereby screening the whole section. To quantify CD3+ 
and CD4+ cells, we used the total area of positively stained cells in the dermis and 
used a standard area per cell (8µ) to calculate the number of positively stained cells. 
Foxp3 and IL-17 could easily be quantified by measuring all particles. The average 
of positively stained cells per corresponding dermis area was calculated. For each 
marker this resulted in number of positive cells mm⁻². 
Statistical analyses
All analyses were conducted using Statistical Package for Social Sciences 17.0 (SPSS, 
Chicago, IL). The results were expressed as mean ± SEM. We performed Wilcoxon 
matched-pairs signed-rank tests to compare the expression of the mentioned T cell 
markers at different biopsy locations in and around a psoriatic plaque. Mann-Whitney 
tests were used to compare psoriatic skin with normal skin of healthy subjects. The 
Friedman test was conducted to test for differences between several related groups. 
P <0.05 was considered to be statistically significant. 
Results
T cell markers in the margin zone of psoriatic lesions
The histopathological features of the different biopsy locations in the margin zone 
of the psoriatic skin are illustrated in Figure 1. Lesional skin revealed the psoriatic 
features of thickened epidermis, parakeratosis, elongated rete ridges and a mixed 
Table 1. Number of CD3, CD4, Foxp3 and IL-17 cells per mm⁻² dermis for each biopsy 
location expressed in mean (± SEM).
CD3 CD4 Foxp3 IL-17
Centre (C) 833 ± 127 434 ± 90 100 ± 16 95 ± 26
Margin (M) 1066 ± 292 703 ± 175 137 ± 22 88 ± 27
Perilesional (Pls) 218 ± 60 * 174 ± 51 ** 35 ± 10 * 53 ± 20 *
Distant uninvolved skin (D) 46 ± 4 *** 24 ± 4 *** 13 ± 3 42 ± 12
Normal Skin (NS) 79 ± 21 60 ± 8 **** 10 ± 1 65 ± 12
*Statistically significant difference of P <0.01 in the perilesional skin compared to the 
margin; **statistically significant difference of P <0.05 in the perilesional skin compared to 
the margin; ***statistically significant difference of P <0.01 in the distant uninvolved skin 
compared with the perilesional skin; ****statistically significant difference of P <0.001 in the 
distant uninvolved skin compared with normal skin.
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cellular infiltrate.2 In perilesional skin we found inflammatory changes, but to a lesser 
extent than in the lesional skin, confirming data from Komine et al.24 The distant 
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Figure 4. Dual-color immunofluorescent stainings of interleukin IL-17A-producing leucocytes 
in the psoriatic dermis. Left panel, objective magnification 20x; right panel, confocal images 
objective magnification 60x. Stainings were performed for (a) CD4 (green) and IL-17 (red), (b) 
mast cell tryptase (green) and IL-17 (red) and (c) neutrophil elastase (green) together with 
IL-17 (red). 4’,6-Diamidino-2-phenylindole (DAPI) was used as a counterstaining. White filled 
arrows, double-positive stained cells; white open arrows, IL-17 single-positive stained cells. 
(c) Extracellular trap formation by neutrophils also demonstrated. 
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uninvolved skin did not reveal any pathological changes.
In order to study the dynamics of anti-inflammatory and proinflammatory Th cells 
in the transition from symptomless to lesional psoriatic skin, we performed IHC. We 
focused on the dermis, where Th cells were much more abundantly present than 
in the epidermis. Figure 2 (left panel) shows a representative example of CD3, CD4, 
Foxp3 and IL-17 staining in the centre of a psoriatic plaque. 
In the transition from symptomless to lesional skin, we found a significant increase 
in both CD3+ and CD4+ cells (in distant uninvolved skin, perilesional skin, margin 
and centre of the plaque, the density of CD3+ cells was 46 ± 4, 218 ± 60, 1066 ± 
292, 833 ± 127 cells mm⁻² dermis and for CD4+ cells this was 24 ± 4, 174 ± 51, 703 
± 175, 434 ± 90 cells mm⁻² dermis, respectively) (shown in Fig. 2, right panel and 
summarized in Table 1). CD3+ and CD4+ cell numbers within the lesion did not differ 
significantly, although we did observe a trend towards slightly higher numbers at the 
margin compared to the centre of the lesion. 
The presence of Treg, as indicated by Foxp3 expression, showed a similar trend in 
the transition from symptomless to lesional skin, as compared to CD3+ and CD4+ 
cells (from distant uninvolved skin, perilesional skin and the lesional margin to the 
centre of the plaque 13 ± 3, 35 ± 10, 137 ± 22 and 100 ± 16 Foxp3+ cells mm⁻² dermis, 
respectively). To characterize Treg cells further we performed an immunofluorescent 
Figure 5. Foxp3/CD4 ratios in patients with psoriasis and in healthy volunteers. For each 
patient Foxp3/CD4 ratios are demonstrated per biopsy location (n=9). The mean Foxp3/CD4 
ratio in normal skin of healthy volunteers is displayed in gray.
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double-staining for CD39 and Foxp3 (Fig. 3). Recently Fletcher et al25 demonstrated 
that CD39, an ectonucleotidase which hydrolyzes ATP, is expressed on a special 
subset of suppressive human Treg cells. We detected Foxp3+CD39+, Foxp3+CD39- as 
well as Foxp3-CD39+ cells. 
IL-17, which may be produced by T cells as well as by other immune cells, was 
increased in the transition from symptomless to lesional psoriatic skin, but the 
increase was less clear than for CD3, CD4 and Foxp3 expression (IL-17+ cells from 
distant uninvolved skin to the centre of the plaque 42 ± 12, 53 ± 20, 88 ± 27 and 95 ± 
26 cells mm⁻² dermis, respectively). Interestingly, we also found high levels of IL-17-
producing cells in the symptomless skin and in the skin of healthy controls. Contrary 
to our expectations, it appeared that most IL-17 expression was not related to T cells. 
Previously it was found that IL-17 in psoriasis was associated with neutrophils and 
mast cells.14,15 Consequently, we performed double-stainings for IL-17 with tryptase 
and elastase as markers for mast cells and neutrophils, respectively (Fig. 4). We 
observed that most of the IL-17 staining at all biopsy locations as well as in the skin 
of healthy controls was associated with mast cells. There was little co-staining for 
IL-17 and neutrophils, except in the presence of parakeratosis or microabscesses of 
Munro. Although psoriasis is a Th17 mediated disease, CD4+IL-17+ double-positive 
cells were absent in the majority of the patients (data not shown). Colocalization of 
CD4 and IL-17 was only present in the T cell infiltrates of a few patients. Possibly the 
presence of these CD4+ IL-17+ double- positive cells depends on the phase of the 
disease (i.e. onset vs. stable vs. exacerbating disease). 
Higher Foxp3/CD4 ratios in the symptomless skin at a distance from the psoriatic 
plaque 
Inflammation may be associated with insufficient Treg function. As it is commonly 
accepted that proper Treg function is associated with a numerical balance between 
Treg and T effector cells, we looked at the ratios of Treg and CD4+ Th cells at each 
of the biopsy locations. Moreover, we questioned whether there is a difference 
between the symptomless skin of patients with psoriasis, which has the potential to 
become affected, and the skin of healthy subjects. We calculated Foxp3/CD4 ratios 
for each of the nine patients and for 10 healthy volunteers (Fig. 5). In seven out of 
nine patients we found a trend toward relatively higher Foxp3+ cell numbers in the 
distant uninvolved skin compared with the perilesional and the lesional skin (P = 
0.104). The two patients with a different tendency of the Foxp3/CD4 ratios, could not 
be distinguished from the other 7 patients by their clinical backgrounds, such as the 
PASI score, SUM score (erythema, scaling, infiltration), or by age.
Remarkably, we observed that in normal skin from healthy subjects the mean 
Foxp3/CD4 ratio was lower (0.18 ± 0.03) in comparison with the mean ratio of the 
symptomless skin at a distance from the psoriatic lesion (0.67 ± 0.20), although this 
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was not statistically significant (P=0.09). This may suggest that while the distant 
uninvolved skin of patients with psoriasis is symptomless, compensating mechanisms 
are actively trying to prevent expansion of disease.
Discussion
The present study lends support for a critical role of the balance of Treg vs Th cells in the 
transition from symptomless to lesional psoriatic skin. We observed that the majority 
of patients had a higher Foxp3/CD4 ratio in the symptomless skin at a distance from 
the psoriatic plaque compared with the perilesional and lesional skin. Remarkably, 
Foxp3/CD4 ratios in the symptomless skin at a distance from the psoriatic plaque 
were higher compared with the ratios in the skin of healthy volunteers. This may 
suggest active immune controlling mechanisms in the symptomless skin at a distance 
from the psoriatic plaque, whereby the tissue is actively trying to prevent expansion 
of disease. Lesions could develop when this control mechanism fails, for example 
upon environmental triggers. This may be exemplified by the reduced Foxp3/CD4 
ratios that we found in lesional and perilesional skin compared with symptomless 
skin at a distance from the plaque. This ratio is likely to be influenced by triggers that 
promote substantial expansion of lesional proinflammatory Th cells, or by triggers 
that promote Treg differentiation, whereby they lose Foxp3 and suppressive capacity 
and even acquire the ability to produce IL-17. 
In any system with homeostasis, a dysbalance may occur when one of the cell 
populations changes. In this case, the balance is influenced by either Treg or Th 
numbers, here shown by the Foxp3/CD4 ratio. This is a numerical balance, associated 
with effective Treg function, but influenced by both arms. The difference in Foxp3/
CD4 ratio between symptomless skin of psoriatic patients and the skin of healthy 
volunteers is mainly influenced by the CD4 arm of the ratio. It is difficult to say 
with any certainty why there are significantly more CD4+ cells present in the skin 
of healthy volunteers compared with symptomless skin of patients with psoriasis, 
while the presence of Foxp3+ cells in both groups is the same. One explanation 
might be that Treg in the symptomless skin of patients with psoriasis are capable of 
suppressing a CD4+ population. On the other hand one can argue that CD4+ cells in 
the symptomless skin migrate towards the lesion. 
The suppressive function of Treg was further examined using two-colour 
immunofluorescence. In accordance with Fletcher et al.,25 we detected both 
Foxp3+CD39+ and Foxp3+CD39- cells. We also found Foxp3-CD39+ cells. 
CD4+CD25highCD39+ and CD4+CD25highCD39- T cells suppress the proliferation 
and interferon-γ production of T cells, while IL-17 production is only suppressed 
by CD4+CD25highCD39+ T cells.25 In the light of the role ascribed to IL-17 in the 
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pathogenesis of psoriasis, these findings are of great interest and require further 
research.
Besides Treg as a representative of anti-inflammatory T cells, we focused on 
proinflammatory IL-17-producing cells, as they have proven to be highly relevant in 
the pathogenesis of psoriasis.1-3 Although there was a significant lower level of IL-17+ 
cells in the lesion than outside the lesion, the difference was not that substantial. Even 
more surprising was the finding that not only symptomless skin of patients contained 
IL-17-expressing cells, but also skin of healthy volunteers. This may be explained by 
the fact that most of the IL-17 was associated with mast cells, known to be involved 
in host defense against skin-invading pathogens, among others mechanisms through 
the production of IL-17.15,26 IL-17 containing neutrophils were only present at sides of 
parakeratosis and microabscesses of Munro.
Recently there has been some discussion about the specificity of anti-IL-17 Abs 
for staining paraffin sections. According to the manufacturer the R&D Systems 
polyclonal goat antihuman IL-17 (AF-317-NA) Ab can cross-react with IL-17F. IL-17F is 
produced by mast cells, which may explain our findings concerning IL-17 expression 
in non-lesional skin. Using the same Ab, others also found that most of the IL-17 
expression was related to mast cells in psoriasis.14,15 The same was seen for other 
autoimmune-like diseases such as rheumatoid arthritis27 and spondylarthritis,28 
including psoriatic arthritis.29 By using immunofluorescence combined with confocal 
microscopy we observed lower levels of IL-17 produced by T cells than by mast cells 
(Fig. 4). It is possible that Th17 cells play a role in a certain phase (i.e. onset vs. stable 
vs. exacerbating disease) of psoriasis and not during the whole pathogenesis, as has 
been suggested in atopic dermatitis.30
We focused our studies on the dermis, where IL-17+ and Foxp3+ cells were much 
more abundantly present than in the epidermis. Moreover, we observed that almost 
all Foxp3+ cells in the dermis also expressed CD4, while the few Foxp3+ cells in 
the epidermis did not. Foxp3+CD4- cells are most likely CD8+ cytotoxic T cells as 
described by Vissers et al.31
In conclusion, most of the information on psoriasis is derived from static models, 
measuring at a single location in the psoriatic lesion. Here we focused on Treg and 
proinflammatory Th cells in a more dynamic approach by using the transition from 
symptomless to lesional psoriatic skin as a model. We found suggestive evidence 
that the ratio of Treg vs. Th cells is higher in symptomless than in lesional skin, and 
even higher than in healthy skin. This may suggest activated and functional immune 
controlling mechanisms in the skin of psoriasis patients, where under certain 
microenvironmental conditions this mechanism may fail and lesions can develop. 
The present study indicates that the symptomless skin of psoriatic patients has a 
changed equilibrium between inflammatory and Treg cells. This balance may be 
important in the understanding of psoriasis as a systemic disease. 
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Abstract
Background Diminished suppressive capacity of regulatory T cells (Treg) has been 
demonstrated in blood and in lesional skin of psoriatic patients. Treatment with anti-
TNFα restored the number and function of circulating Treg in psoriasis.
Objectives We aimed to study Treg in the skin of psoriatic patients undergoing topical 
treatment with calcipotriol-betamethasone dipropionate (CBD) ointment (N=12) or 
systemic treatment with anti-TNFα agent adalimumab (N=10).
Methods Skin biopsies were collected from patients with chronic plaque 
psoriasis, that responded to the above mentioned treatments with a SUM-score 
improvement of at least 50% (at the end of treatment). Biopsies were processed 
for immunohistochemistry. As Treg function is associated with a numerical balance 
between Treg and effector T cells, Foxp3/CD4 ratios were calculated.  
Results Both treatments cause a significant decrease in the presence of Foxp3+ cells. 
However, in patients that were treated with CBD ointment we observed lower Foxp3/
CD4 ratios after 8 weeks of treatment compared to baseline (t=0: 0.41 ± 0.08; t=8: 
0.22 ± 0.04, P=0.033), whereas in patients that were treated with adalimumab we 
observed an increase of the Foxp3/CD4 ratios after 1,5 and 16 weeks of treatment 
compared to baseline (t=0: 0.25 ± 0.04; t=1.5: 0.32 ± 0.06; t=16: 0.49 ± 0.10, P=0.15). 
Conclusions Based on Foxp3/CD4 ratios, we can conclude that adalimumab treated 
skin differs from CBD treated skin with regard to the anti-inflammatory/inflammatory 
balance. We suggest that, in contrast to CBD ointment, adalimumab favors local Treg 
function in the skin.
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Introduction
Regulatory T cells (Treg) play an important role in mediating inflammatory responses 
and maintaining immune homeostasis through their capacity to suppress the function 
of different cell types including lymphocytes and antigen presenting cells (APC).1 
Treg are identified by CD4, CD25high and CD127low expression in combination with 
expression of master transcriptional factor Foxp3.2 Expression of Foxp3 is pivotal 
for Treg function,3 for it is known that mutations in the Foxp3 gene cause Treg 
deficiency, as is the case in patients with IPEX syndrome (immune dysregulation, 
polyendocrinopathy, entheropathy, X-linked syndrome).2 Dysfunction of Treg has 
been described in several chronic (auto)inflammatory diseases,4 including psoriasis.5,6 
It was found that Treg in the blood and in lesional skin from psoriatic patients had 
diminished suppressive capacity as compared to healthy controls.5,7 Furthermore, it 
was shown by our group that these dysfunctional Treg lost Foxp3 expression and had 
an increased tendency to differentiate into proinflammatory IL-17 producing cells.7 
Yet it might not only be the quality of Treg, but also the quantity of Treg that plays an 
important role in the pathogenesis of psoriasis. However, studies on Treg numbers in 
peripheral blood of psoriatic patients are inconclusive. It is still debated whether Treg 
percentages of patients with psoriasis are either the same,8,9 lower10,11 or even higher 
as compared to healthy controls. 
In the past, several studies looked at peripheral blood derived Treg and Treg 
functioning in psoriatic patients undergoing treatment. It was found that bath-
PUVA restores Treg numbers and Treg function in peripheral blood mononuclear 
cells (PBMCs) of patients with psoriasis.8,12 Anti-TNFα biological therapy caused an 
up regulation of circulating CD4+CD25highFoxp3+ Treg cells in psoriasis, associated 
with clinical improvement.10,11 Also in other autoimmune-like diseases, such as 
rheumatoid arthritis, it appeared that TNFα blockade by adalimumab induced a 
potent and stable Treg cell population in vitro, able to restrain the progression of IL-
17 associated inflammation via IL-6.13
Effective Treg function has been associated with a numerical balance between Treg 
and effector T (Teff) cells.14 Sufficient numbers of functional Treg are necessary to 
maintain immune tolerance/homeostasis. As mentioned above, previous studies 
in psoriasis focused on peripheral blood derived Treg during treatment. However, 
information on the status of Treg in psoriatic skin lesions during anti-psoriatic 
treatment is lacking. We here analyzed the presence of Foxp3+ Treg and Treg/Teff 
cell ratio by immunohistochemistry (IHC) and fluorescence in psoriatic skin biopsies 
before and following treatment with calcipotriol-betamethasone dipropionate (CBD) 
ointment which is used as an important combination therapy in first line topical 
treatment,15 and adalimumab which is  frequently used anti-TNFα systemic agent.16
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Methods
Patients and treatments 
In this study, we analyzed skin biopsies from patients with chronic plaque type 
psoriasis, attending in two different observational open label studies, with either 
topical calcipotriol-betamethasone dipropionate (CBD) ointment (unpublished data 
by Hendriks et al.) or systemic treatment with adalimumab.17 See Table 1 for patient 
characteristics. Of all patients representative target lesions were selected. Clinical 
response of the target lesion was measured using the SUM-score (the sum of redness, 
thickness and scaling as used in the psoriasis area severity (PASI) score, however 
without the area). Only patients that responded to the above treatments, with a 
SUM-score improvement of at least 50% at the end of treatment, were included in 
this study.
Twelve patients (nine male and three female, mean age of 62, range 48 – 71 years) 
with mild-to-moderate psoriasis were treated twice daily with topical CBD ointment 
during 8 weeks. Two biopsies (diameter 4 mm) were taken; one biopsy was taken from 
an untreated lesion (t=0) and one biopsy was taken from a lesion that was treated 
for 8 weeks (t=8). The patients were not allowed to use systemic anti-psoriatic drugs. 
Before start of the treatment, a washout period of 2 weeks for all topical treatments 
was taken into account.
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Characteristic CBD-ointment adalimumab
Patients, n 12 10
Male 9 5
Female 3 5
Age (years) 62 (48-71) 55 (42-73)
SUM score at 
baseline
6.1 (4-7) 6.9 (5-9)
Inclusion 
criteria
• Mild-to-moderate plaque psoriasis
• ≥ 18 years
• Patients had to be a candidate for 
topical therapy
• Moderate-to-severe plaque psoriasis 
• ≥ 18 years
• Failed/intolerated/had contraindications to 
methotrexate, phototherapy and cyclosporine
Exclusion 
criteria
• Use of systemic anti-psoriatic 
treatment
• History of allergic reaction or hypersensitivity 
to adalimumab
• Non-plaque psoriasis
• Recent infections
• HIV
• Hepatititis B or C
• Active tuberculosis
• History of malignancies
• Female patients who were breast feeding or 
pregnant, or considered becoming pregnant
Table 1. Patient characteristics.
SUM-score; score of erythema, infiltration and desquamation. Values represent mean (range).
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Ten patients, five male and five female with a mean age of 55 (range 42 – 73 years), 
received 16 weeks of adalimumab treatment. Initial dosing of 80 mg adalimumab 
subcutaneously was followed by 40 mg adalimumab subcutaneously every other 
week starting one week after the initial dose. Biopsies (diameter 4 mm) were taken 
before treatment and after 1.5 and 16 weeks of treatment. A washout period of 
1 month for systemic anti-psoriatic treatment and phototherapy was taken into 
account. To control disease severity during the wash-out period for systemic 
treatments, 4 patients used topical agents until baseline. Six patients banned the use 
topical treatments for at least 2 weeks prior to baseline. Upon scrutiny, it appeared 
that this did not influence the outcome of this treatment group.
The design of the study (CBD ointment as well as adalimumab) was approved by the 
local medical ethics committee. All patients gave their written informed consent and 
were recruited according to the Declaration of Helsinki. 
Immunohistochemistry
Tissue sections of 4 µm were generated out of paraffin-embedded biopsies. 
Immunohistochemical (IHC) stainings were performed as described before,18 using 
the following primary antibodies (Abs) and dilutions: CD4 1:100 (4B12; Monosan, 
Uden, The Netherlands) and Foxp3 1:100 (PCH101; eBioscience, San Diego, CA). 
In short, after deparaffination and rehydration, heat induced antigen retrieval was 
performed in Tris/EDTA (50 mM Tris + 2 mM EDTA, pH 9.0) during 10 minutes at 100 
°C. Endogenous peroxidase activity was blocked using 2% H₂O₂ in PBS. The sections 
were pre-incubated with 1% bovine serum albumin (BSA; Dako, Glostrup, Denmark) 
dissolved in PBS for 15 minutes. Primary Abs dissolved in 1% BSA were incubated over 
night at room temperature. After washing the slides, reactions were amplified using 
horseradish peroxidase (HRP) labeled polymer (Envision; Dako for CD4) or avidin-
biotin complex–HRP solution (1:50) (Vectastain ABC-elite kit; Vector-Laboratories, 
Burlingame, CA for Foxp3) depending on the species used. Abs were visualized with 
3,3’-diaminobenzidine tetrahydrochloride (DAB) solution (Sigma-Aldrich, St. Louis, 
MO). After counterstaining with Mayer’s Hematoxylin (Sigma-Aldrich), the sections 
were dehydrated and mounted. Substitution of the primary Abs with 1% BSA (Dako) 
dissolved in PBS served as a negative control. 
Foxp3 expressing cells were characterized by performing immunofluorescent (IF) 
double stainings as described before,18,19 using the following primary Abs and dilutions: 
Foxp3 1:50 (PCH101; eBioscience, San Diego, CA) and CD25 1:50 (4c9; Bio SB, Santa 
Barbara, CA). Epitope retrieval was conducted in Tris/EDTA during 1 minute at 100 °C 
(for Foxp3) and in citrate buffer (pH6.7; for CD25) during 15 minutes at at 100 °C. The 
sections were pre-incubated with 1% BSA (Dako) dissolved in PBS and subsequently 
with the primary Abs overnight at room temperature. The next day, a mix of matched 
secondary Abs at room temperature was added to the slides for 6 hours. Depending 
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on the combination used, secondary Abs that were covalently linked with IgG Alexa 
Fluor 488 (1:200; Invitrogen, Carlsbad, CA) and Alexa Fluor 594 (1:400; Invitrogen) 
were used. Counterstaining was done using DAPI 1:3 (Vector Laboratories).
Quantification of cells
An Axioskop2 MOT microscope (Zeiss, Oberkochen, Germany) and digital camera 
(Axiocam MRc5; Zeiss) were used to capture imaged of the dermis of the stained 
tissues. Of each section, 2 sequential photographs were taken at a magnification of 
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Figure 1. Representative immunofluorescent double-stainings for Foxp3 (green) and CD25 
(red) during treatment with CBD ointment (at t=0, t=1.5 and t=16) and adalimumab (at t=0 
and t=8). DAPI was used as a counterstaining. Bar=50 μm.
CBD ointment
adalimumab
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100x, thereby screening the whole length of the biopsy. As described before, ImageJ 
(National Institutes of Health, Bethesda, MD) was used to automatically count 
the positively stained cells in the dermis until a depth of 350 µm.18 Results were 
expressed as number of positive cells mm-2.
Statistical analysis
All results are expressed as means ± SEM. The data were considered to be 
nonparametrically  distributed. To test for differences between more than 2 groups, 
we performed a Friedman test followed by a Bonferroni correction to correct for 
multiple testing. To test for differences between 2 groups, we used the Wilcoxon 
matched-pairs signed rank test. A P value of <0.05 was considered to be statistically 
significant. Values were considered to be outliers when being higher/lower than the 
mean ± 2x SD. Consequently, one Foxp3 value was excluded from statistical analysis. 
Statistical analyzes were conducted using SPSS 20.0 (Statistical Package for Social 
Sciences, IBM, Armonk, NY).
Results
SUM-scores drop during treatment with CBD ointment and adalimumab
Clinical response was measured using the SUM-score (the sum of redness, thickness 
and scaling as used in the psoriasis area severity (PASI) score) of the selected 
target lesion. All biopsies were taken from the target lesions. Only patients with a 
SUM-score improvement of at least 50% during treatment were considered to be 
responders and were included in this study. Treatment with CBD ointment greatly 
improved the SUM-scores of the target lesions from 6.08 ± 0.31 at baseline to 1.33 ± 
0.31 after 8 weeks of treatment (P=0.0024, N=12) (unpublished data from Hendriks 
et al). Similarly, treatment with adalimumab also gave a SUM-score improvement, 
being 6.90 ± 0.35 at baseline, 6.00 ± 0.69 after 1.5 weeks of treatment and 0.40 ± 
0.27 after 16 weeks of treatment, respectively (P<0.0001 , N=9).17
Treatment with CBD ointment or adalimumab causes a decrease in the numbers of 
Treg in the skin of psoriatic patients that respond well to therapy
Treg were quantified by Foxp3 expression. All Foxp3+ cells co-expressed CD25 at all 
time-points before and during treatment with CBD ointment and adalimumab (Fig. 
1). Treg cell numbers in the dermis were quantified during anti-psoriatic treatment 
with CBD ointment or adalimumab. We found less Foxp3+ cells after 8 weeks of 
topical treatment with CBD ointment as compared to baseline (t=0: 149.99 ± 25.61; 
t=8: 51.31 ± 15.29, P=0.01, N=11) (Fig. 2a). This trend was observed for 11 out of 12 
patients (Fig. 2b).
56
Interestingly, we found a trend towards an up-regulation of the number of Foxp3+ cells 
after 1.5 weeks of systemic treatment with adalimumab (t=0: 98.39 ± 14.67; t=1.5: 
124.97 ± 25.54, P=0.074, N=10). Thereafter, the number of Foxp3+ cells declined, as 
was measured after 16 weeks of treatment (t=1.5: 124.97 ± 25.54; t=16: 34.19 ± 8.79, 
P=0.009, N=10) (Fig. 2c). This trend was observed for 8 out of 10 patients (Fig. 2d).
Foxp3/CD4 ratios behave differently on treatment with topical CBD versus systemic 
treatment with adalimumab 
Skin inflammation, and consequently the pathogenesis of psoriasis may be associated 
with defective Treg function. It is commonly accepted that proper Treg function is 
associated with a numerical balance between Treg and Teff cells.14 Until now, it is 
unknown how the balance of these cells in the skin is affected by treatment. Therefore 
we calculated Foxp3/CD4 ratios based on the immunohistochemical stainings, before 
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Figure 2. Treatment with CBD ointment and adalimumab causes a down regulation of Treg 
in the sporiatic skin skin. (a) Number of Foxp3+ cells mm¯² dermis before and after 8 weeks 
of treatment with CBD ointment. (b) In 11 out of 12 patients we found less Foxp3+ cells 
mm¯² dermis after 8 weeks of treatment as compared to baseline. (c) Number of Foxp3+ cells 
mm¯² dermis before, after 1.5 weeks and after 16 weeks of treatment with adalimumab. (d) 
In 8 out of 10 patients we observed an increase in the number of Foxp3+ cells mm¯² dermis 
after 1.5 weeks of treatment compared to baseline, while declining thereafter. ** Statistically 
significant difference of P < 0.01.
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and during treatment with CBD ointment and systemic treatment with adalimumab.
In 10 out of 12 patients that responded well to treatment with CBD ointment we 
observed a lower Foxp3/CD4 ratio after treatment than before treatment (t=0: 
0.41 ± 0.08; t=8: 0.22 ± 0.04, P=0.033, N=12) (Fig. 3a-b). However, in patients that 
responded well to treatment with adalimumab we found an increase in Foxp3/CD4 
ratio during treatment (t=0: 0.25 ± 0.04; t=1.5: 0.32 ± 0.06; t=16: 0.49 ± 0.10, P=0.15, 
N=10) (Fig. 3c). This trend was observed for 9 out of 10 patients (Fig. 3d). 
Discussion
It is generally known that proper Treg function is associated with a numerical balance 
between Treg and Teff cells and is measured by means of the Foxp3/CD4 ratio.14,18 
1   3   9   7   5   10  2   4   8  11           6   12t = 0 t = 8
t = 0 t = 1.5
a b
c d
t = 16 9   4   10  8   6   2   5   3   7         1
Figure 3. Foxp3/CD4 ratios during treatment, based on immunohistochemical stainings.
(a) Mean (± SEM) Foxp3/CD4 ratios of patients that were treated with CBD ointment.
(b) Foxp3/CD4 ratios set out for each patient (as numbered in Fig. 2) and grouped by similar 
trend. (c) Mean (± SEM) Foxp3/CD4 ratios of patients that were treated with adalimumab.
(d) Foxp3/CD4 ratios set out for each patient (as numbered in Fig. 3) and grouped by similar 
trend. * Statistically significant difference of P < 0.05.
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We found evidence that this balance in the skin is differently influenced, depending 
on the anti-psoriatic treatment that is given to the patient. Patients that responded 
well to therapy were included in this study. Topical treatment with calcipotriol-
betamethasone dipropionate (CBD) ointment leads to a decrease of the Foxp3/
CD4 ratio after 8 weeks of treatment, while 16 weeks of systemic treatment with 
adalimumab leads to a clear increase of this ratio. Although we observed a significant 
decrease in the presence of Foxp3+ cells as well as CD4+ cells during both treatments, 
patients that were treated with adalimumab seemed to preserve relatively more 
Treg than Teff cells as compared to patients that were treated with CBD ointment. 
As a result, adalimumab treated skin differs in local immune status from CBD treated 
skin, with regard to the anti-inflammatory/inflammatory balance. It is attractive to 
speculate that anti-TNFα therapy adalimumab promotes Treg preservation in the 
skin and that CBD ointment does not. Therefore CBD treated skin might be more 
prone to relapse. In peripheral blood of psoriatic patients, it has already been shown 
that anti-TNFα therapy induces an up-regulation of circulating Treg.10,11 Similarly, 
we also found an up-regulation of the number of Foxp3+ cells after 1.5 weeks of 
treatment with adalimumab, although this finding was not statistically significant as 
compared to t=0. Also for other diseases, such as rheumatoid arthritis (RA)23 and 
inflammatory bowel disease,24 it was found that anti-TNFα therapy enhances the 
number and function of circulating Foxp3+Treg. However, more recent studies in RA 
and Crohn’s disease patients, do not confirm these results.25,26 Proposed mechanisms 
for Treg induction by blocking TNFα come from in vitro studies. Valencia et al showed 
that TNF inhibits the function of CD4+CD25high Treg via TNFRII by down-regulating 
Foxp3 expression.27 However, it should be noted that in ex vivo expansion protocols 
Tregs can be stabilized by using TNFRII agonists.28 Therefore the precise function of 
TNF on Treg remains to be elucidated.
On a different note, it cannot be excluded that the differences in balance between 
Treg and Teff cells during treatment with CBD ointment vs treatment with adalimumab 
result from patient characteristics differing between the two treatment-groups. First, 
patients eligible for topical treatment were shown to differ from patients eligible for 
systemic treatment with respect to objective severity scores (PASI), patient reported 
outcomes and historical severity (treatment responses in the past).29  Even though 
the SUM-scores (scoring system of one single lesion) in both treatment groups 
were comparable, patients on adalimumab generally have a more extended disease 
than patients that are solely treated with topical agents. In patients treated with 
adalimumab more often the joints are affected by their psoriatic disease. Moreover, 
patients treated with adalimumab often have a lengthy treatment history and tried 
multiple treatments. Second, localization of the plaque may also influence the 
balance between Treg and Teff cells, taking into account that 25% of the patients 
koebnerize on external stimulation of the skin.30
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Importantly, the Foxp3/CD4 ratio is a numerical balance, associated with effective 
Treg function, but influenced by both arms. In any system with homeostasis, a 
dysbalance may occur when one of the cell populations changes. In this case, 
the balance may be influenced by either Treg or Teff cell numbers. Thus, the ratio 
represents the outcome of both cell populations relative to each other.
Naturally occurring Treg are generally identified by expression of transcription factor 
Foxp3, high expression of CD25 and low expression of CD127.31 Unfortunately, by 
using immunohistochemistry, we were unable to combine all these markers. Foxp3 
is not only expressed by Treg but also by activated T cells, albeit transiently and only 
for a short period of time.32 By staining for CD25 and Foxp3 (Fig. 1), we can say with 
increased certainty that the Foxp3+ cells we detected are indeed likely to be Treg. 
Previously, our group reported on Foxp3/CD4 ratios found in the transition from 
symptomless to lesional psoriatic skin.18 We observed relatively high Foxp3/CD4 
ratios in symptomless skin of psoriatic patients suggesting active immune controlling 
mechanism distant from the psoriatic plaque, while in the psoriatic plaque this ratio 
was lower and appeared skewed towards effector cells associated with inflammation. 
Interestingly, treatment with adalimumab seemed to restore the Foxp3/CD4 ratios 
towards a level that is comparable to the symptomless skin of psoriatic patients 
(adalimumab; 0.49 ± 0.10; symptomless skin: 0.67 ± 0.20,18 respectively). 
In conclusion, previous studies showed that circulating Treg numbers in psoriasis are 
enhanced by treatment with anti-TNFα.10,11 Here, as a first, we report on numbers of 
Treg in the skin during topical as well as systemic treatment. As a measurement of 
Treg function, we calculated the balance between Treg and Teff cells. In the skin of 
patients treated with adalimumab we found a trend towards enhanced preservation 
of Treg as compared to Teff cells, in contrast to the skin of patients treated with CBD 
ointment. It is attractive to hypothesize that adalimumab attributes to self-tolerance 
in the skin of psoriatic patients. Consequently, cutaneous Treg preservation might 
thus contribute as an additional mechanism, to the mode of action and clinical 
improvement of patients on adalimumab.
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Abstract
Background Regulatory T cells (Treg) prevent autoimmunity and are necessary to 
maintain immune homeostasis. Hence, dysfunction or low numbers of Treg have 
been associated with development of chronic (auto)immune inflammation. In 
psoriasis, a Th17 cytokine-associated disease, it was found that circulating Treg 
easily differentiate into IL-17 producing Treg in vitro and lose Foxp3 expression. We 
hypothesized that this so-called Treg instability might also occur in CD4+CD25high Treg 
obtained from patients with chronic inflammatory skin disease atopic dermatitis 
(AD), which unlike psoriasis, is known as a Th2-associated disease. 
Methods Peripheral blood was drawn from 10 patients with AD and 9 healthy controls. 
CD4+CD25high cells (Treg)  were isolated using high purity FACS sorting. Subsequently, 
ex vivo stimulation cultures were performed and studied by flowcytometry.
Results We found that isolated peripheral CD4+CD25high Treg from patients with 
AD have an increased potential to produce IL-4 compared to healthy controls. This 
process was accompanied by easy loss of Foxp3 expression, suggesting Treg instability 
in AD patients. Profound IL-4 production was especially found in Treg that lost Foxp3. 
Notably, also GATA-3 which was recently demonstrated to be crucial for immune 
tolerance, by sustaining Foxp3 stability in Treg, was lost in these IL-4 producing Treg. 
Conclusions As shown for Treg in psoriasis, rheumatoid arthritis, multiple sclerosis 
and inflammatory bowel disease, also Treg in AD reveal an unstable phenotype. In AD 
this phenotype is associated with an increased producing potential of Th2 cytokine 
IL-4 and increased loss of the Treg supporting transcription factors Foxp3 and GATA-3.
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Introduction
Foxp3+ CD4+ CD25high regulatory T cells (Treg) play a key role in maintaining immune 
tolerance due to their capacity to suppress the effector functions of lymphocytes 
and antigen presenting cells.1 Here we focus on peripheral CD4+CD25highCD127low 
Foxp3+ cells, so called naturally occurring Treg.2 Foxp3 expression is obligate for a 
stable Treg phenotype.3 Recently it was demonstrated that transcription factor GATA-
3 is crucial for Foxp3+ Treg stability.4 Dysfunction of Treg has been associated with 
several human chronic (auto)inflammatory diseases, including skin diseases such as 
psoriasis and atopic dermatitis (AD).5 In psoriasis, a T helper (Th) 1 (interferon (IFN) 
γ)) and Th17 (interleukin (IL)-17A) cytokine mediated skin disease, it was shown that 
Treg of patients had an impaired suppressive capacity6,7 and could easily differentiate 
into proinflammatory cytokine (eg. IL-17A)-producing cell types.7 Conversion of Treg 
into proinflammatory cells has been shown in various (auto)inflammatory diseases 
such as psoriasis,7 multiple sclerosis,8 arthritis9 and inflammatory bowel disease.10 
AD is predominantly considered to be a Th2 cytokine (IL-4, IL-5 and IL-13)-mediated 
disease.11 AD is a prominent symptom in patients with IPEX (immune dysregulation, 
polyendocrinopathy, entheropathy, X-linked) syndrome, where mutations in FOXP3, 
the gene needed for expression of the Treg transcription factor Foxp3, cause Treg 
deficiency.2 These findings paved the way to study Treg in AD. Interestingly, patients 
with AD have increased numbers of Treg in peripheral blood compared to healthy 
controls.12-14 Based on these findings it was hypothesized that not the quantity of 
Treg, but rather the quality of Treg plays a role in the pathogenesis of AD. 
It has been established that human CD4+CD25high Treg show plasticity and can 
differentiate into IL-17A-producing cells.15-17 However, there are also indications 
that human CD4+CD25high Treg can produce Th2 cytokines.14,15,18 In line with reduced 
stability of Treg in psoriatic patients, marked by an increased potential to produce 
IL-17A and heightened loss of Foxp3 expression, we hypothesized that Treg from 
patients with AD have an instable phenotype characterized by an increased potential 
to differentiate in to IL-4-producing Th2 cells with reduced Foxp3 and GATA-3 
expression. 
Methods
Peripheral blood was drawn from 10 patients (male:female, 6:4; age, mean ± SD, 49.3 
± 7.4 years) with AD and 9 healthy controls (male:female, 1:8; age, mean ± SD, 26.6 ± 
0.8) according to the Declaration of Helsinki principles and after approval by the local 
medical ethics committee. Mild AD was defined as Body Surface Area (BSA) of being 
affected for less than 15% (n=3) and moderate-severe AD was defined when the 
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BSA was affected for more than 15% (n=7). All patients signed for informed consent. 
Patients on systemic medications or undergoing phototherapy were excluded from 
participation. The use of topical agents was allowed. 
T cell phenotyping on peripheral blood mononuclear cells (PBMCs) was performed 
as previously described.7 After positive selection of CD4+ T cells using magnetic 
activated cell sorting CD4-beads (Miltenyi Biotec GmbH, Bergisch Gladbach, 
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Figure 1. Intracellular cytokine production by CD4+ cells. Intracellular flow cytometry of 
IL-4, IL-17 and IFNγ-production by freshly isolated CD4+ T cells or CD4 gated cells derived 
from healthy controls (n=9) and patients with AD (n=10), upon 4 hours of stimulation with 
phorbol-12-myristate 13-acetate plus ionomycin in the presence of Brefeldin A. (a) Flow 
cytometry of intracellular cytokine production and Foxp3 expression in CD4+ cells from 
healthy controls (upper panel; n=9) and patients with AD (lower panel; n=10). Representative 
dotplots are shown of Foxp3 (X-axis) and IL-4/IL-17/IFNγ (Y-axis) expression. (b) Summarized 
flow cytometry data, showing percentages of IL-4/IL-17/IFNγ-producing cells (Y-axis). Each 
data point represents one separate experiment conducted on cells from healthy controls (left 
panel) and patients with AD (right panel).
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Germany), CD4+CD25high (Treg) and CD4+CD25- conventional T cells (Tconv) were 
isolated by high-purity flow cytometric cell sorting using using FacsAria cell sorter 
(BD Biosciences, San Jose, CA, USA) (purity >98%) and stimulated with CD3/CD28 
beads (ratio 1:5; Gibco Life Technologies, Oslo, Norway) plus IL-2 (25U/ml; IL-2, 
Novartis Pharma GmbH, Nürnberg, Germany). The gate settings were defined based 
on isotype controls. Results were expressed as mean ± SEM. Statistical comparisons 
between different subject groups were calculated using a one or two-tailed Mann-
Whitney’s U-test.
Results
As reported by others,12-14,19 we confirmed an increase in the absolute number of 
CD4+CD25highCD127low Treg in peripheral blood of patients with moderate-severe 
AD (n=7) as compared to healthy controls (n=7) (7.6*105 ± 2.5*105 and 1.9*105 ± 
2.7*104, respectively; P=0.0041). As expected, CD4+CD25highCD127low cells expressed 
the transcription factor Foxp3 (data not shown). 
Next, we analyzed the cytokine producing potential of freshly isolated cells, including 
CD4+Foxp3+ Treg, by flow cytometric intracellular cytokine staining after stimulating 
the cells with phorbol-12-myristate 13-acetate (PMA) plus ionomycin in the presence 
of brefeldin A for 4 hours.15 In contrast to CD4+Foxp3- conventional T cells (Tconv), 
CD4+Foxp3+ Treg were hardly able to produce cytokines such as IL-4, IL-17A or IFNγ 
(Fig. 1a). No differences in intracellular cytokine producing potential were observed 
between AD patients (n=10) and healthy volunteers (n=9) (IL-4: 6.33 ± 2.47 vs 4.80 ± 
1.48, P=0.55; IL-17: 2.00 ± 0.34 vs 1.79 ± 0.44, P=0.66; IFNγ: 12.42 ± 3.20 vs 12.67 ± 
1.73, P=0.66) (Fig. 1b). 
To study possible conversion of Treg into proinflammatory cytokine producing cells, 
high purity fluorescence activated cell sorting (FACS; BD Biosciences, San Jose) isolated 
CD4+CD25high Treg were stimulated ex vivo with CD3/CD28-beads plus recombinant 
IL-2 for 7 days. FACS-sorted CD4+CD25- Tconv were included for comparison. Next, 
the intracellular cytokine (IL-4, IL-17A and IFNγ)-producing potential of these ex vivo 
cultured Treg was measured by flow cytometry. Interestingly, we found significantly 
higher percentages of IL-4-producing cells in case of Treg derived from AD patients 
(n=5) as compared to healthy controls (n=5) (IL-4: 35.09 ± 3.67 vs 20.46 ± 1.62, 
P=0.0079), while the potential to produce IL-17 and IFNγ was similar between 
healthy controls and AD patients (IL-17: 0.88 ± 0.73 vs 0.59 ± 0.21, P=0.60; IFNγ: 0.63 
± 0.36 vs 0.85 ± 0.25, P=0.84) (Fig. 2a & b). This process was not influenced when the 
cells were stimulated under Th2 or Th17 polarizing conditions (data not shown). In 
contrast, the IL-4, IL-17A and IFNγ-producing capacity of Tconv was similar between 
AD patients (n=5) and healthy controls (n=5) (IL-4: 11.71 ± 2.86 vs 16.19 ± 3.67, 
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P=0.42; IL-17: 0.03 ± 0.02 vs 0.23 ± 0.14, P=0.67; IFNγ: 0.98 ± 0.67 vs 1.79 ± 1.13, 
P=0.31), indicating that the heightened conversion of Treg into an IL-4-producing 
phenotype is a specific hallmark for the Treg cell lineage in AD patients.
After having established that Treg from AD patients have a strong potential to 
produce the Th2 cytokine IL-4, we wondered whether this feature was accompanied 
by the loss of the transcription factor Foxp3. Indeed, Treg from patients with AD 
(n=5) showed an increased loss of Foxp3 upon ex vivo stimulation as compared to 
Treg from healthy controls (n=5) (44.37 ± 5.06 vs 61.64 ± 6.27, P=0.0476) (Fig 3a 
& b). Profound IL-4 production was observed in the Treg population that had lost 
Foxp3 (Fig. 4a). Remarkably, these IL-4-producing cells also lost the expression of 
transcription factor GATA-3 (Fig. 4b). This is of interest since GATA-3, next to its role 
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Figure 2. Ex vivo stimulated CD4+CD25high cells from patients with AD show enhanced IL-4 
production. Flow cytometry of intracellular IL-4/IL-17/IFNγ production after stimulation with 
CD3/CD28 beads and recombinant IL-2 for 7 days. (a) Representative dotplots are shown of 
IL-4-production (X-axis) by CD4+CD25high (Treg) cells derived from a healthy control (left panel; 
n=5) and a patient with AD (right panel; n=5). Cells were gated on CD3. (b) Summarized flow 
cytometry data, showing percentages of IL-4/IL-17/IFNγ-producing cells (Y-axis). Experiments 
were performed in 5 healthy controls (left panel) and 5 patients with AD (right panel). Note 
that the values on Y-axes vary.
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in Th2 polarization20,21 has shown to be critical in Foxp3 stability.22 Freshly isolated 
Treg are typically Foxp3+ and GATA-3- (data not shown), while ex vivo stimulation 
with antiCD3/CD28 beads + IL-2 results in co-expression of both transcription factors, 
as was also shown by Wohlfert et al.4 Apparently Treg of AD patients have a higher 
propensity to lose both of these Treg stability supporting transcription factors. 
Discussion
In conclusion, our findings indicate that Treg in patients with AD have an instable 
phenotype that is characterized by an increased potential to produce IL-4 and 
loss of the Treg stabilizing transcription factors Foxp3 and GATA-3. Although GATA-
3 is known as a prototypic Th2 driving transcription factor20,21 it has recently been 
demonstrated that GATA-3 is crucial for Foxp3 stability, thereby exerting a critical 
function in regulating immune tolerance.22 In mice, deletion of GATA-3 in Treg led 
to an inflammatory syndrome that can be ascribed to dysfunctional Treg.22 In fact, 
Foxp3 expression was down-regulated in GATA-3 deficient Treg.22 Furthermore, it 
appeared that GATA-3 limits Treg polarization towards an effector T cell phenotype.4 
Here we found that strong IL-4 production by Treg from AD patients is associated 
with a reduced expression of both Foxp3 and GATA-3. This deficiency in Treg from AD 
patients might play a role in the pathogenesis of AD. 
Recently it has been shown that human CD4+CD25high Treg can produce Th2-like 
100          101          102       103
50
40
30
20
10
0
Co
un
t
Foxp3
Healthy control AD patienta b
100          101          102       103
50
40
30
20
10
0
Co
un
t
Foxp3
80
60
40
20
0F
ox
P3
 e
xp
re
ss
io
n
Treg
Figure 3. Ex vivo stimulated CD4+CD25high cells from patients with AD show a reduced 
number of Foxp3 expressing cells. Flow cytometric results are shown after stimulation with 
CD3/CD28 beads and recombinant IL-2 for 7 days. (a) Histograms of Foxp3 expression (X-axis) 
and number of events (Y-axis) are shown for a representative healthy control (left panel; n=5) 
and a patient with AD (right panel; n=5). Percentages of Foxp3-expressing cells are indicated 
in the histograms. Cells were gated on CD3. (b) Summarized data showing percentages of 
Foxp3 expressing cells (Y-axis) in CD4+CD25high cells from healthy controls (left panel; n=5) 
and patients with AD (right panel; n=5).
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cytokines cells.14,15,18,23 Here, studying intracellular cytokine production at the single 
cell level we demonstrate that ex vivo stimulation of isolated Treg from AD patients 
leads to an increased percentage of IL-4 producing cells as compared to healthy 
controls. This is in contrast to the findings of Reefer et al.,14  who showed that ex vivo 
stimulated Treg can produce IL-5 and IL-13, as measured in the culture supernatants, 
but were unable to demonstrate that Treg of AD patients showed higher level of these 
Th2 cytokines as compared to healthy controls. Differences in detection methodology 
and ex vivo culture conditions might very likely explain this discrepancy.
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Figure 4. Profound IL-4 production was especially observed in Foxp3- and GATA-3- cells. 
Flow cytometric results after stimulation with CD3/CD28 beads and recombinant IL-2 for 7 
days. Representative dotplots of a healthy control (left panel; n=5) and patient with AD (right 
panel; n=5) are shown. (a) Profound IL-4 production (X-axis) was especially observed in Foxp3 
negative cells. (b) Loss of Foxp3 expression (Y-axis) coincided with loss of GATA-3 expression 
(X-axis).
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Instability of human Treg, characterized by loss of Foxp3 expression and production 
of IL-17A, has been previously described in Treg from healthy donors.15-17 Increased 
differentiation of Treg into proinflammatory cytokine (IL-17A and IFNγ)-producing 
cells has been shown in various Th1- and Th17-associated (auto)inflammatory 
diseases, such as psoriasis.7-10 Here we demonstrate that a similar phenomenon 
might occur in Treg derived from patients with Th2-associated inflammatory skin 
disease AD. If Treg convert, depending on the disease associated cytokine milieu, 
into Th1, Th2, or Th17 like cells24 or whether (epi)genetic changes drive a Th1,Th2 or 
Th17 profile in Treg that subsequently contribute to a Th1, Th2 or Th17 associated 
disease, is an open question. 
In conclusion, CD4+CD25high Treg derived from patients with AD showed enhanced IL-4 
production as compared to healthy controls. This Treg instability was associated with 
loss of Foxp3. After ex vivo activation, coexpression of Foxp3 and GATA-3 is necessary 
to maintain a stable Treg phenotype. Conversion of Treg into a Th2 phenotype may 
contribute to the pathogenesis of AD, as was also described for other inflammatory 
diseases.7-10 A better understanding of this Treg conversion might help in designing 
new therapeutics for the treatment of AD.
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Abstract
Humanized mouse models offer a challenging possibility to study human cell function 
in vivo. In the huPBL-SCID-huSkin allograft model human skin is transplanted onto 
immunodeficient mice and allowed to heal. Thereafter allogeneic human peripheral 
blood mononuclear cells are infused intra peritoneally to induce T cell mediated 
inflammation and microvessel destruction of the human skin. This model has great 
potential for in vivo study of human immune cells in (skin) inflammatory processes 
and for preclinical screening of systemically administered immunomodulating 
agents. 
Here we studied the inflammatory skin response of human keratinocytes and 
human T cells and the concomitant systemic human T cell response. As new findings 
in the inflamed human skin of the huPBL-SCID-huSkin model we here identified:
1. Parameters of dermal pathology that enable precise quantification of the local 
skin inflammatory response exemplified by acanthosis, increased expression of 
human β-defensin-2, Elafin, K16, Ki67 and reduced expression of K10 by microscopy 
and immunohistochemistry. 2. Induction of human cytokines and chemokines using 
quantitative real-time PCR. 3. Influx of inflammation associated IL-17A-producing 
human CD4+ and CD8+ T cells as well as immunoregulatory CD4+Foxp3+ cells using 
immunohistochemistry and -fluorescence, suggesting that active immune regulation 
is taking place locally in the inflamed skin. 4. Systemic responses that revealed 
activated and proliferating human CD4+ and CD8+ T cells that acquired homing 
marker expression of CD62L and CLA. Finally, we demonstrated the value of the newly 
identified parameters by showing significant changes upon systemic treatment with 
the T cell inhibitory agents cyclosporine-A and rapamycin.
In summary, here we equipped the huPBL-SCID-huSkin humanized mouse model 
with relevant tools not only to quantify the inflammatory dermal response, but 
also to monitor the peripheral immune status. This combined approach will gain 
our understanding of the dermal immunopathology in humans and benefit the 
development of novel therapeutics for controlling inflammatory skin diseases.
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Introduction
The in vivo study of human biological processes is severely limited by ethical and 
technical constraints. An attractive relevant alternative is the use of humanized mice 
or “mouse-human chimaeras”. Humanized mice are immunodeficient mice that are 
engrafted with human tissue or cells, such as hematopoietic stem cells (HSCs) or 
peripheral blood mononuclear cells (PBMC). Humanized mice offer a valuable tool 
in pre-clinical drug testing in translational medicine and investigations of human 
biology in areas like cancer, (auto)inflammation/immunity, infectious diseases and 
immunotherapy.1,2
Several humanized mouse models have been described to study T cell mediated 
skin diseases.3-7 In these models, healthy human skin, diseased-prone skin or 
bioengineered skin is transplanted onto immunodeficient mice, allowed to become 
vascularized and heal, and in some of these models human immune cells are 
infused that will reconstitute the recipient with human immune cells to induce skin 
inflammation.5,6 Although all these models have advantages and disadvantages their 
application to drug discovery and for the development of cellular therapies has 
already proven to be fruitful.8-11
To study the local inflammatory as well as the systemic human T cell response in 
vivo we focused on the human peripheral blood lymphocyte reconstituted severe 
combined immunodeficient mouse (SCID) human skin allograft model (huPBL-SCID-
huSkin model) initially described by Pober’s group.5,6 In this model human skin is 
transplanted on to immunodeficient SCID/beige mice, and since these recipients 
lack functional mature T and B cells and have impaired NK cell- and macrophage 
function,12,13 human skin is revascularized and accepted. After healing of the human 
skin, allogeneic human PBMC are infused intra peritoneally (i.p.), resulting within 2–3 
weeks in microvascular cell injury and human T cell infiltration of the human skin.5,6 
This model is of particular interest to study the local pathology of skin inflammation. 
For this purpose it is crucial to be able to quantify the cutaneous inflammatory 
response by clinical relevant parameters associated with dermal inflammation, such 
as inflammation-associated deregulated expression of keratinocyte differentiation 
markers and characterization and enumeration of skin infiltrating human lymphocytes. 
This information has not previously been published regarding this model.
Most studies on inflammation in humanized mouse models focus on the local site of 
inflammation. A caveat in these humanized mouse models is the study of the systemic 
immunological response, which besides the local site of inflammation is crucial in the 
generation and regulation of the immune program (e.g. effector T helper (Th)1, Th2, 
Th17, or regulating suppressor Treg). Important steps in mounting a T cell immune 
response include T cell activation, differentiation and expansion in the draining lymph 
nodes. Activated T cells leave the lymph node via the efferent lymphatics and enter 
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the circulation through the lymph-vascular system and depending on their homing 
imprint the cells migrate into tissues or colonize other immune compartments.14,15 
Moreover, inflammatory skin diseases, such as moderate to severe psoriasis, are 
traditionally treated with systemic medication such as methotrexate, retinoids, and 
cyclosporine A and more recently with biologicals such as anti-tumor necrosis factor 
(TNF) or anti-p40 therapy. This systemic treatment will not only influence the local 
skin immune response, but will also interfere systemically with T cell activation, 
differentiation, expansion and homing. At present, little information is available on 
the effects of systemic medication on systemic immune responses in humanized 
mouse models. This information is crucial to identify treatment-related systemic 
biomarkers for immunomonitoring of patients undergoing clinical trials.
In the present study, both local human skin inflammatory processes as well as 
systemic human CD4+ and CD8+ T cell responses in the huPBL-SCID-huSkin model 
were studied. As new findings in this model we identified relevant markers of human 
skin pathology such as aberrant expression of hBD2, Elafin, keratin-10 (K10) and 
keratin-16 (K16), enabling quantification of the local skin inflammatory response by 
keratinocytes, markers for T cell mediated responses in the skin, as well as, chemokine 
and cytokine induction and analysis of IL-17A-producing and Foxp3+ T cells. Also, we 
determined markers that enable quantitative analysis of systemic immune activation 
responses. Human skin inflammation was paralleled by the presence of CD4+Foxp3+ 
T cells, suggesting that immune regulatory pathways are serving to limit human 
tissue inflammation. Unraveling these pathways of human cells in this in vivo model 
will undoubtedly offer novel therapeutic strategies for controlling autoimmune 
tissue responses.
Methods
Mice
Female B17.B6-PrkdcscidLyst bg/Crl (SCID/beige) mice, 6–8 weeks old, were purchased 
from Charles River Breeding Laboratories and housed in the SPF (specifi-pathogen-
free) facility of the Central Animal Laboratory of the Radboud University Nijmegen 
Medical Centre (RUNMC). All the animal experimental procedures were in 
accordance with the international welfare guidelines taking in consideration the 
3Rs (Refinement, Reduction, Replacement) and approved by the institutional ethical 
animal care committee of the Radboud University Nijmegen (number 2008167).
Humanized mouse model; huPBL-SCID-hu Skin allograft model
The huPBL-SCID-hu Skin allograft model used in our study is with slight adaptations 
based on the model described by Murray et al.5 Superficial human skin, 600 to 700 µm 
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thick, was harvested using a dermatome and kept in culture medium with penicillin/
streptavidin at 4°C and within max. 30 hours transplanted onto the back of SCID/beige 
mice. Abdominal skin from healthy individuals was obtained from elective surgeries 
through the RUNMC Department of Plastic Surgery. After healing of the human skin 
(21 days), 150×106 ficoll density gradient isolated (Lymphoprep; Nycomed-Pharma 
AS, Oslo, Norway) human peripheral blood mononuclear cells (huPBMC), obtained 
from buffy coats of blood donors, purchased from Sanquin Blood Bank, Nijmegen, 
The Netherlands, were infused i.p in a volume of 0.8 ml phosphate buffered saline 
(PBS). Mice were killed at the end of the experiment and tissues of interest were 
collected.
The use of human skin and peripheral blood were approved and in accordance with 
the regulations set by the Medical Ethical Committees for human research of the 
RUNMC. Human skin and buffy coats from healthy donors, who gave written informed 
consent for scientific use of the human materials. Buffy coats were purchased from 
Sanquin Blood Bank, Nijmegen, The Netherlands
Drug treatment
Cyclosporine–A (Sandimmune, Novartis®) was administered at a concentration of 0.4 
mg/kg/day s.c. via mini-osmotic pump (pumping rate was 1 µl/h , reservoir volume 
200 µl). The control group was implanted with a mini-osmotic pump filled with PBS. 
Rapamycin was injected intraperitoneally (i.p.) at a dose of 0.4 mg/kg body weight 
in a volume of 100 µL PBS at alternating days, starting 7 days after the infusion of 
huPBMC.
Histology & Immunohistochemistry
Human skin grafts were fixed in neutral buffered 4% formalin (Mallinckrodt Baker, 
Inc Deventer, The Netherlands) for 4 hours, processed and embedded in paraffin. 
Sections (6 µm) were stained with hematoxilin and eosin (H&E) or processed for 
immunohistochemical staining.
Keratinocyte differentiation was analyzed using primary, antibodies directed 
against: Elafin (rabbit 92-1), hBD-2 (ab9871, Peprotech, London,UK), K10 (RKSE60, 
Eurodiagnostica) and K16 (LL025, Novocastra Laboratories, Newcastle upon 
Tyne,UK). Cell division was studied using antibodies against Ki67 (MiB-1, Dako 
cytomation). To enumerate CD4+ and CD8+ T cells antibodies against CD4 (BC/F6, 
Santa Cruz Biotechnology, Santa Cruz, CA) and CD8 (144B, Dako Cytomation) were 
used. IL-17 production was detected using polyclonal goat IL-17A antibody (R&D-
systems). To detect Foxp3 expression anti-FoxP3 (PCH101) was used. To detect the 
presence of human neutrophils and mast cells, antibodies against human neutrophil 
elastase (NP57; Dako) or human mast cell tryptase (AA1; Dako) were used. Antibody 
stainings were visualized using the Dako Cytomation EnVision+system-HRP (ABC) 
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kit (DAKO, Glostrup, Copenhagen, Denmark) combined with 3,3′-diaminobenzidine 
tetrahydrochloride (DAB, brown) (Sigma-Aldrich, St. Louis, USA) or using that 
Labeled Streptavidin Biotin method (Universal LSAB Kit/AP; Dako) combined with 
either Permanent Red (Dako) or 5-Bromo-4-Chloro-3-Indolyl Phosphate/Nitro Blue 
Tetrazolium (BCIP/NBT) (Dako).
Sections were photographed using a microscope (Axioskop2 MOT; Zeiss, Sliedrecht, the 
Netherlands), digital camera (Axiocam MRc5; Zeiss) and AxioVision software (Zeiss).
Image analysis of immunohistochemistry
To enumerate huCD4+ and huCD8+ cells, representative pictures were made at 10× 
magnification. A representative region of interest (ROI) was drawn from the lowest 
epidermal papilla till 300 µm dept into the dermis. Cell quantification was performed 
by setting a threshold and relating this to a number of cells per mm2. For evaluation 
of number of CD4+ and CD8+ IL-17A-secreting cells, double-positively stained cells 
were counted manually in CD4 CD8 infiltrated areas of the tissues and the numbers 
were reported per mm2. Ki67+ cells were counted manually and related to the length 
of basement membrane. For quantification of hBD-2, Elafin, K10 and K16 positive 
cells, photographs were made at 10× magnification. The total epidermal area and K10 
or K16 positive area was measured in the ROI (epidermal compartment). Epidermal 
differentiation was defined as: % K10 or K16 positive epidermal area. Each photo was 
analyzed using ImageJ software (NIH, http://rsb.info.nih.gov/ij).
Determination of epidermal thickness
Histologic assessment of the grafts was performed by light microscopy both before 
and after transplantation of human skin. The mean epidermal thickness was 
calculated using the program Visiopharm Integrator System (Visiopharm, Hørsholm, 
Denmark) as epidermal area divided by epidermal surface length.
Flow cytometry
Mesenteric/peripheral lymph nodes and spleen were processed to obtain a single 
cell suspension. Retro-orbital blood samples were collected and lymphocytes were 
isolated by density gradient centrifugation. For cell surface staining, the following 
conjugated mAbs were used: anti-CD45 PE (Beckman-Coulter), anti-CD3 PE (Beckman-
Coulter), anti-CD4 PE-Cy7 (SFCI12T4D11, Beckman-Coulter), anti-CD8 PE-Cy5(B9.11 , 
Beckman-Coulter), anti-CD62L (DREG56, Beckman-Coulter) anti-CD45RA FITC (HI100, 
BD), anti-CD45RO ECD (UCHL1, Beckman-Coulter) and anti-CLA FITC (HECA-452, BD). 
Intracellular Foxp3 staining was performed after fixation and permeabilization of the 
cells as indicated by the supplier (Ebioscience). Cell samples were measured on a 5 
color FC500 flowcytometer (Beckman-Coulter), and the data were analyzed using 
CXP software (Beckman-Coulter).
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Gene expression analysis
Tissues were homogenized using a TissueLyser (Qiagen). RNA was extracted using 
the RNeasy Lipid Tissue Mini Kit (Qiagen) and reverse-transcribed by use of the High-
Capacity cDNA Reverse Transcription Kit (Applied Biosystems). The samples were 
amplified by quantitative real-time Polymerase Chain Reaction (PCR) using Applied 
Biosystems validated gene expression assays and PRISM7900HT sequence detection 
system (SDS 2.3). Expression of GAPDH was used for normalization and fold changes 
calculated by the comparative Ct method.
Gene expression assay ID: IL1B-Hs00174097_m1, IL6-Hs00985639_m1, IL8-
Hs00174103_m1, CCL5-Hs00174575_m1, CCL20-Hs00171125_m1, CXCL1-
Hs00236937_m1, CXCL10-Hs00171042_m1, DEFB4-Hs00823638_m1, 
IFNG-Hs00174143_m1, IL12B-Hs00233688_m1, IL23A-Hs00372324_m1, 
IL17A-Hs00174383_m1, IL22-Hs00220924_m1, IL20-Hs00218888_m1, GAPDH-
Hs99999905_m1.
Statistics
The results were analyzed by a two-tailed Mann Whitney t test using GraphPad Prism 
software. *, P value <0.05; **, P value <0.01; ***, P value <0.001.
Results
Acanthosis and aberrant epidermal marker expression of hBD2, Elafin, K10 and K16 
in the inflamed human skin in the huPBL-SCID-huSkin allograft model
Here we set out to define and quantify clinical relevant epidermal parameters in the 
inflamed human skin the huPBL-SCID-huSkin allograft model as initially described by 
Pober’s group.5,6 The model in brief, after grafting and healing of human skin onto 
immunodeficient SCID beige recipients, allogeneic human PBMC are infused i.p. which 
results in microvessel destruction and human T cell influx of the human skin graft.5,6
Using histological microscopic examination of the human skin (Fig. 1a) we 
demonstrated hyperkeratosis (thickened keratinized upper layer), parakeratosis 
(nucleated keratinocytes in the cornified layer), acantosis (abnormal epidermal 
thickening, 155,1 ± 10,6 vs 315,9 ± 39,4 µm; PBS vs huPBMC, resp, P <0,01)(Fig. 1b), 
exocytosis (lymphocytes in the epidermis), spongiosys (intercellular edema between 
the keratinocytes and elongated rete ridges (fingerlike epidermal projections into the 
dermis) such as often observed in psoriatic lesions (Fig. 1a).
Using immunohistochemistry we quantitatively demonstrated that the changes in 
skin morphology were paralleled by a significant induction of keratinocyte associated 
inflammatory markers such as human β-defensin-2 (hBD2; 12,5 ± 2,1 vs 31,7 ± 10,9, 
P <0,01), Elafin (22,4 ± 2,5 vs 43,0 ± 14,7, P <0,05) and the hyper-proliferative marker 
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K16 (11,3 ± 1,0 vs 38,6 ± 12,5, P <0,01) , and down regulation of normal supra-basal 
K10 (59,3 ± 1,6 vs 11,6 ± 4,9, P <0,01) (Fig. 1c).
Up-regulation of Ki67 expression by the keratinocytes indicated the presence of 
an increased number of dividing cells in the epidermis, which supports ongoing 
epidermal hyper-proliferation (Fig. 1d). Normal supra-basal K10 expression was 
found in the human skin transplants in the absence of PBMC infusion, indicating that 
the transplant procedure did not disturb normal supra-basal K10 expression (Fig. 1c).
In summary, as a new finding we defined deregulated epidermal marker expression 
of hBD2, Elafin, K10, K16 and Ki67 in the inflamed human skin of the huPBL-SCID-
huSkin model that can be employed to analyze the local inflammatory skin response 
in quantitative way.
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Human T cell infiltration and detection of human chemokines and cytokines in the 
inflamed human skin
Next to the epidermal changes described above, we found mononuclear cell 
infiltrates, including human CD3+ T cells, with a diffuse distribution throughout 
the human skin, but not in the mouse skin (Fig. 2a+b). Control mice that were 
transplanted with human skin and which received PBS instead of huPBMC showed 
no evidence of inflammation in either epidermis or dermis (Fig. 1a).
Inflammation of lymphocytes is regulated by proinflammatory cytokines and 
chemokines that attract these immune cells. To assess if human cytokines and 
chemokines might be involved in the development of skin inflammation in the huPBL-
SCID/skin allograft model we determined gene expression levels in the skin grafts using 
quantitative real time PCR (qPCR). To this end the human skin grafts were removed 
Figure 1. Acanthosis and aberrant epidermal marker expression of hBD2, Elafin, K10 and 
K16 in the inflamed human skin of the huPBL-SCID-hu Skin allograft model. (a) Histology 
(H&E staining) of human skin grafts from SCID beige mice 21 days after infusion (i.p.) of 
huPBMC. Representative photographs are shown after PBS (left photograph) and huPBMC 
infusion (right photograph). Photograph shows increased epidermal thickness (acanthosis) 
and elongated fingerlike epidermal projections into the dermis (rete ridges) and large 
lymphocyte infiltration after huPBMC infusion. Abnormal presence of nuclei in the stratum 
corneum (parakeratosis) and infiltration of lymphocytes in the epidermis (exocytosis) 
(bottom-right photograph). 20x, 20x, 40x magnifications respectively. (b) Quantitative 
microscopic histological analysis of the epidermal thickness (mm) of human skin grafts 
following infusion of PBS and huPBMC. Mean ± SEM are shown for n=3 and 6 upon PBS and 
huPBMC infusion resp. (c) Immunohistochemistry of K10, K16, hBD2 and Elafin (brown) in 
human skin grafts from SCID beige mice 21 days after infusion (i.p.) of PBS (top panels) or 
huPBMC (lower panels). Photographs show representative examples, summarized data are 
given in the figures. Mean ± SEM percentages of the area positive for the indicated markers 
is shown for n=3 and 5–8 upon PBS and huPBMC infusion resp. 10x magnification. (d) Ki-
67 expression (brown) in the stratum basale of the epidermis. The insert shows a higher 
magnification. A representative example of n=12 is shown. 20x magnification. Graphs show 
summarized data of Ki67+ cells/mm length of basement membrane after PBS or huPBMC 
infusion in human skin biopsies (mean ± SEM, of n=4 and 6, resp.).
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21 days after infusion of PBMC, at this time point clear inflammation hallmarks were 
observed by histology and immunohistochemistry (Fig. 1,2a). From the centre of the 
human skin grafts 4 mm punch biopsies were taken and subsequently prepared for 
qPCR analysis. A clear increase in gene expression of the proinflammatory human 
cytokines IL1B, IL6 and IL8 was observed in the PBMC-injected skin compared to 
the PBS-treated controls (Fig. 2c). Also, we found increased gene expression of the 
human chemokines CXCL1, CXCL10 and CCL5, as well as DEFB4, the gene encoding 
the antimicrobial peptide human beta defensin-2 (hBD2) which was recently 
demonstrated to attract CCR6 expressing cells.16 mRNA levels of human cytokines 
exclusively or predominantly expressed by immune cells were close to or below the 
detection limit in either some of the PBS-injected controls (e.g. IFNγ which is clearly 
induced in the treated skin) or in both treated and control skin samples (such as 
IL12B, IL23A, IL17A, IL22 and IL20)
Infiltration of CD4+ and CD8+ IL-17A-producing T cells and CD4+ Foxp3-expressing 
T cells in the inflamed human skin
Next, we further characterized the mononuclear cell infiltrate in the skin by 
immunohistochemistry, and focused our analysis on quantification of human CD4+ 
and CD8+ T cells. As reported previously on the huPBL-SCID/skin allograft model5,6 
the human skin contained both CD4+ and CD8+ T cells (Fig. 3a). CD4+ T cell infiltrates 
were predominantly present within the dermis (296,56 ± 86,52 vs 954,68 ± 35,9 
cells/mm2, PBS vs huPBMC, respectively, P <0,01), while CD8+ T cells were present 
in both dermis (245,42 ± 10,3 vs 1162,85 ± 107,8 cells/mm2 P <0,05) and epidermis 
(296,6 ± 86,5 vs 954,7 ± 309,4 cells/mm2 P <0,05).
The cytokine interleukin 17A, which amongst other cell types is produced by T 
cells, has strong proinflammatory potential and has been clearly associated with 
psoriasis,17-19 and it also contributes to the pathology of atopic dermatitis.20,21 
Therefore, we analyzed the in vivo potential of the human CD4+ and CD8+ T cells 
to produce IL-17A in this huPBL/SCID model. IL-17A-producing cells were clearly 
present in the dermis, at the basal layer and also in the epidermis (Fig. 3b); both 
human CD4+/IL-17A+ and CD8+/IL-17A+ (41.95 ± 12.38 and 27.8 ± 5.97 cells/mm2, 
resp.) were observed (Fig. 3c). Next to these IL-17A-producing T cells, also CD3 
negative IL-17-producing cells were observed. Mast cells and neutrophils are known 
for their IL-17A producing potential.22 Here, we could clearly demonstrate that in 
the inflamed human skin human IL-17 production was associated with tryptase+ 
human mast cells. As expected, we did not find neutrophils, and consequently no 
IL-17 expressing neutrophils, within this humanized mouse model (Fig. 3d). We could 
not demonstrate IL-17A in the serum of the mice 3 weeks after infusion of huPBMC 
(data not shown), which suggests that IL-17 plays a predominant role in the local 
inflammatory skin response.
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As opposed to proinflammatory cells, anti-inflammatory cells are needed to regulate 
the immune response. CD4+ regulatory T cells that express the transcription 
factor Foxp3 are renowned for their immunosuppressive potential and control of 
proinflammatory T cells. Therefore we analyzed the presence of human Foxp3+ cells 
in the human skin of the huPBL-SCID-huSkin model. CD4+ Foxp3+ cells were mainly 
present at the basal layer (Fig. 3e).
Taken together, inflammation of the human skin transplant of the huPBL-SCID-huSkin 
model is characterized by aberrant epidermal differentiation, presence of human 
cytokines and chemokines and influx of CD4+ and CD8+ T cells and mast cells that 
a b
c
Figure 2. Induction of human chemokines and 
cytokines and influx of human T cells in the 
dermis and in the epidermis of huPBLSCID-
hu Skin allograft model. (a) Images show 
representative panoramic overviews (H&E 
staining) of human skin grafts from SCID beige 
mice 21 days after infusion (i.p.) of PBS (top) or 
huPBMC (below). Note that human epidermis is 
thicker than the mouse epidermis (present in the 
left edge of the specimen in the top image and in 
both edges in the bottom image) and in contrast 
with human skin, mouse skin has closely spaced 
hair folicules troughout the epidermis. Images were composed using PTGui software (New 
House Internet Services B.V.; http://www.ptgui.com/). (b) Immunohistochemistry of human 
CD3+ (brown) T cell infiltration in the human dermis and epidermis, 21 days after infusion of 
huPBMC. Representative example of n=12 are shown. 20x magnification. (c) Gene expression 
analysis using quantitative real-timePCR of human cytokine and chemokine transcripts in the 
human skin 21 days after infusion of huPBMC. Figure shows fold increase in cytokine and 
chemokine mRNA expression levels after huPBMC infusion as compared to PBS infusion (n=5 
and 3; huPBMC and PBS resp.).
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Figure 3. Infiltration of human IL-17A-producing T cells and CD4+ Foxp3-expressing T cells 
in the inflamed human skin in the SCID/skin allograft mouse model.
(a) Immunohistochemistry of human CD4 (brown, top) and CD8 (brown, bottom) expression 
in human skin grafts from SCID beige mice 21 days after infusion or huPBMC. Photographs 
show representative examples. 20x magnification. (b) Immunohistochemistry of human IL-
17A expression in human skin grafts from SCID beige mice 21 days after infusion of PBS 
(left) or huPBMC (right). Photographs show representative examples of n=6 (huPBMCs) n=3 
(controls). 20x magnification. Graph shows summarized data of IL-17A positive cells/mm2 
following PBS or huPBMC infusion in the human skin biopsies (mean ± SEM, of n=4 and 10). 
(c) Immunohistochemistry of coexpression of human CD4 (blue) and IL-17A (red, top) and 
CD8 (blue) and IL-17A (red, bottom) in human skin grafts from SCID beige mice 21 days after 
infusion of huPBMC (20x magnification). Inserts show a higher magnification (40x) of single 
CD4/CD8 and IL-17A staining and CD4/IL-17A or CD8/IL-17A co-staining. Photographs show 
representative examples of n=6. (d) Immunohistochemistry of IL-17A (red) in human mast cell 
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are able to produce the proinflammatory cytokine IL-17 as well as the presence of 
putative anti-inflammatory Foxp3 expressing CD4+ T cells.
Local human skin inflammation in the huPBL-SCID-huSkin model is paralleled by 
systemic CD4 and CD8 T cell activation, proliferation and acquisition of homing 
markers
In addition to the analysis of the local inflammatory response in the human skin, 
we studied the systemic response of the CD4+ and CD8+ T cells in the huPBL-SCID-
huSkin model. Mice were transplanted with human skin that was allowed to heal for 
3 weeks and subsequently inoculated with 150×106 human PBMC (i.p.) as describe 
above. After 3 weeks the CD4+ and CD8+ T cells were enumerated in peripheral 
blood, spleen and lymph nodes, and these cells were analyzed for cell division status, 
activation and homing marker expression using flow cytometry.
Anti-human CD45 monoclonal antibody was used to detect human lymphocytes in 
the humanized mice. CD45-expressing CD4+ and CD8+ T cells were observed in the 
peripheral blood, spleen and lymph nodes of the huPBL-SCID-huSkin model (Fig. 4a). 
In the peripheral blood equal percentages of CD4+ (42,3 ± 5,5%) and CD8+ (48,5 ± 
7,6%) T cells were found (Fig. 4a), whereas in the lymph nodes CD4+ T cells (58,9 ± 
3,7%) were more predominant as compared to CD8+ T cells (27,7 ± 3,9%)(Fig. 4b). 
Although less clear, the spleen seemed to contain more CD8+ (55,0 ± 6,9%) than 
CD4+ T cells (30,2 ± 2,0%) (Fig. 4b).
The majority of human T cells present in spleen, lymph nodes and peripheral blood 
expressed the memory marker CD45RO (Fig. 4c,d). Given that the inoculated huPBMC 
population pre-infusion contained about 60% CD45RA expressing T cells (Fig. 4d), 
which is indicative for the presence of naïve T cells, this suggests that the naïve T cells 
became activated in vivo. The presence of an allogeneic human skin transplant was 
required to induce this activated phenotype in vivo, as in the absence of a human 
skin transplant higher number of naïve CD45RA+ were observed spleen and lymph 
nodes (Fig. 4c). Irrespective of whether human skin was grafted, in peripheral blood 
we found similar percentages (>90%) of CD45RO+ cells (Fig. 4c). It should however 
be emphasized that higher absolute CD45RO+ numbers were found when a skin 
transplant was present (approx. 5×104 vs. 1×102 CD45RO+ cells in 20 µl retro-orbital 
blood samples after human skin transplantation vs. no transplantation, resp.) In 
tryptase (brown) and granulocyte elastase (brown) in human skin biopsies from SCID beige 
mice 21 days after infusion of PBS (left) or huPBMC (right). Photographs show representative 
examples of n=6 (huPBMCs) n=3 (controls). 20x magnification. (e) Immunohistochemistry of 
coexpression of human Foxp3 (brown) and CD4 (blue) in human skin grafts from SCID beige 
mice 21 days after infusion of PBS (left) or huPBMC (right) (40x magnification). Inserts show 
a higher magnification (63x) of single Foxp3 and CD4+ staining and Foxp3/CD4 co-staining. 
Photographs show representative examples of n=6 (huPBMCs) n=3 (controls).
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Figure 4. Systemic human CD4 and CD8 T cell activation, proliferation and acquisition of 
homing markers in the SCID/skin allograft mouse model. (a) Flow cytometry showing side 
scatter (SSC, X-axis) and CD45 expression (Y-axis) (top panel) and CD4 (X-axis) and CD8 (Y-axis) 
expression (lower panel) in peripheral blood and lymph node and spleen cell suspensions 
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peripheral blood, and spleen we found proliferating human CD4+ and CD8+ cells, as 
indicated by Ki67 staining (Fig. 4e,f). Interestingly, we observed that the presence of 
a human skin graft led to the induction of cutaneous lymphocyte associated antigen 
(CLA) expression on peripheral CD3+ T cells (Fig. 4g,h). This was not the case for the 
lymph node homing marker CD62L (Fig. 4g,h). It appeared that in particular CD8+ 
T cells had acquired CLA expression which was observed in both peripheral blood 
cells and spleen, but not in the case of lymph nodes (Fig. 4i,j). This indicates that 
the human skin can instruct homing receptor expression of the inoculated human 
cells in this humanized mouse model. Moreover, we found that more CD4+ T cells as 
compared to CD8+ T cells in the peripheral blood expressed the lymph node homing 
marker CD62L (Fig. 4i,j).
In summary, the flowcytometric analysis of human CD4+ and CD8+ T cells in peripheral 
blood and lymphoid organs in the huPBL-SCID-huSkin humanized mouse enables the 
study of the immune status and homing of human T cells in vivo. This together with 
the study of the local inflammatory response, as described above, empowers the 
huPBL-SCID-huSkin model as an important tool in the development and preclinical 
evaluation of novel systemic immunomodulating agents.
21 days after infusion of huPBMC. Representative dot plots are shown (n=4–7). CD4/CD8 
expression is shown after gating on huCD45+ cells. In case of PBS infusion hardly any human 
CD45+ lymphocytes were detected (data not shown). (b) Summarized flow cytometry data of 
human CD4+ and CD8+ cells upon huPBMC infusion as shown in a. (n=6). (c) Flow cytometry 
of human CD45RO+ (X-axis) and CD45RA+ (Y-axis) cell populations in peripheral blood and 
lymph node and spleen cell suspensions 21 days after infusion of huPBMC in SCID beige mice 
that either lacked (top panel) or were previously grafted with human skin (lower panel). 
Representative dot plots gated on huCD45+ cells are shown. (d) Summarized flow cytometry 
data of CD45RO+ and CD45RA+ cells upon huPBMC infusion in SCID beige mice that were 
grafted with human skin as shown in c. (n=6). (e) Flow cytometry of Ki67 expression in CD4+ 
(top panel) and CD8+ (lower panel) human T cells in peripheral blood (left) and spleen (right). 
(f) Summarized flow cytometry data of Ki67 expression in CD4+ and CD8+ human T cells as 
shown in e. (n=6). (g) Flow cytometry of CLA (top panel) and CD62L (lower panel) expression 
on human CD3+ cells populations in peripheral blood, 21 days after infusion of huPBMC in 
SCID beige mice that either lacked (right panel) or were previously grafted with human skin 
(right panel). Representative dot plots gated on huCD45+ cells are shown. (h) Summarized 
flow cytometry data of CLA and CD62L expression on human CD3+ cells as shown in g. (n=4–
5). (i) Flow cytometry of CLA (top panel) and CD62L (lower panel) expression on human 
CD4+ (left) and CD8+ (right) cells in peripheral blood, 21 days after infusion of huPBMC in 
SCID beige mice that were previously grafted with human skin. Representative dot plots 
gated on huCD45+ cells are shown. (j) Summarized flow cytometry data of CLA and CD62L 
expression on human CD4+ and CD8+ cells as shown in peripheral blood, lymph nodes and 
spleen (n=4–5).
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Cyclosporin-A and rapamycin prevent human T cell mediated skin inflammation 
and systemic activation and proliferation of the human T cells
Next, we studied the value of the above mentioned newly identified parameters in 
the huPBL-SCID-huSkin allograft model by analyzing the effect of systemic treatment 
with the T cell inhibitory agents cyclosporine-A and rapamycin. We used the 
combination of Cyclosporine (CsA) and rapamycin (Rapa), which has previously been 
demonstrated to decrease the extent of mononuclear cell infiltration and reduce 
the degree of microvessel injury in a huPBL-SCID-huSkin model.6 Administration of 
CsA (0,4 mg/kg/day) was started at the day of inoculation with the huPBMC. Co-
administration of Rapa (0,4 mg/kg/day) was initiated at day 7 and given on alternate 
days until the end of the immunosuppressive treatment.
Macroscopic evaluation 21 days after inoculation with huPBMC indicated that 
treatment with CsA and Rapa reduce visible signs of inflammation; the skin graft 
looked healthier and less inflamed, as indicated by a reduction in erythema, scaling 
and skin thickness (Fig. 5a). Histological analysis revealed that the epidermal 
thickening, elongated rete ridge formation and mononuclear cell infiltrates induced 
in this humanized mouse model was effectively inhibited by combined CsA and 
Rapa treatment (Fig. 5b). Quantitative microscopic analysis clearly demonstrated 
Figure 5. Cyclosporin-A and rapamycin treatment restores aberrant human epidermal 
differentiation marker expression and prevents infiltration of inflammation associated IL-
17A producing human T cells of the human skin in the huPBL-SCID/skin allograft mouse 
model. (a) Macroscopic (top panel) and histological (H&E) (lower panel) appearance of 
human skin graft from SCID beige mice 21 days after infusion of huPBMC with no treatment 
(left panel) and treatment with CsA and Rapa (right panel). (b) Quantitative microscopic 
histological analysis of the epidermal thickness (mm) of skin grafts following infusion of 
huPBMC with or without CsA and Rapa. Mean ± SEM are shown for n=3 and 5 upon PBS 
and huPBMC infusion resp. 20x magnification. (c) Immunohistochemistry of K10, K16, hBD2 
and Elafin in human skin grafts from SCID beige mice 21 days after infusion (i.p.) of huPBMC 
without (top panel) and with CsA and Rapa treatment (lower panel). Representative examples 
are show. 10x magnification. (d) Summarized data represented in c. are given in the figures. 
Mean ± SEM percentages of the area positive for the indicated markers is shown for n=3 and 
4–6 upon no treatment and treatment with CsA and Rapa, resp. (e) Immunohistochemistry 
of CD4 (top panel) and CD8 (lower panel) in human skin grafts from SCID beige mice 21 
days after infusion (i.p.) of huPBMC without (left panel) and with CsA and Rapa treatment 
(right panel). Representative examples are show. 20x magnification. (f) Summarized data 
represented in e. are given in the figures. Mean ± SEM percentages of CD4 (top) and CD8 
(bottom) positive cells are shown for n=3 and 4–5 upon no treatment and treatment with 
CsA and Rapa, resp. (g) Immunohistochemistry of IL-17A (brown) (representative examples 
of n=5 are shown) 106magnification. Graph shows summarized data of IL-17A positive 
cells/mm2 present in human skin biopsies following infusion of huPBMC in the absence or 
presence of Rapa/CsA resp. (mean ± SEM, of n=3 and 4–5).
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a significant reduction in epidermal thickening by CsA and Rap treatment (315,9 
± 68,2 vs 135,4 ± 45,1 µm, no treatment vs CsA+Rapa, resp, P <0,05)(Fig. 5b). 
Immunohistochemistry revealed that the aberrant epidermal differentiation, as 
indicated by the increased hBD2 and Elafin expression, and dysregulated K10/K16 
expression, in the human skin were significantly inhibited following CsA and Rapa 
treatment (hBD2; 40,2 ± 2,9 vs 12,2 ± 5,2, Elafin; 24 ± 2 vs 14,4 ± 4,K10; 18,9 ± 3,4 vs 
43,6 ± 6,8, K16; 73,3 ± 4,7 vs 17,8 ± 10% positive area, no treatment vs CsA+Rapa, 
resp, P <0,05) (Fig. 5c,d). As expected, the number of CD4+ and CD8+ T cells in the 
human dermis (CD4; 783,5 ± 38,8 vs 251,1 ± 42,9, CD8; 1162,9 ± 716,3 vs 71,3 ± 
38,4 cells/mm2, no treatment vs CsA+Rapa, resp, P <0,05 and P <0,01) and epidermis 
(CD4; 605,8 ± 76,6 vs 296,6 ± 35,6, CD8; 1232,5 ± 648,4 vs 183,9,9 ± 10,7 cells/mm2, 
both P <0,01) were significantly reduced by the immunosuppressive treatment (Fig. 
5e,f). Interestingly, the numbers of IL-17A-producing T cells were also substantially 
inhibited (Fig. 5g). CsA+Rapa treatment resulted in a substantial reduction of Foxp3+ 
cells in both the human skin graft and spleen (data not shown).
Next, using flow cytometry, we analyzed the effect of CsA and Rapa treatment on 
the systemic immune response. We found that following CsA and Rapa treatment 
the number of human CD4+ and CD8+ T cells was reduced in peripheral blood of 
the mice (CD4+, 6,66×105 ± 6,08×103 vs 1,47×105 ± 2,78×104 and CD8+, 5,78×105 ± 
5,51×103 vs 1,96×105 ± 1,00×105 total cell numbers, no treatment vs CsA+Rapa, resp. 
(P <0,01) Fig. 6a).
Moreover, after CsA and Rapa treatment the number of proliferating (Ki67 expressing) 
(Fig. 6b) and activated/differentiated (CD45RO expressing) (Fig. 6c) human CD4+ and 
CD8+ T cells in the peripheral blood was substantially decreased.
Discussion
In our current work we further advanced the huPBL-SCID-huSkin allograft model 
initially described by Pober’s group5,6 for studying local skin inflammation, by 
identifying new local (skin) – as well as systemic parameters that turn this model into 
an even more powerful tool to study human skin immunopathology in vivo. A good 
understanding of the human skin immunopathology is crucial in the development of 
novel therapeutics for the treatment of (auto) inflammatory skin diseases.
Although the major focus of the huPBL-SCID-huSkin allograft model is on skin 
immune pathology, we also directed our attention on the systemic immune response 
of the human PBMC. We here demonstrate systemic proliferation, activation, and 
induction of homing marker acquisition by human T cells. This was prevented by 
systemic treatment with the immunosuppressive agents CsA and Rapa. Systemic 
analysis of the immune response in this preclinical humanized model is important 
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for two reasons. First, the induction of a local T cell immune response is a multistep 
phenomenon taking place locally at the affected skin site (antigen recognition), in 
the draining lymph nodes (antigen presentation, T cell activation, differentiation, 
expansion) and peripheral blood (migration of activated T cells to the affected site 
and to other lymph nodes).14 Second, during the last decade there is an increasing 
use of systemic agents, like anti-inflammatory drugs or biologicals, to treat severe 
inflammatory skin diseases.23,24 At present, little information is available on the 
effects of systemic medication on systemic immune responses in humanized mouse 
models. This information is crucial to identify treatment-related systemic biomarkers 
for immunomonitoring of patients undergoing clinical trials. For analysis of the 
systemic human immune response in the huPBL-SCID-huSkin model, peripheral 
blood samples containing relatively few cells can be used to analyze the effects of an 
anti-inflammatory drug by multi-color flow cytometry over time.
In the huPBL-SCID-huSkin model we observed that the presence of the human skin 
graft instructs CLA expression on a fraction of the peripheral human CD8+ T cells. 
This suggests that migration of T cells from skin or skin draining lymph nodes to the 
periphery is taking place. In mice it has been demonstrated that memory/effector 
phenotype T cells migrated from the skin to the draining lymph nodes in the steady state 
conditions, and this process was increased during a cutaneous immune response.25 
Early in a primary cutaneous immune response, proliferating T cells were released 
from the skin-draining lymph nodes and migrated via the circulation to antigen free 
lymph nodes that drain other tissues.26 This migration of dividing T cells from the skin 
draining lymph nodes might explain the presence of human dividing Ki67+ T cells that 
we identify in the peripheral blood and spleen in the huPBL-SCID-huSkin model. Little 
Figure 6. Cyclosporin-A and rapamycin treatment prevents systemic activation and 
proliferation of human CD4+ and CD8+ T cells in the huPBL-SCID/skin allograft mouse 
model. (a) Enumeration of CD4+ and CD8+ cell populations by flow cytometry in peripheral 
blood 21 days after infusion of huPBMC without (white bars) or with CsA (black bars) and 
Rapa. Summarized flow cytometry data are presented (n=6). (b) Flow cytometry of Ki67 in 
human CD4+ of CD8+ cells in peripheral blood 21 days after infusion of huPBMC without 
(white bars) or with CsA and Rapa (black bars). Summarized data of n=6 are shown. (c) Flow 
cytometry of CD45RO and CD45RA expression on human CD3+ T cells in peripheral blood 
after infusion of huPBMC without (white bars) or with CsA and Rapa (black bars). Summarized 
data of n=6 are shown.
a b c
8
6
4
2
0To
ta
l c
el
l n
um
be
rs
 (1
05
)
CD4+ CD8+
no treatment
CsA + Rapa
no treatment
CsA + Rapa
no treatment
CsA + Rapa
20
15
10
5
0
%
 o
f K
i6
7+
 c
el
ls
CD4+ CD8+
30
20
10
0
%
 o
f p
os
iti
ve
 c
el
ls
CD45RO+ CD45RA+
94
is known about the migratory capacity of human T cells in vivo, the huPBL-SCID-huSkin 
model will be a helpful tool in improving our understanding in this respect.
IL-17-producing CD4+ T cells, designated Th17 cells, are important in the protection 
against extracellular pathogens, but Th17 cells are also associated with inflammatory 
and autoimmune conditions in humans.27 IL-17 is a cytokine that acts as a potent 
proinflammatory mediator by increasing chemokine production to recruit monocytes 
and neutrophils to the site of inflammation. Immunity mediated by Th17 cells is 
particularly important at epithelial and mucosal surfaces.28 IL-17-producing T cells 
appear to be important in the pathogenesis of psoriasis; Th17 cells have been 
demonstrated by both immunohistochemistry and flow cytometry in psoriatic 
lesions.17,18 Furthermore, a recent phase-II clinical study with a human antibody 
to IL-17A (AIN457, secukinumab) in psoriasis patients showed promising results 
supporting a role for Th17 in the pathophysiology of psoriasis.19 Also in the early 
stages of atopic dermatitis IL-17-producing cells seem to contribute to the pathology 
of the disease.20,21 In the inflamed skin of the huPBL-SCID-huSkin model we observed 
the presence of IL-17A-producing CD4+ and CD8+ cells. Although Th17 cells, which 
are classically defined as CD4+ IL-17-producing cells, previously has received the 
major focus, it has recently been established that also CD8+ IL-17-producing cells 
contribute to inflammatory skin disorders including psoriasis.29,30
Regulatory T cells (Treg) are important in the control of immune homeostasis 
and tolerance.31 In particular CD4+ regulatory T cells expressing the Treg master 
transcription factor Foxp3 were extensively studied over the last decade. Skin 
resident CD4+ Foxp3+ Treg were identified in mice and men.25,32 In mice, skin 
resident CD4+Foxp3+ Treg suppress inflammation and appear to migrate from 
the skin to the draining lymph nodes under steady state conditions. During a 
cutaneous immune response migration of Treg was increased.25,32 Moreover, Treg 
that migrated from the skin returned to the skin upon skin antigen exposure.25 
In normal human skin under steady state conditions between 5 and 10% of the 
skin resident T cells are CD3+/FOXP3+ Treg33 and proliferation of CD4+/Foxp3+ 
Treg was induced after a cutaneous challenge.34 Together these data suggest 
that Treg circulate between blood, skin, and lymphoid tissues and that local Treg 
proliferation takes place in order to regulate peripheral skin immune responses. In 
the affected human skin of the huPBL-SCID-huSkin model, we now demonstrate 
the presence of human CD4+Foxp3+ T cells in the dermis of the human skin, which 
suggests active immune regulation in the inflamed human skin of this humanized 
mouse model. A possible reason why Foxp3+ Treg in this model do no inhibit the 
IL-17A production by CD4+ and CD8+ T cells might be explained by the fact that 
Treg can become unstable under proinflammatory conditions and lose suppressor 
function and even gain proinflammatory characteristics, resulting in an increased 
inflammatory response.35 Also human Treg have this propensity to convert into 
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proinflammatory cytokine secreting cells, in particular when activated under 
proinflammatory conditions.36
We studied gene expression levels of cytokines and chemokines by quantitative real-
time PCR in the affected human skin of the mice 3 weeks after the inoculation with 
PBMC when inflammation of the human skin was established. We found an increase 
in gene expression of human IL1B, IL6, IL8, CXCL1, CXCL10, CCL5 and DEFB4. The 
upregulation of DEFB4 correlated with the increased protein levels of hBD2 found 
by immunohistochemistry. Besides the chemokines and cytokines presented in 
Figure 2c, we analyzed a number of other relevant cytokines that might play a role 
in skin inflammation (such as IL12, IL23, IL17, and IL22). Gene expression levels of 
these cytokines, arising from immune cells, were close to or below the detection 
limit. The reason for this is probably related to the fact that we have been analyzing 
gene expression at a late time point when overt inflammation was taken place (3 
weeks after infusion of human PBMC) combined with the low levels of immune cells 
compared to keratinocytes in the skin biopsy. Future studies are needed to reveal 
time-kinetics of gene expression.
In the humanized inflammatory skin model that we here present, we showed 
differential expression of epidermal pathology-related proteins such as increased 
human β-defensin-2, Elafin, K16, and Ki67 levels, and reduced expression of K10. 
Most chronic inflammatory skin diseases are characterized by increased proliferation 
of keratinocytes, resulting in epidermal thickening (acanthosis). Proliferating 
keratinocytes are further characterized by upregulation of the proliferation marker 
Ki67. The proliferative response is further accompanied by a shift in keratin expression 
in the supra-epidermal layers. K16 is upregulated, while K10 is downregulated in 
keratinocytes. K16 expression, which is not expressed in healthy epidermis, was first 
explained as the specific result of hyperproliferation. However, more recent studies 
show K16 expression to be a marker of general trauma and stress of the skin.37,38 
Elafin and hBD-2 are anti-microbial peptide/proteins secreted by keratinocytes, they 
constitute part of the innate immune defense and participate in skin protection 
against invading microorganisms.39 Elafin and hBD-2 are not present in healthy human 
epidermis, but they are highly induced under chronic inflammatory conditions of the 
skin (eg. psoriasis) and in case of skin barrier disruption.40-43 The proinflammatory 
cytokine IL-17A can induces the expression of hBD2 in keratinocytes.44-46 Next to its 
antimicrobial activity, hBD2 acts as proinflammatory chemoattractant for immune 
cells such as T cells, dendritic cells, mast cells and neutrophils.47 The upregulation 
of these anti-microbial peptides in our model is most likely the result of the influx 
of activated T cells and other immune cells and points to involvement of the innate 
immune system and impaired skin barrier function.
Psoriasis is a highly prevalent T cell mediated chronic inflammatory skin disease, which 
has both environmental and genetic causes to its etiology.48,49 The multi factorial and 
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complex pathophysiology of the disease results in disturbed communication between 
cells of the immune system and epidermal cells, leading to abnormal differentiation 
and hyperproliferation of keratinocytes.50 Recently it emerged that the disease is 
strongly associated with IL-2351 and IL-17-producing T helper cells.17-19 Psoriatic 
plaque lesions are histologically characterized by an increase in epidermal thickness, 
caused by disturbed keratinocyte differentiation and hyper proliferation (acanthosis), 
elongated epidermal rete ridges and influx of immune cells among which many T 
cells.50 Clinically these alterations are represented by scaling, plaque thickening, and 
erythema.50 At the molecular level, a regenerative epidermal differentiation program 
is induced that includes expression of genes such as Keratin 16 (K16), elafin, psoriasin 
and β-defensin-2 (hBD-2), and because differentiation is impaired keratinocytes 
loose expression of normal supra-basal K1052-55 and increase expression of Ki67 in 
basal keratinocytes.50 The association of psoriasis and hBD-2 induction52 has recently 
been further substantiated by demonstrating increased β-defensin copy numbers in 
psoriasis patients.42
In the inflamed human skin of the huPBL-SCID-huSkin model we here demonstrate that 
the skin inflammatory phenotype resembles human plaque-type psoriasis at multiple 
levels; macroscopically we found erythema and skin thickening, microscopically using 
histology we demonstrated acanthosis, parakeratosis and psoriasis like rete ridges, 
and by immunohistochemistry we found increased expression of hBD-2, elafin, K16 
and Ki67 and reduced K10 expression. Moreover, we detected CLA expressing human 
CD8+ T cells in the peripheral blood of the huPBL-SCID-huSkin model. The presence 
of CLA-expressing CD8+ T cells in the peripheral blood of psoriasis patients is a 
hallmark of the disease.56,57 Most of the huPBMC-induced changes were significantly 
inhibited or completely prevented after CsA and rapamycin treatment. Together 
these findings suggest that the huPBL-SCID-huSkin model is of potential interest to 
study the pathology of psoriasis at the level of skin and immune biology.
In conclusion, employing the huPBL-SCID-huSkin allograft model of human skin 
inflammation combined with the local and systemic markers for human cells that 
we here identified enable preclinical evaluation of novel immuno-modulating agents 
and cell-based therapy. Also, it will contribute to our understanding of inflammatory 
and regulatory processes by human T cells and keratinocytes in the pathology of skin 
inflammatory disorders in vivo.
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Abstract
Background Research has revealed new insights into the pathogenesis of psoriasis, 
leading to new therapeutic options. So far the order of changes in the pathogenesis 
of psoriasis is unclear. The responses to cutaneous leukotriene B4 (LTB4) application 
have been studied in the past as an in vivo model for skin inflammation. The aim of 
the present study is to find out the order of changes of key steps in inflammation, 
which all have been shown to be involved in mature psoriatic lesions.
Objectives To study the dynamics of the consecutive stages of inflammation in 
challenged skin as a reflection of a psoriasis-like inflammatory response.
Methods We examined the dynamics of epidermal growth control and the key 
representatives of the innate and acquired immune system during the first 72 hours 
after challenging the skin with the application of LTB4. 
Results Interleukin (IL)-17 positive cells dominate the acute phase of inflammation, 
whereas T-Bet positive cells seem to increase gradually during the entire observation 
period. This indicates a more important role for IL-17 in the unstable phase of 
inflammation and a more prominent role for T-Bet positive cells within the chronic 
phase.
Conclusions The present model is highly reproducible and is useful in studying 
the dynamics of a psoriasis-like inflammation with respect to key components of 
immunity. It could function as a useful tool to study the immediate biological effects 
of new therapies like anti-IL-17 drugs on IL-17 production and effects on cutaneous 
inflammation and epidermal proliferation in vivo.
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Introduction
Affecting about 2% of the population, psoriasis is one of the most common chronic 
inflammatory skin disorders, causing an extensive burden for both patients and 
health care systems. The pathogenesis of psoriasis is still unclear but research 
revealed important drivers in the pathogenesis of this disease, which also appeared 
to be targets for anti-psoriatic treatments. It is known from the classical picture of 
the histopathology of psoriasis that polymorphonuclear (PMN) leucocytes, cells 
of the innate immune system, are well represented within active psoriatic lesions. 
Accumulations of PMN leucocytes in micropustules of Kogoj (spongiform pustules in 
the stratum spinosum) and in microabscesses of Munro (accumulation of remnants 
of PMN leucocytes in the stratum corneum) are pathognomonic for psoriasis. These 
accumulations of PMN leucocytes are a key component of the innate immune system 
in psoriasis. Further exploration of the role of the immune system has revealed an 
important assignment for T cells. At first, psoriasis was thought to be a T helper 
(Th) 1 cell-mediated process.1 However, a few years ago a novel T cell subset was 
discovered: Th17 cells.2,3 Since their discovery, researchers found that Th17 cells play 
an important role in several inflammatory diseases including psoriasis, rheumatoid 
arthritis, inflammatory bowel disease and atherosclerosis.4,5 Moreover, new drugs 
targeting the interleukin (IL)-17 pathway seem to be very effective in psoriasis.6,7
To further unravel the pathogenesis of psoriasis, research on the consecutive cascade 
of events, finally leading to psoriatic lesions, is essential. Unfortunately, studying 
psoriasis before it becomes clinically manifest is rather difficult since examining the 
very first changes would require the prediction of the formation of new lesions. 
At this point, our knowledge is mainly based on existing psoriatic lesions and the 
clinically uninvolved skin from patients with psoriasis, without the various phases in 
between. 
To enable the investigation of the early alterations and consecutive cascades leading 
to cutaneous inflammation and a disease-specific phenotype, the inflammatory 
processes have to be imitated in a controlled manner. One way to study single 
aspects of the important drivers of psoriasis is to use in vitro experiments. These 
experiments allow studying single cell types and isolated events over time while all 
other environmental influences can be controlled. Unfortunately, these experiments 
are often carried out under rather artificial conditions. 
During the past decades, the inflammatory response to epicutaneous application 
of leukotriene B4 (LTB4) has been studied extensively and can be regarded as an 
established model to mimic psoriasis-like inflammation of the skin.8-12 It is known 
that in psoriatic lesions high levels of LTB4 are present,
13,14 produced by activated 
innate immune cells.15,16 Furthermore, LTB4 is a potent chemoattractant for 
inflammatory cells,15,17 and cutaneous application triggers acute inflammation, with 
104
PMN leucocytes penetrating into the psoriatic epidermis, mimicking micropustules 
of Kogoj and microabscesses of Munro. These microscopic collections of PMN 
leucocytes are found within the stratum spinosum and stratum corneum of lesional 
skin and are indicative for active disease. By application of LTB4 directly on the skin, 
it is possible to introduce an isolated influx of PMN leucocytes and to induce a 
psoriasis-like inflammatory reaction. Because this inflammatory reaction of the skin 
is induced in a controlled manner, all processes can be followed over time. With 
respect to newly discovered drivers in the field of psoriasis, this model may enable 
us to be informed on the consecutive events in an inflammatory process, sharing the 
pathognomonic PMN leucocyte accumulations as seen in psoriasis. 
The aim of this research was to further elucidate the dynamics of the early and 
consecutive stages of psoriasis-like skin inflammation. Therefore, early epidermal 
and dermal changes caused by challenging the skin were studied at subsequent 
moments after LTB4 application. In particular, the epidermal compartment [i.e. 
epidermal proliferation (Ki-67) and differentiation (keratins-10 and keratin-16, K10 
and K16, respectively)], the innate [i.e. neutrophils (elastase), epithelial proteinase 
inhibitor (Elafin) and antimicrobial peptides (human β-defensin-2, hBD2)] and 
adaptive immune system [Th1 cells (T-Bet)], and key cytokine IL-17 were studied. 
Material and Methods
Subjects
Ten healthy volunteers (7 females and 3 males, 19 – 56 years) without signs or history 
of skin disorders participated in this study. Written informed consent was given by 
all volunteers before inclusion. The experiments were approved by the local medical 
ethics committee and were conducted according to the Declaration of Helsinki 
principles. 
LTB4 application 
Aliquots of 100 ng LTB4 dissolved in 10 µl ethanol were applied in a plastic cylinder (8 
mm diameter) on 5 sides of the lower back skin. The ethanol was evaporated under a 
stream of nitrogen gas, leaving the LTB4 on the skin. To prevent the LTB4 from being 
displaced, the test sites were covered with impermeable dressings and held in place 
by tape. After 8 hours the dressings were removed by the investigators. 
Biopsy procedures
Punch biopsies with a diameter of 3 mm were taken after local anesthesia. Biopsies 
were taken 8, 24, 32, 48 and 72 hours after the application of LTB4. Time intervals were 
based on previous studies. One additional biopsy was taken from non-challenged 
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6skin serving as an internal control. All specimens were formalin fixed, embedded in paraffin and sectioned at 4 µm. 
Immunohistochemistry 
Staining procedures were performed using the Envision Kit (Dako, Glostrup, Denmark) 
according to the regulations of our laboratory. Paraffin-embedded sections were 
deparaffinezed and rehydrated. Antigen retrieval was achieved by using 0.1% trypsin 
solution (pH 7.8, 10 minutes at 37 ⁰C) for K10, citrate buffer (pH 6.0, 10 minutes at 
100 ⁰C) for K16 and Ki-67, and Tris/ethylenediaminetetraacetic acid (EDTA) buffer (pH 
9.0, 10 minutes at 100 ⁰C) for IL-17. The other primary antibodies (Abs) used, did not 
require antigen retrieval steps. Endogenous peroxidase activity was blocked by using 
2% H2O2 in phosphate buffered saline (PBS), and sections were incubated with 1% 
bovine serum albumin (BSA; Dako) for 15 minutes. Sections were incubated overnight 
at room temperature with primary Abs dissolved in 1% BSA (Table 1). Visualization of 
the primary Ab was achieved with 3,3’-diaminobenzidine tetrahydrochloride solution 
(Sigma-Aldrich, St. Louis, MO) and counterstaining with Mayer’s Hematoxylin (Sigma-
Aldrich). Substitution of the primary Ab with 1% BSA served as a negative control.
Microscopic quantification of immunohistochemical markers
Skin sections were assessed semi-quantitatively using an Axioskop2 MOT (Zeiss, 
Oberkochen, Germany) at a magnification of x100, digital camera (Axiocam MRc5; 
Zeiss) and AxioVision software (Zeiss). The whole section was analyzed. All microscopic 
Biochemical 
specifity
Marker for Designation and source of 
antibodies
Dilution
K10 Normal epidermal differentiation RKSE60; Euro-Diagnostica, Malmö, 
Sweden
1:5,000
K16 Abnormal epidermal differentiation LL025; Sanbio BV, Uden, The 
Netherlands
1:50
Ki-67 Epidermal proliferation MIB-1, Dako, Glostrup, Denmark 1:100
Elastase Neutrophils NP57, Dako, Glostrup, Denmark 1:10,000
hBD2 Antibiotic peptide Abcam, Cambridge, UK 1:50
Elafin Epithelial proteinase 
Inhibitor
TRAB2F, Hycult Biotech Inc., 
Plymouth Meeting, PA
1:500,000
T-Bet Th 1 cells H-210 sc-21003, R&D-Systems, 
Minneapolis, MN
1:1,500
IL-17 Interleukin 17 cytokine Polyclonal goat IgG, R&D-Systems, 
Minneapolis, MN
1:500
Table 1. Primary antibodies
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evaluations were performed by two observers (A.H. and R.K.) and repeated on 
two different occasions per specimen. With respect to the epidermis an area was 
measured across the whole section, without stratum corneum, using ImageJ 1.38× 
software (National Institutes of Health, Bethesda, MD). The region of interest of the 
dermal compartment was defined as the surface from the basement membrane until 
350 µm deep in the dermis across the whole section and was assessed using the 
same software. For analysis of T-Bet, IL-17 and elastase, the dermal surface area was 
measured as square millimeter, and positive cells were counted. The cell counts were 
expressed as number of positive cells per square millimeter dermis. Cells positive for 
Ki-67 were counted and expressed as positive cells per millimeter length of basement 
membrane. For quantification of epidermal K10, K16, Elafin and hBD2 stainings, the 
percentage of the epidermis with a positive signal was measured using the ImageJ 
macro ‘color deconvolution’, adapted from Ruifrok and Johnston.18 
Statistical Analysis 
The results were expressed as means ± standard error of the mean (SEM). Time-
related changes in immunohistochemical variables were assessed using a Wilcoxon 
matched-pairs signed-rank test. Throughout the analyses, P-values <0.05 were 
considered statistically significant.
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Figure 1. H&E stainings of normal skin at baseline and after LTB4 application. (a-f) 
Representative photographs of H&E stainings of the skin at baseline and 8, 24, 32, 48 and 
72 after LTB4 application, showing acanthosis, parakeratosis and an inflammatory infiltrate, 
resembling histological hallmarks of psoriasis. After 24 h, accumulating elastase+ cells were 
present in the subcorneal zone of the stratum corneum. Bars represent 200 µm.
a b c
d e f
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Results
In all healthy subjects a slight to moderate erythematous discoloration of the skin 
appeared after LTB4 application. At baseline and at 8, 24, 32, 48 and 72 hours 
after application, biopsies were taken. During the study, LTB4 application led to 
acanthosis, parakeratosis and an inflammatory infiltrate as is displayed in Figure 1. 
Figure 2 provides an overview of the histological data over time. Subsequently, 2 
representative photographs of all makers used, are depicted in Figure 3. 
Already after 8 hours, LTB4 application induced an influx of the first immune cells 
within the dermis. Almost all of these infiltrating cells stained positive for elastase, 
mainly consisting of PMN leucocytes. Maximal accumulation in the dermis was 
seen after 24 and 32 hours (P=0.0020 for both time points). Within the epidermal 
compartment, the accumulations of microscopic collections of PMN leucocytes 
were found within the stratum corneum after 24 hours. Thereafter, the number of 
elastase+ cells started to decline. 
Within the normal unchallenged skin at t=0, there were already some IL-17+ cells 
present in the dermal compartment. The course of IL-17 nicely coincided with the 
elastase+ cells with a significant increase after 24 hours and declining after 32 hours. 
Figure 2. Quantification of several markers. Number of 
elastase+ (a), IL-17+ (b), and T-Bet+ (c) cells per square 
millimeter of dermis, the percentage Elafin+ (d), hBD2+ 
(e), and K16+ (f) epidermal surface, and number of Ki-67+ 
cells (g) per millimeter length of basement membrane 
at baseline and 8, 24, 32, 48 and 72 hours after LTB4 
application. Mean ± SEM. * P <0.05: statistically significant 
compared to baseline. 
a b c
d e f
g
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At the same time, a statistically significant but modest increase in cells positive for 
the transcription factor for Th1-specific cytokines (T-Bet+ cells) was seen at 24 hours 
(P=0.0195). In contrast to the course of elastase+ cells and IL-17+ cells, the number 
of cells positive for T-Bet lasted until 72 hours without declining. 
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Figure 3. Representative images of several immunohistochemical markers. Representative 
images of elastase+ (a, b), IL-17+ (c, d), and T-Bet+ (e, f) cells at baseline and 32 h after 
application of LTB4, and of Elafin+
 (g, h), hBD+ (i, j), and K16+ (k, l) epidermal surface, and 
number of Ki67+ cells (m, n) at baseline, and 72 h after LTB4 application. Bar represents 100 µm.
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The peak accumulation of elastase+ and IL-17+ cells at 32 hours within the dermis 
and epidermis was accompanied by the onset of epidermal differentiation, 
compatible with subsequent activation of the innate immune system. The latter was 
depicted by an increase of the percentage epidermis expressing elastase-specific 
protease inhibitor Elafin (Elafin+ epidermal surface) and skin antimicrobial peptide 
hBD2 (hBD2+ epidermal surface). The same pattern was seen for both Elafin as well 
as hBD2+ epidermis. Both markers showed a significant increase at 32 hours and 
increased until 72 hours to reach a maximum, well after the maximum of elastase+ 
and IL-17+ cells. 
Furthermore, the expression of K10 within the epidermal compartment showed the 
same overall expression pattern at all time points (results not shown). LTB4 application 
led to an increase in the expression of K16 at 48 hours and further expansion at 
72 hours (P=0.0195 and P=0.0020, respectively). This was followed at 72 hours by 
a marked increase in the number of cycling epidermal cells, reflecting keratinocyte 
proliferation, depicted by an increasing number of both basal and suprabasal Ki-67+ 
nuclei (P=0.0039). 
 
Discussion 
In this study the dynamics of the consecutive stages of inflammation were investigated 
in normal skin challenged by topical LTB4 application as a reflection of a psoriasis-like 
inflammatory response. Changes in both the innate and adaptive immune system, 
which followed during the first 72 hours after challenging the skin, were related to 
epidermal proliferation and differentiation. 
The hematoxylin-eosin staining displayed acanthosis, parakeratosis and an 
inflammatory infiltrate within the tissue samples, resembling the histological hallmarks 
of psoriasis (Fig. 1). This was confirmed by the other observed staining patterns 
which were quite similar to those found in psoriasis, with an increase in epidermal 
proliferation and an influx of epidermal and dermal PMN leucocytes, resulting in 
characteristic intra-epidermal accumulations and presence of T lymphocytes within 
the dermis. These results confirm that challenging the skin by LTB4 application can be 
used as a model to investigate psoriasis-like skin inflammation in a dynamic fashion.
Furthermore, the changes in proliferation and differentiation markers found after 
challenging the skin with LTB4, resemble the findings of previous studies,8,9,19 
indicating that this model is highly reproducible and that the application of LTB4 was 
done accurately. 
In psoriatic lesions, inflammatory changes within the epidermal and dermal 
compartments are accompanied by vascular changes. Histologically, elongated, 
dilated and tortuous blood vessels can be observed within the dermal papillae. In 
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the present study, the course of the vascularization was not taken into account. 
However, since there is a remarkable and rapid increase in various immune cells due 
to the application of LTB4, it is attractive to hypothesize that there is an increase in 
the vascularization that makes this substantial influx of immune cells possible. LTB4 
is an arachidonic acid derivative, involved in inflammation and is able to induce the 
adhesion and activation of leukocytes directly. However, it is a chemical compound 
that has to penetrate the stratum corneum first to turn on the inflammatory cascade. 
First elastase+ cells are attracted, which in turn trigger the influx of Th1 lymphocytes. 
In addition, LTB4 is able to induce the formation of reactive oxygen species in 
neutrophils and subsequently the release of lysosomal enzymes, which in turn affect 
the epidermal compartment. We observed an increase in the percentage of Elafin+ 
and hBD2+ epidermal surface, and an increase in K16 expression just after the peak 
accumulation of the elastase+ cells. 
For years, psoriasis was considered a Th1 dominated disease. However, nowadays 
Th17 cells and their key cytokine IL-17 are thought to play an important role, along 
with Th1 cells. To visualize the specific T cell subsets, transcription factor T-Bet was 
used as a unique marker to identify Th1 cells.20 Within the unchallenged skin there 
were already some T-Bet+ cells present. In addition, skin biopsies also showed an 
elementary level of IL-17, which may be produced by mast cells, present at baseline. 
Previous studies found IL-17+ mast cells within complicated atherosclerotic plaques 
and in the synovium in rheumatoid arthritis.21,22 These cells were also found within 
chronic plaque psoriasis by our group.23 After challenging the skin, a quick influx of 
elastase+ cells was seen with an identical increase in IL-17+ cells. After the early 
peak of elastase+ and IL-17+ cells, these subsets tended to decrease already after 24 
hours. Regarding the T-Bet+ cells, only a minimal increase was observed which lasted 
until 72 hours. Accordingly, the influx of elastase+ and IL-17+ cells seems to play a 
more important role in the acute phase of inflammation rather than T-Bet+ cells. This 
suggests that in this model, elastase+ PMN leucocytes may play an important role 
in producing IL-17, rather than Th17 cells, as described before by Lin et al.24 Using 
dual-color immunofluorescence, the authors showed that neutrophils contain IL-17 
and concluded that the release of IL-17 from innate immune cells may be central in 
the pathogenesis of psoriasis, representing a fundamental mechanism by which the 
IL-23/IL-17 axis mediates host defense and autoimmunity.24
Moreover, it was already proposed by Christophers25 that there are two different 
immune pathways which orchestrate the lesional activity leading to the different 
phenotypes of psoriasis. It was suggested that the IL-23/IL-17-directed pathway 
leads to active eruptive psoriasis with formation of new lesions, whereas the 
pathway directed by Th1 cells marked by the IL-12/interferon-y pathway is 
predominantly associated with chronic plaque psoriasis. Moreover, Christophers25 
argued that rerouting the cutaneous inflammation from the IL-12 pathway towards 
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the IL-23 pathway, and vice versa, affected the diversity of both phenotypes and 
their instability, which is one of the characteristics of psoriasis. In addition, Choe et 
al26 showed that IL-17A was more elevated in patients with an eruptive inflammatory 
psoriasis as compared to patients with chronic stable psoriasis. 
Importantly, we used a model to study psoriasis-like skin inflammation, not psoriasis 
itself. It would be interesting to examine different phenotypes of psoriatic lesions, 
both acute and more chronic, for the same set of markers. This could learn us 
more about the importance of the above-mentioned cells and ultimately about the 
pathogenesis of psoriasis. 
In conclusion, this study showed that the response to epicutaneous application of 
LTB4 is highly reproducible and is useful in studying the dynamics of a psoriasis-like 
inflammation. Elastase+ and IL-17+ cells dominate the acute phase of inflammation, 
indicating a more important role in an unstable phase of inflammation, whereas 
T-Bet+ cells seem to have a more gradual role and could probably be more prominent 
within a stable situation. 
In addition, the present study describes the course of different immunohistochemical 
markers over time, including the course of IL-17+ cells, which may be expected after 
LTB4 has been applied to the healthy skin. The LTB4 model could serve as a useful 
tool to study the biological effects of new therapies such as anti-IL-17 drugs, and 
provide information on the production of IL-17 and IL-17-driven changes in vivo 
during a short period of only 72 hours. 
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Abstract
Background In healthy skin, tape-stripping induces a transient wave of histological 
changes resembling immune-mediated skin diseases, such as psoriasis. The response 
to surface trauma may harbor mechanisms which are also relevant to the development 
of Koebner-positive skin disorders. However, studies on newly discovered drivers of 
inflammation in regenerative skin are lacking.
Methods The course of epidermal proliferation and keratinization as well as key 
representatives of innate and acquired immunity were studied during the first 72 h 
after tape-stripping.
Results Epidermal rupture rapidly activates various epidermal processes, which 
remain upregulated for 72 h. Elastase+ and IL-17+ cells dominate the acute phase 
and their numbers decrease rapidly thereafter. The number of T-Bet+ cells increases 
more gradually, reaching a maximum when the presence of other cell types already 
decreases.
Conclusions This model permits investigations on the sequence of crucial 
inflammatory processes that are presumed to play a role within the pathogenesis of 
immune-mediated skin diseases exhibiting the Koebner phenomenon.
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Introduction
The skin separates the body’s internal environment from the external environment 
and provides a barrier to the outside world. The skin barrier function results from the 
physical properties of the outer layer of the epidermis, the stratum corneum, which 
exists out of terminally differentiated keratinocytes.1,2 Recently, research showed 
that the epidermal compartment, and more particularly the skin barrier function, 
is involved in the pathogenesis of immune-mediated skin disorders such as atopic 
dermatitis3 and psoriasis.4 In addition, some skin diseases like lichen planus, vitiligo 
and psoriasis, arise at sites of a disrupted skin barrier, which is known as the Koebner 
phenomenon.5
Already in 1876, the appearance of psoriatic lesions in the uninvolved skin of 
psoriasis patients, following disruption of the skin barrier due to surface-trauma, was 
described by Heinrich Koebner.6,7 Studies have shown that about 25% of psoriasis 
patients have a history of developing new psoriatic lesions following a skin trauma.8,9 
However, the Koebner phenomenon is not restricted to psoriasis; diseases such 
as lichen planus and vitiligo proved to respond to surface injury with skin lesions 
as well.5 Consequently, koebnerization is not a disease-specific phenomenon but 
rather a pathogenetic principle, occurring in several immune-mediated diseases. In 
healthy individuals, skin injury induces transient changes in the epidermis such as 
hyperproliferation, abnormal keratinization and inflammation, however this does 
not lead to the development of persisting inflammatory skin lesions. It is speculated 
that the response to surface trauma in normal skin might harbor some mechanisms 
which are also relevant to the development of skin conditions exhibiting the Koebner 
response. 
Removing the stratum corneum by tape-stripping has been used for decades as an 
in vivo model to mimic skin barrier disruption in studies focusing on regenerative 
epidermal proliferation and keratinization.10-12 Regenerative skin transiently presents 
histological features resembling histological hallmarks of skin inflammation, such 
as epidermal thickening, parakeratosis and a mixed cellular infiltrate. Repeated 
application and removal of tape induces a highly reproducible regenerative response 
with respect to proliferation and differentiation. Not only the magnitude of the 
response, but also the time frame between injury and appearance of epidermal 
changes, was highly reproducible. The skin regenerating from standardized surface 
trauma is at risk for the development of skin disease. The induction of inflammatory 
cells and relevant cytokines by tape-stripping have not been studied in depth in this 
context. 
In the present study, regenerative skin after standarized barrier disruption was 
used as a simplified model to immunohistochemically study the dynamics of newly 
discovered drivers in the pathogenesis of immune-mediated diseases. We focused 
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on T-Bet+ T helper (Th) 1 cells as important players of the adaptive immune system, 
elastase+ polymorphonuclear (PMN) leukocytes as important representatives of the 
innate immune system, human β defensin 2 (hBD2) and elastase proteinase inhibitor 
(Elafin) as host defense proteins, and key cytokine interleukin 17 (IL-17). In addition, 
epidermal differentiation (Ki-67) and proliferation (keratin-10 and keratin-16, K10 
and K16) as well as established markers for epidermal regeneration were studied.
Methods
Subjects
Ten healthy volunteers, three men and eight women, aged between 18 and 46 years, 
participated in this investigation. None of the subjects had any signs or history of skin 
disorders. The experiments were approved by the local medical ethics committee 
and were conducted according to the Declaration of Helsinki principles. After signing 
for informed consent, the subjects were seen five times for tape-stripping and biopsy 
procedures. 
Tape-stripping and biopsy procedures
Tape-stripping was performed on two areas of the lower back skin, measuring 3 x 2
centimeter. Sellotape® was applied on the skin and removed repeatedly (50 - 80 
times) until the skin surface became slightly shining. After local anaesthesia, three-
millimeter punch biopsies were taken from the centre of the tape-stripped sides, 
after 16, 24, 48, and 72 h. Time intervals were based on previous studies. At baseline, 
one additional biopsy was taken from non-challenged skin, thereby serving as an 
internal control. Tissue samples were formalin-fixed, embedded in paraffin and 
sectioned at 4 µm. 
Histological assessments
Staining procedures were performed using the Envision Kit (Dako, Glostrup, Denmark) 
according to the regulations of our laboratory. Paraffin-embedded sections were 
deparaffinezed and rehydrated. Antigen retrieval was achieved by 0.1% trypsin 
solution (pH 7.8, 10 minutes at 37 ⁰C) for K10 (RKSE60, 1:5000; Euro-Diagnostica, 
Malmö, Sweden), citrate buffer (pH 6.0, 10 minutes at 100 ⁰C) for K16 (LL025, 1:50; 
Sanbio BV, Uden, The Netherlands) and Ki-67 (MIB-1, 1:100; Dako) and Tris/ethylene-
diaminetetraacetic acid (EDTA) buffer (pH 9.0, 10 minutes at 100 ⁰C) for polyclonal 
goat IgG IL-17 (1:500; R&D-Systems, Minneapolis, MN). The other primary antibodies 
(Abs) used, elastase (NP57, 1:10000; Dako), HBD2 (1:50; Abcam, Cambridge, UK), 
Elafin (TRAB2F, 1:500000; Hycult Biotech Inc., Plymouth Meeting, PA), and T-Bet 
(H-210 sc-21003, 1:1500; R&D-Systems), did not require antigen retrieval steps. 
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Endogenous peroxidase activity was blocked by 2% H2O2 in phosphate buffered saline 
(PBS), and sections were incubated with 1% bovine serum albumin (BSA; Dako). 
Sections were incubated overnight at room temperature with primary Abs dissolved 
in 1% BSA. Visualization of the primary Ab was achieved with 3,3’-diaminobenzidine 
tetrahydrochloride solution (Sigma-Aldrich, St. Louis, MO) and counterstaining with 
Mayer’s Hematoxylin (Sigma-Aldrich). Substitution of the primary Ab with 1% BSA 
served as a negative control.
Microscopic quantification of immunohistochemical markers
Skin sections were assessed semi-quantitatively using an Axioskop2 MOT (Zeiss, 
Oberkochen, Germany) at a magnification of x100, digital camera (Axiocam MRc5; 
Zeiss) and AxioVision software (Zeiss). All microscopic evaluations were performed 
by two observers (A.H. and R.K.) and repeated on two different occasions per 
specimen, analyzing the whole section. With respect to the epidermis, across 
the whole section a region of interest was selected, without stratum corneum, 
using ImageJ 1.38× software (National Institutes of Health, Bethesda, MD). For 
quantification of epidermal expression of K10, K16, Elafin and hBD2, the percentage 
of the epidermis with a positive signal was measured using the ImageJ macro ‘color 
deconvolution’, adapted from Ruifrok and Johnston.13 The region of interest of the 
dermal compartment was defined as the surface from the basement membrane until 
350 µm deep in the dermis across the whole section and was assessed using the 
same software. For analysis of T-Bet, IL-17 and elastase, the dermal surface area was 
measured in square millimeter and positive cells were counted. The cell counts were 
expressed as number of positive cells per square millimeter dermis. Cells positive 
for Ki-67 were counted and expressed as positive cells per mm length of basement 
membrane. 
Statistical methods
The results were expressed as means ± standard error of the mean (SEM). Time-
related changes in immunohistochemical variables were assessed using a Wilcoxon 
matched-pairs signed-rank test. Throughout the analyses, P-values <0.05 were 
considered statistically significant.
Results
Within all volunteers, erythematous erosions with finally some crust formation were 
observed on the tape-stripped sites. Also, in some of the test areas pinpoint bleedings 
were seen immediately after tape-stripping, reminiscent of the Auspitz phenomenon 
(Fig. 1). Figure 2 shows an example of a hematoxylin and eosin staining of the skin 
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before and 16 h after tape-stripping. An overview of the immunohistological results 
is shown in figure 3.
Removal of the stratum corneum led to a rapid activation of the epidermal 
compartment. At baseline, there was barely any sign of abnormal differentiation as 
illustrated by the absence of K16 expression throughout the epidermis. Only in some 
of the tissue samples a minimal staining was found. Already 16 h after disrupting 
the skin barrier, the expression of K16 significantly increased (P=0.0273) compared 
to baseline. K16 expression increased further during the course of the study, with a 
peak expression at 48 h. 
Approximately the same pattern was seen for the expression of the elastase-specific 
protease inhibitor Elafin (percentage of Elafin-positive epidermal surface) in the 
epidermal compartment. After 16 h the expression of Elafin started to increase with 
a maximal expression at 24 h (P=0.0020), and declining after 48 h. Along with the 
onset of the Elafin expression, tape-stripping led to an increased expression of the 
skin antimicrobial peptide hBD2 (percentage of hBD2-positive epidermal surface) at 
16 h (P=0.0020). However, in contrast to the expression of K16 and Elafin, no further 
increase in expression of hBD2 was observed thereafter. 
The number of deviding epidermal cells, illustrated by Ki-67+ nuclei, decreased 
significantly as compared to baseline at 16 and 24 h after tape-stripping (P=0.0039, 
and P=0.0098, respectively). This was followed by a marked increase at 48 h 
(P=0.0078). The expression of K10 showed the same gross overall intensity at all time 
intervals (results not shown).
Along with the expression of these epidermal markers, tape-stripping resulted in an 
influx of immune cells within the dermis at 16 h. Many immune cells stained positive 
for elastase, indicative for neutrophils and monocytes (Fig. 2b). In contrast to the 
ongoing activation of the epidermal compartment, the number of elastase+ cells 
started to decline immediately after peaking at 16 h (P=0.0020); 72 h after the skin had 
been traumatized, the number of elastase+ cells was almost restored back to normal. 
Along with the influx of the elastase+ cells at 16 h, a significant increase of IL-17+ cells 
was observed (P=0.0020). During the course of the study, their presence coincided 
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after tape stripping. Erythematous erosion 
with pinpoint bleedings.
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with the elastase+ cells, with a peak accumulation 16 h after removal of the stratum 
corneum and declining thereafter.
Already at baseline, a small number of T-Bet+ cells were present within the dermis. 
Along with an increase of the above mentioned immune cells, the T-Bet+ cells 
showed a significant but modest increase (P=0.0020) 16 h after tape-stripping as 
compared to baseline. However, where the other cell types started to decline after 
16 h, the amount of T-Bet+ cells remained more or less consistently increased until 
72 h after tape-stripping.
Discussion
In the present study, we used epidermal barrier disruption as a model to 
immunohistochemically study regenerative skin thereby providing further insights 
into the development of Koebner positive diseases. It was demonstrated that 
epidermal rupture by tape-stripping results in the activation of the epidermal 
compartment, accompanied by a reproducible inflammatory reaction of the 
skin. Biological markers representing epidermal differentiation and keratinization 
processes, as well as markers representing components of the innate and adaptive 
immune system, were rapidly activated by removal of the stratum corneum. 
Tape-stripping led to the formation of erythematous erosions at all test sites. The 
well established reproducibility of the clinical responses could be reconfirmed.
The epidermal compartment was activated within 16 h after romoving the stratum 
corneum. Keratinocytes expressed almost no K16 at baseline, whereas an increased 
expression was already seen after 16 h. As the expression of K10, which is known as 
a marker for normal differentiation, showed the same gross overall expression at all 
Figure 2. H&E staining before and 16 h after removal of the stratum corneum.
(a) H&E staining at baseline. (b) H&E staining 16 h after tape stripping at an objective 
magnification of 10x and 40x. Arrows show polymorphonuclear leukocytes.
a b
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time intervals (results not shown), the expansion of K16 is more likely a consequence 
of the mechanical stress and not the result of abnormal differentiation. Moreover, 
the innate immune system was activated, demonstrated by an increase in the 
percentage of hBD2-positive and Elafin-positive epidermal surface. 
A peak incidence of deviding epidermal cells was found 48 and 72 h after tape-
stripping, thereby reconfirming earlier observations.10,14 Surprisingly, before this 
significant increase in epidermal proliferation became evident, 16 and 24 h after skin 
barrier disruption the number of Ki-67+ nuclei was significantly lower as compared 
to baseline. This transient early decrease has not been reported before. One may 
speculate that mechanical stress, such as tape-stripping, transiently paralyzes the 
basal keratinocytes, resulting in a significant decrease in the amount of cycling cells 
at 16 and 24 h.
Sixteen h after traumatizing the skin, an influx of elastase+ cells was seen, confirming 
earlier observations.10 Thereafter, the number of elastase+ cells already started to 
decline. These findings indicate that neutrophils play an important role within the 
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Figure 3. Quantification of several immunohistochemical markers. Percentage K16+ (a), 
Elafin+ (b) and hBD2+ (c) epidermal surface, number of Ki-67+ cells (d) per millimeter 
length of basement membrane, and number of elastase+ (e), IL-17+ (f) and T-Bet+ (g) 
cells per square millimeter dermis at baseline and 16, 24, 48 and 72 h after removal of 
the stratum corneum by tape-stripping are shown. Columns represent means ± SEM.
* P <0.05: statistically significant compared to baseline.
a b c
d e f
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acute phase after skin injury.
Together with elastase+ cells, IL-17+ cells appeared within the dermis. Interestingly, 
it is known that, in addition to Th17 cells, various other immune cells, such as 
elastase+ PMNs and mast cells, are also able to express IL-17.15-18 Based on these 
studies together with our findings that the course of the IL-17+ cells coincides with 
the course of the elastase+ cells, it is attractive to speculate that, within this model, 
IL-17 is produced by the elastase+ cells rather than by Th17 cells. The present study 
suggests that both elastase+ and IL-17+ cells play a predominant role in the acute 
inflammatory response.
On the other hand, Th1 cells marked by the expression of T-Bet,19 showed an 
entirely different course over time. Along with the above-mentioned immune cells, a 
significant increase of T-Bet+ cells was seen at 16 h. While all other cell types started 
to decline after 16 h, the amount of T-Bet+ cells remained increased until the end of 
the study period. 
The Koebner phenomenon was first described in psoriasis.6 However, koebnerization 
is also observed in other cutaneous diseases, such as vitiligo and lichen planus.5 The 
pathogenesis of both vitiligo and lichen planus are only partly understood. In vitiligo, 
oxidative stress in combination with players of both the adaptive and innate immune 
system, appears to play a role in initiating this disease.20 Lichen planus is thought to 
be a T cell mediated skin disease, where a variety of cytokines play a role.21 In all three 
cutaneous diseases a dysbalance of the immune system seems to play an important 
role in the pathogenesis. The results of this study confirm that disruption of the skin 
barrier triggers the epidermal compartment, subsequently leading towards a broad 
array of immunological changes in the normal skin. This may suggest that regulation 
of the activated immune system in Koebner positive diseases may be impaired, 
leading towards an ongoing cutaneous inflammation, whereas in the normal skin the 
immune response extinguishes within several days. 
In summary, the present findings demonstrate that tape-stripping is a highly 
reproducible in vivo model. Mechanical removal of the upper layers of the skin leads 
to a rapid activation of the epidermal compartment and causes accumulation of 
immune cells within the dermis. Furthermore, key processes which are presumed 
to play a role within the pathogenesis of Koebner positive skin disorders, may be 
studied in a dynamic fashion.
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Abstract
Clinical trials successfully using antibodies targeting IL-17 in psoriasis support the 
importance of IL-17 in the pathophysiology of this disease. However, there is debate 
concerning the source and dynamics of IL-17 production in inflamed skin. Here 
we characterized IL-17-producing immune cells over time, using two established 
in vivo models of human skin inflammation that share many histological features 
with psoriasis, i.e., leukotriene B4 application and tape-stripping. Both treatments 
revealed a clear influx of neutrophils and T cells. Staining for IL-17 revealed that 
the majority of IL-17 was expressed by neutrophils and mast cells, in both models. 
Neutrophils, but not mast cells, coexpressed the IL-17-associated transcription factor 
RORyt and were able to form extracellular traps. While the presence of mast cells 
remained steady during the skin inflammatory process, the presence of neutrophils 
was clearly dynamic in time. Therefore, it is attractive to hypothesize that IL-17+/
RORyt+ neutrophils contribute to human skin inflammation in vivo and possibly to 
the pathogenesis of skin diseases such as psoriasis. Surprisingly, T cells represented 
a minority of the IL-17-expressing cell population. These observations challenge 
the classical opinion that IL-17 is predominantly associated with T cells in skin 
inflammation.
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Introduction
Psoriasis is an autoimmune-like chronic inflammatory skin disease affecting 
approximately 2% of the population worldwide.1 It results from an impaired epidermal 
barrier function in combination with a dysfunctional immune system. Psoriasis 
has a strong genetic component with 36 associated loci identified by genome-
wide association scans.2 It is a neutrophilic dermatosis characterized by epidermal 
hyperplasia, accumulation of polymorphonuclear (PMN) cells in the epidermis 
(microabscesses of Munro), increased vascularity, and dermal infiltrates containing 
T lymphocytes and neutrophils.1,3 The general opinion is that in the pathogenesis 
of psoriasis, T helper (Th) 17 cells and subsequently their key cytokine interleukin 
(IL)-17 are important mediators.3 Evidence to further support a crucial role of this 
pathway in the pathogenesis of psoriasis results from recently conducted clinical 
trials. Treatment with antibodies (Abs) targeting IL-17A is highly effective in psoriasis 
and causes a rapid improvement of the disease.4-6 Although initially Th17 cells were 
considered the main source of IL-17; recently this paradigm shifted, as summarized 
by Krueger.7 It appears that not only CD4+, CD8+ and γδ T cells but also mast cells 
and neutrophils are potential sources of IL-17 in psoriasis. Mast cells and neutrophils 
release IL-17 through the formation of extracellular traps (ETs).8 Moreover, γδ T cells 
and innate immune cells may contribute substantially more to the development of 
psoriasis than conventional Th17 cells.9,10 Of interest, not only in psoriasis but also 
for other autoimmune and inflammatory pathologies it appeared that IL-17 is mainly 
associated with mast cells and neutrophils, and not so much with T cells.11-13
At present, conclusive evidence on which cells in psoriasis are in fact the main 
producers of IL-17 and at which time point in the inflammatory process they enter 
the stage is lacking. In vivo studies on clinically involved psoriatic skin provide us 
with static information of the disease at a time point where symptoms are already 
present. Ex vivo and in vitro studies provide a more dynamic picture, but lack the 
complex environment, and often make use of lengthy in vitro culture methods not 
always resembling the natural situation. To date, only limited data on the dynamics 
preceding and during early clinical disease are available. In the present study, we 
made use of two established human models for the induction of skin inflammation 
in vivo that both result in different histological changes that are associated with 
psoriasis: the application of leukotriene B4 (LTB4) and tape-stripping.14,15
Leukotrienes are lipid mediators generated in a variety of inflammatory and allergic 
conditions affecting the skin, joints, gastrointestinal system, and respiratory system.16 
High levels of LTB4 were found in lesional skin of psoriasis.17,18 LTB4 is produced by the 
metabolism of arachidonic acid through the 5-lipoxygenase pathway19 and is rapidly 
generated from activated innate immune cells.20,21 Ligation of BLT1 (LTB4 receptor-1) 
by LTB4 causes activation and recruitment of inflammatory cells. LTB4 is a potent 
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chemoattractant for neutrophils, eosinophils, monocytes, macrophages, mast cells, 
dendritic cells, and effector T cells.20,22 In vitro LTB4 stimulates epidermal growth.14 
Topical application of LTB4 causes epidermal proliferation, influx of PMN cells in the 
epidermis (where they accumulate and form small abscesses), and dermis, followed 
by a mononuclear cell infiltrate. Clinically, the application of LTB4 causes mild 
erythema and edema at the site of application. 
Tape-stripping results in removal of the stratum corneum, leading to an impaired 
epidermal barrier function, such as found in psoriasis. Tape-stripping has been 
extensively used as an in vivo model to study epidermal proliferation, keratinization,15,23 
and accumulation of PMN cells.24 
These two established human models for synchronized skin inflammation in vivo 
affect the skin in different ways, resulting in different histological changes, although 
both are associated with the histopathology of psoriasis.14,15 In both models the 
innate and adaptive inflammatory immune response is induced. This provides a 
unique platform to study immune cell dynamics and characteristics in vivo in humans. 
The successful anti-IL-17 treatments in psoriasis emphasized the role of this cytokine 
in the pathogenesis of psoriasis. We here assessed innate and adaptive immune cell 
influx associated with the initiation and maintenance of the inflammatory reaction, 
i.e., before and during early clinical manifestation of human skin inflammation, and 
evaluated which cells at which time point were associated with the production of 
IL-17. 
Methods
Healthy volunteers
After approval by the local medical ethics committee, 20 healthy adults, 6 men and 
14 women, with a mean age of 27 years (range 18-56 years), were recruited according 
to the Declaration of Helsinki. All subjects gave their written informed consent. No 
one suffered from an inflammatory skin disease or had a history of skin disease. 
Furthermore, immunocompromized volunteers or volunteers with an activated 
immune system, e.g., during the flu or after a recent vaccination, were excluded from 
participation. 
In vivo models and tissue handling 
Volunteers were assigned to either the application of LTB4 (n=10) or tape-stripping 
(n=10). In case of LTB4 application, aliquots of 100 ng of LTB4 dissolved in 10 µl 
ethanol were applied in an 8-millimeter cylinder on the lower back skin. The ethanol 
was evaporated under a stream of nitrogen gas, leaving the LTB4 on the skin. The 
LTB4 application sites were covered with patch test chambers for 8 hours to prevent 
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the LTB4 from being displaced. The LTB4 solution was applied on 5 sites. Previous 
experiments showed that application of pure ethanol in the absence of LTB4, as 
a control, did not lead to histological changes, and that the skin was comparable 
to normal skin.25 Therefore, a biopsy of normal skin served as an internal control. 
Subsequently, 3-mm punch biopsies were taken after 8, 24, 32, 48 and 72 hours, 
respectively.
In the tape-stripping group, adhesive tape (Sellotape®) was applied on metal guard 
with an opening of 1 x 2 centimeter². The tape was repeatedly applied and removed 
(20-80 times) until the stratum corneum was removed, indicated by a glistening skin. 
Tape-stripping was performed on 2 areas on the lower back. Again, a biopsy of intact 
unstripped skin functioned as internal control. After 16, 24, 48 and 72 hours, 3 mm 
punch biopsies ware taken from the tape-stripped skin. 
All time intervals were based on literature search in combination with in vivo imaging 
using reflectance confocal microscopy.26,27 On the basis of morphology, we were able 
to validate various time points where influx of lymphocytes and PMN leukocytes 
were expected. 
Histochemistry 
Immunohistochemical stainings were conducted using antihuman primary Abs in the 
following dilutions: CD3 1:500 (F7.2.38; Abcam, Cambridge, UK), CD4 1:100 (BC/1F6; 
SantaCruz Biotechnology, Santa Cruz, CA), CD8 1:100 (C8/144B; Dako, Glostrup, 
Denmark), Foxp3 1:100 (PCH101; eBioscience, San Diego, CA), IL-17 polyclonal goat 
IgG 1:500 (R&D-Systems, Minneapolis, MN), RORγ polyclonal rabbit 1:1000 (Novus 
Biologicals, Littleton, CO), elastase 1:10.000 (NP57; Dako), and tryptase 1:100.000 
(AA1; Dako). 
Paraffin-embedded sections (of 4 µm thickness) were deparaffinized and rehydrated. 
Heat induced antigen retrieval with Tris/ethylenediaminetetraacetic acid (EDTA) (50 
mM/L Tris + 2 mM/L EDTA, pH9.0 for Foxp3, IL-17 and tryptase) or EDTA/Tween (EDTA 
pH 8.0 + 0.5% Tween for CD3, CD4 and CD8) was performed during 10 minutes. To 
retrieve the epitopes for the RORγ Ab, slides were incubated with trypsin solution 
(pH 7.8) for 10 minutes at 37 °C. Endogenous peroxidase activity was blocked with 
2% H2O2 in phosphate buffered saline (PBS) and sections were incubated with 1% 
bovine serum albumin (BSA; Dako). Primary Abs dissolved in 1% BSA were applied 
over night. Reactions were amplified using horseradish peroxidase (HRP) labeled 
polymer (Envision; Dako for CD3, CD4, CD8, RORγ, elastase and tryptase) or avidin-
biotin complex–HRP solution (1:50) (Vectastain ABC-elite kit; Vector-Laboratories, 
Burlingame, CA for Foxp3 and IL-17) depending on the species used. Abs were 
visualized with 3,3’-diaminobenzidine tetrahydrochloride solution (Sigma-Aldrich, 
St. Louis, MO). After counterstaining with Mayer’s Hematoxylin (Sigma-Aldrich), the 
sections were dehydrated and mounted. 
132
Chapter 8
Negative controls were treated with either HRP labeled polymer or avidin-biotin 
complex–HRP solution to enhance the signal. Instead of the primary Ab, 1% BSA 
dissolved in PBS was used. Negative controls showed no signal. Representative 
immunohistochemical stainings including negative controls are illustrated in 
Supplemental Figure 1.
Immunofluorescent double-stainings were carried out to characterize RORγ+ and 
IL-17+ cells. Immunofluorescence was performed using the Abs as described for 
immunohistochemistry in the following dilutions: CD3 1:100, elastase 1:3000, IL-17 
1:500, RORγ 1:100 and tryptase 1:100. Additional immunofluorescent staining were 
performed using myeloperoxidase (MPO) polyclonal rabbit 1:2000 (A0398; Dako) in 
combination with elastase 1:2000 and Foxp3 1:50 in combination with CD25 1:50 
(4c9; Bio SB, Santa Barbara, CA). Epitope retrieval was conducted. Subsequently, the 
sections were incubated with a mix of matched secondary Abs at room temperature. 
Depending of the combination used, primary Abs were labeled with IgG Alexa Fluor 
488 (1:200; Invitrogen, Carlsbad, CA), Alexa Fluor 594 (1:400; Invitrogen) or Alexa 
Fluor 647 (1:200; Invitrogen). Alexa Fluor 647 was used for IL-17 in combination with 
CD3 and was digital converted to Alexa 488. The slides were counterstained with 
4’,6-Diamidino-2-phenylindole (DAPI) (1:3; Vector Laboaratories) and mounted using 
Fluoromount-G (Southern Biotech, Birmingham, Al). RORγ in combination with CD3, 
IL-17 and tryptase had to be sequentially stained (first CD3/IL-17/tryptase followed 
by RORγ) without using a mix of primary and secondary Abs, as antigen retrieval with 
trypsine decreased the expression of IL-17 and tryptase. 
Quantification of cells and epidermal thickness
The tissues were visualized and photographed by means of a microscope (Axioskop2 
MOT; Zeiss, Oberkochen, Germany) and digital camera (Axiocam MRc5; Zeiss). Two 
sequential photographs of each section were taken at an objective magnification of 
10x, thereby screening the entire epidermis and dermis. ImageJ (National Institutes 
of Health, Bethesda, MD) was used as a tool to automatically count positively stained 
cells, as previously described.28 This resulted in number of positive cells mm⁻². 
Epidermal thickness was measured as follows: of each sample, the most thickest 
and the most thinnest part of the epidermis were measured (using ImageJ) and 
mediated.
Flow cytometry
Three volunteers were challenged with 100ng LTB4 dissolved in 10 µl ethanol. Two 
4-millimeter skin biopsies were taken after 48 hours and were incubated in Dispase 
II (neutral protease, grade II; Roche Diagnostics GmbH, Mannheim, Germany) over 
night at 4 °C. The epidermis was separated from the dermis. Dermal tissue was 
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Figure 1. Application of LTB4 causes thickening of the epidermis, influx of immune cells, 
and small abscesses. (a) Hematoxilin and eosin (H&E) stainings of the skin 0, 8, 24, 32, 48 
and 72 hours after the application of leukotriene B4 (LTB4). LTB4 causes a gradual increase of 
epidermal thickness (indicated by arrow), influx of immune cells (indicated by #), and small 
abscesses in the subcorneal zone of the epidermis (indicated by *). Bar=200 μm. (b) Mean 
thickening of the epidermis in µm at all time points after application of LTB4 (n=10). (c) Means 
± SEM number, as analyzed by immunohistochemistry of CD3+, CD4+, CD8+, Foxp3+, IL-17+, 
RORγ+, elastase+ and tryptase+ cells mm⁻², present in the dermis at six consecutive time 
points after the application of LTB4 (n=10). *P <0.01 to the previous measurement in time.
a
c
b
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Figure 2. Dual-color immunofluorescent stainings of inflamed skin after the application 
of LTB4 and after tape-stripping. Immunofluorescence of (a) RORγ (red) and elastase 
(green), (b) IL-17 (red) and RORγ (green), (c) IL-17 (red) and tryptase (green), (d) RORγ (red) 
and tryptase (green), (e) CD3 (red) and IL-17 (green) and (b) CD3 (red) and RORγ (green). 
4’,6-Diamidino-2-phenylindole (DAPI) was used as a counterstaining. Arrowheads point 
toward double-positively stained cells. Bar=100 μm.
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dissociated to single-cell suspensions by combining mechanical dissociation using a 
gentleMACS™ Dissociator with enzymatic degradation using Collagenase I (Sigma-
Aldrich, St. Louis, MO) and DNase I (EMD Chemicals, San Diego, CA). Cells were 
phenotypically analyzed by four color flow cytometry using a FC500 flow cytometer 
(Beckman Coulter, Miami, FL). The following conjugated antibodies were used: 
CD45-PE (Dako), CD15-PC5 (Beckman Coulter, Marseille, France) and CD117-PC5 
(Beckman Coulter, Marseille, France), CD3-PC7 (Beckman Coulter, Fullerton, CA). 
Before intracellular analysis of IL-17A Alexa Fluor 488 (eBioscience), fixation and 
permeabilization was performed using Fix and Perm reagent (eBioscience).
Staining with propidium iodide (Calbiochem Merck Bioscience, Darmstadt, Germany) 
was used for the identification of dead cells. Viability was over 95%. Furthermore, 
blanks (primary Abs were omitted) as well as isotype controls were included in the 
experiments. The gate settings were adapted accordingly.
Transcriptional analysis
mRNA was detected in paraffin-embedded tissue sections of 4-µm thickness with 
the QuantiGene ViewRNA ISH Tissue Assay (2-plex), using the manual as provided 
by the manufacturer (Affymetrix, Santa Clara, CA). The following probes were 
used: type 1 antihuman IL-17 probe, type 6 antihuman MPO probe and type 6 
antihuman RPLP0 probe. In short, after deparaffinization, tissue pretreatment was 
performed by heating the slides for 5 minutes in pretreatment solution at 95 °C. 
Thereafter, the tissues were incubated for 10 minutes with protease solution at 
40 °C. The target probes (diluted 1:40) were applied and incubated during 2 hours 
at 40 °C for hybridization. After building the signal amplification using bDNA, the 
probes were labeled. Type 1 probes were labeled with fast red substrate (alkaline 
phosphatase) and type 6 probes were labeled with fast blue substrate (alkaline 
phosphatase), respectively. The samples were visualized under a fluorescence 
microscope (Leica DMRA, Wetzlar, Germany); type 1 probes were visualized in red, 
and type 6 probes were visualized in green. 4’,6-Diamidino-2-phenylindole was 
used as a counterstain.
Statistical analysis 
For each time point after the application of LTB4 and tape-stripping, the results 
were expressed as means ± SEM. The Friedman test with Bonferroni correction 
was performed to test for differences between all time-points. If the Friedman test 
showed a statistically significant result (P <0.01), post hoc analysis with Wilcoxon 
matched-pairs signed-rank test was conducted by comparing each time point with 
t=0. Analyses were conducted using SPSS 20.0 (Statitical Package for Social Sciences, 
IBM, Armonk, NY). 
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Topical application of LTB4 leads to subsequent influx of innate immune cells 
followed by adaptive immune cells; IL-17+ cells reside mainly within the innate cell 
population
Skin of healthy volunteers was challenged with LTB4. Subsequently, biopsies were 
taken at t=0 and after 8, 24, 32, 48 and 72 hours. Over time, LTB4 caused a gradual 
increase of epidermal thickness, influx of immune cells and small abscesses in the 
subcorneal zone of the epidermis (Fig. 1a and b). 
The tissues were then characterized for the presence of CD3, CD4, CD8, Foxp3, IL-17, 
RORγ, elastase and tryptase using immunohistochemistry. The number of positive 
cells for each marker in the dermis following time after LTB4 application was calculated 
(Fig. 1c and Supplemental Table 1). As early as 8 hours after the application of LTB4, 
the number of immune cells present in the dermis increased. Most of these cells 
proved to be elastase+ neutrophils. Elastase is a convenient and sensitive marker for 
the quantification of neutrophils in the skin.29 However, elastase is also expressed 
by macrophages.30 Therefore, we additionally stained for MPO, a naturally occurring 
constituent of neutrophils, often used to detect neutrophils in the skin.8,31 The MPO 
staining pattern matched completely the elastase staining, thereby supporting that 
the elastase+ cells that we describe are neutrophils (Supplemental Fig. 2).
The influx of elastase+ cells in the dermis exponentially increased with a peak 
incidence at 24-32 hours, declining thereafter. Elastase+ cells even entered the 
epidermis, causing microabscesses in the subcorneal zone after 24 hours. RORγ+ 
and IL-17+ cells showed a similar trend as compared to the elastase+ cells, with a 
maximum accumulation at 24-32 hours. Thereafter, their presence declined. While 
RORγ+ cells were no longer present in the tissue at 72 hours, the number of IL-17+ 
cells returned to normal levels, i.e., the same level as before the application of LTB4. 
The presence of dermal tryptase+ cells, indicative for mast cells, was stable and did 
not change upon the application of LTB4. 
At 48 hours, we observed an influx of T cells, both T helper and cytotoxic T cells, in the 
dermis, marked by the presence of CD3+, CD4+, and CD8+ cells. This influx coincided 
with the influx of Foxp3+ cells. All Foxp3+ cells coexpressed CD25 (Supplemental Fig. 
3), suggesting that these regulatory T cells (Treg) are indeed functional Treg.32 T cell 
numbers in the epidermis were low.
The influx of immune cells upon LTB4 application appeared biphasic, with first 
an influx of neutrophils at 24 hours, followed by T cells at 48 hours. As RORγt 
and IL-17 are considered the key transcription factor and cytokine of Th17 cells, 
respectively,33 we were surprised to find the expression of these markers coinciding 
with granulocyte influx, rather than with the influx of the adaptive immune cells. 
This prompted us to further characterize the IL-17+ and RORγ+ cells, using dual-color 
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immunofluorescence. Notably, we observed that of all the cell types tested for, only 
a subpopulation of elastase+ neutrophils expressed RORγ (Fig. 2a). The majority of 
these RORγ+ cells coexpressed IL-17 (Fig. 2b). Expression of RORγ was not found in 
the absence of elastase (Fig. 2a). Interestingly, although we found that all tryptase+ 
mast cells expressed IL-17 (Fig. 2c), they appeared negative for RORγ (Fig. 2d). T cells 
lacked both the expression of RORγ and IL-17 at all time points (Fig. 2e and f).
IL-17 expression by dermal immune cells was verified by carrying out flow cytometry 
on cell suspensions derived from skin biopsies. Preliminary results are shown in 
Supplemental Figure 4. In agreement with our immunohistochemical experiments, IL-
17A expression was particularly linked to CD45+CD3-CD15+ cells, that we considered 
to be neutrophils. The majority of the CD45+CD3-CD15+ population coexpressed IL-
17A. Most of the mast cells, identified as CD45+CD3-CD117+ cells, also expressed 
IL-17A. In contrast to what we observed by immunohistochemistry, flow cytometry 
enabled the detection of a small population of IL-17A-expressing CD45+CD3+ T cells.
Neutrophils in the epidermis formed specialized structures called neutrophil ETs (Fig. 
3),34 whereas the formation of these structures was not observed in mast cells.
Now that we established the presence of IL-17 protein in neutrophils, we wondered 
whether these cells can make IL-17 themselves. Therefore we analyzed the presence 
Figure 3. Extracellular trap formation of neutrophils after the application of LTB4. Confocal 
laser scanning microscopy of (a) neutrophils showing neutrophil extracellular traps formed 
of nuclear material and (b) neutrophils with intact nuclei. Both images show neutrophils that 
display both elastase (green) and IL-17 (red). Bar=10 μm.
a b
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of IL-17 mRNA in neutrophils by 2-Plex QuantiGene ViewRNA ISH Tissue Assay 
(Affymetrix, Santa Clara, CA) on paraffin-embedded sections of the skin, upon the 
application of LTB4 (Fig. 4). We observed that in the inflamed skin, IL-17 mRNA was 
present in microabscesses, localized in the subcorneal zone of the epidermis. IL-17 
mRNA colocalized with MPO mRNA. As already shown by immunohistochemical 
stainings, the abscesses typically consist of accumulated neutrophils. The 
housekeeping gene RPLP0 was expressed in LTB4-challenged skin, as well as in normal 
skin. Other than in these subcorneal abscesses, we saw only little presence of IL-17 
mRNA in dermal neutrophils. This may be due to the detection level of the essay; 
whereas IL-17 produced by accumulated neutrophils with consequently higher levels 
can easily be detected, IL-17 levels produced by solitary neutrophils may be missed.
Tape-stripping leads to a simultaneous influx of innate and adaptive immune cells; 
IL-17+ cells again mainly reside within the innate cell population
Having established that after LTB4 application the immune cell influx is biphasic and 
that the main source of IL-17 are neutrophils and mast cells, we next challenged the 
skin with tape-stripping, to investigate whether we could confirm our findings in a 
different setting. 
Biopsies were taken at t=0 and after 16, 24, 48 and 72 hours upon tape-stripping 
and were processed for immunohistochemistry, as described for the LTB4 model. 
Figure 4. Accumulated neutrophils in the subcorneal zone of the LTB4-challenged skin 
contain IL-17 mRNA. (a) Immunohistochemical stainings of microabscesses in the subcorneal 
zone of the epidermis, caused by the application of LTB4. The microabscesses stain positively 
for elastase and IL-17 (arrows). Bar=100µm. (b) Representative immunofluorescent mRNA 
stainings (from n=4 experiments) for IL-17 (red), RPLP0 (housekeeping gene) (green) and 
myeloperoxidase (MPO) (green) on LTB4-challenged skin and normal skin. As a negative 
control anti-rat probes were used instead of anti-human probes. DAPI was used as a nuclear 
stain. Microabscesses are marked by the white dotted line.
a protein stainings
elastase IL-17
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Figure 5. Tape-stripping results in thickening of the epidermis with hyperkeratosis, 
parakeratosis, and influx of immune cells. (a) H&E stainings of the skin 0, 16, 24, 48 and 72 
hours after tape-stripping. Tape-stripping leads to (partial) removal of the stratum corneum 
at t=16 hours. This results in a gradual thickening of the epidermis (indicated by an arrow) 
with hyperkeratosis, parakeratosis (indicated by *), and influx of immune cells (indicated by 
#). Bar=200 μm. (b) Mean thickening of the epidermis in µm at all time points after tape-
stripping (n=10). (c) Means ± SEM number, as analyzed by immunohistochemistry, of CD3+, 
CD4+, CD8+, Foxp3+, IL-17+, RORγ+, elastase+ and tryptase+ cells mm⁻², present in the 
dermis at five consecutive time points after tape-stripping (n=10). *P <0.01 to the previous 
measurement in time.
a
b
c
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As expected, removal of the stratum corneum resulted in a gradual thickening of 
the epidermis with hyperkeratosis, parakeratosis, and influx of immune cells (Fig. 
5a and b). 
The number of CD3+, CD4+, CD8+, Foxp3+, IL-17+, RORγ+, elastase+ and tryptase+ 
cells in the dermis following time after tape-stripping were calculated (Fig. 5c and 
Supplementary Table 2). At the first measurement, 16 hours after tape-stripping, 
the accumulation of elastase+ cells in the dermis already reached its maximum. 
Elastase+ cells only sporadically infiltrated the epidermis. Seventy-two hours after 
tape-stripping, the presence of elastase+ cells was drastically diminished and almost 
comparable to t=0. Again, the same pattern was seen for IL-17+ and RORγ+ cells in 
the dermis. Similar to what we noticed after the application of LTB4, RORγ+ cells 
disappeared from the tissue, while IL-17+ cells stayed present at the same level as 
before tape-stripping. The number of tryptase+ mast cells did not change over time.
We not only observed a peak incidence of neutrophils (elastase+ cells) 16 hours 
after tape-stripping, but also the influx of CD3+, CD4+, CD8+ and Foxp3+ T cells in 
the dermis reached a maximum at 16 hours. The numbers of these T cell subsets 
remained at this high level up to the last measurement at 72 hours. T cells rarely 
penetrated the epidermis.
In contrast to the LTB4 model, where a biphasic response was observed, tape-
stripping led to a simultaneous influx of innate and adaptive immune cells. The 
number of neutrophils present in the tissue peaked at 16 hours and almost dropped 
to undetectable levels at 72 hours. T cell numbers remained stable from 16 up to 72 
hours after challenging the skin.
The immunohistochemical expression pattern of RORγ and IL-17 by different 
immune cell subsets after challenging the skin with tape-stripping was similar to that 
found in the LTB4 skin model. This may suggest that this pattern is, at least in part, 
independent of the mechanism causing the skin trauma.
Discussion
The general consensus at this moment is that IL-17 is a major driver in the psoriatic 
process. This notion is strongly supported by successful treatments with anti-IL-17 
Abs in patients with psoriasis.4-6 However, the debate on the cellular source(s) of 
IL-17 continues. The goal of the present study was to track the different innate and 
adaptive immune cells that have been associated with IL-17 in time, before and 
during early human skin inflammation, and establish which of these cells in fact 
produce IL-17 under these circumstances. To this end, we used two human in vivo 
models for skin inflammation that share mechanistic and histological features with 
psoriasis. The application of LTB4, a potent PMN cell chemoattractant, led to an initial 
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influx of neutrophils, with a peak incidence at t=24-32 hours, followed by an influx 
of T cells at t=48 hours. A disrupted epidermal barrier function, as induced by tape-
stripping, led to a simultaneous influx of neutrophils and T cells already at 16 hours. 
Immunohistochemical characterization of IL-17-associated cells led to the finding that 
neutrophils in both models for skin inflammation have the ability to express IL-17 from 
t=16 hours onward. Furthermore, neutrophils have the machinery to produce IL-17, 
marked by the presence of transcription factor RORγt in IL-17-containing neutrophils. 
IL-17 mRNA transcripts were detected in accumulated neutrophils that were present 
in the epidermis of our LTB4-skin model, implicating that neutrophils can make IL-17 
themselves. Moreover, we found that neutrophils were able to release IL-17 via the 
formation of extra cellular traps. Although the presence of neutrophils was clearly 
dynamic, the presence of mast cells remained stable during the skin inflammatory 
process induced by LTB4 and tape-stripping. Mast cells appear to constitutively 
express IL-17 in the skin, as was also confirmed by Lin et al.8 To our knowledge, it is 
previously unreported that these mast cells lack the expression of the IL-17-related 
transcription factor RORγt. ET formation by mast cells was not observed in this study. 
T cells represented only a minority of the IL-17-expressing cells in these models and 
lacked the expression of transcription factor RORγt. Similarly, Lin et al conducted 
a study in psoriatic patients where they demonstrated that neutrophils and mast 
cells, but not T cells, were the predominant cell types containing IL-17 in the human 
skin.8 These predominant cell types release IL-17 via the formation of ETs. In this 
study, no significant increase was observed in the presence of IL-17+ T cells in the 
skin of psoriatic patients versus healthy individuals. Altogether, these observations 
challenge the classical opinion that IL-17 is predominantly associated with T cells.
Upon the application of LTB4, neutrophils in the epidermis were able to form 
specialized structures to release IL-17, termed ETs. They are composed of granule 
and nuclear constituents34 and result from a specialized process of cell death, called 
ETosis.35 The formation of ET by neutrophils (NETs) is, aside from degranulation and 
phagocytosis, a manner to disarm and kill bacteria extracellularly.34 ET formation 
by neutrophils was only observed after the application of LTB4 and not after tape-
stripping. This might suggest that LTB4-driven processes, and not skin barrier 
disruption, are important in NET formation in the skin. In these models we did not 
observe extracellular trap formation by mast cells (MCETs).36 
As expected, the influx of Treg in the tissue occurred simultaneously to the influx of 
proinflammatory CD4+ and CD8+ T cells, confirming that during skin inflammation 
both the proinflammatory as well as the anti-inflammatory component of the 
immune system are simultaneously activated.37,38 Although IL-17-producing Treg 
were previously identified in severe psoriasis,39 these dysfunctional Treg could not be 
detected in the present setting, suggesting that disease severity and duration might 
have a role in the actual involvement of certain cell types.
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In conclusion, psoriasis is usually studied in the context of present disease. These 
studies provide us with static information of the disease at a time point where 
symptoms are already present. As limited data are available involving the dynamics 
of immune cells preceding and during early clinical disease, we used two established 
models for skin inflammation that share similarities with psoriasis. By targeting the 
skin in two distinct ways, we were able to confirm that our findings were reproducible 
and largely independently of the skin model that was used. Although the dynamics of 
the innate and adaptive immune response varied, the cellular sources of IL-17 proved 
identical in both models. However, it should be noted that IL-17-expressing cells do 
not necessarily release the cytokine. Consequently, it needs to be established whether 
IL-17A levels in the cell match the IL-17A levels present in the microenvironment. A 
further limitation of our study concerns the healthy volunteers participating in the 
study. They probably lacked genetic susceptibility to the skin disease because they 
were free of any signs or history of skin disease. 
Most importantly, we found that not T cells, but neutrophils expressing IL-17 in the 
presence of transcription factor RORγt, and mast cells were the main source of IL-17. 
Although the presence of mast cells remained steady during the skin inflammatory 
process, presence of neutrophils was clearly dynamic, suggesting a more important 
role for neutrophils in these skin models. Moreover, neutrophils were able to form 
specialized structures to release IL-17. On the basis of increasing evidence from 
literature, and the present findings using dynamic skin models, we might have to 
adjust the current paradigm on cellular sources of IL-17 in the skin in the near future. 
Extrapolation of these results may also have implications for the pathogenesis of 
psoriasis. 
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Supplemental Figure 1. Representative immunohistochemical stainings before and 48 
hours after tape-stripping. (a) CD3 (b) CD4 (c) CD8 (d) Foxp3 (e) IL-17 (f) RORγ (g) elastase 
(h) tryptase (i) negative control using horseradish peroxodidase (HRP) labeled polymer (j) 
negative control using avidin-biotin complex-HRP solution. Bar=200 μm.
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Supplemental Figure 2. Representative immunofluorescent double-staining for elastase 
and myeloperoxidase (MPO). Bar=10 μm.
Supplemental Figure 3. Immunofluorescent double-stainings for CD25 and Foxp3. 
Representative pictures are shown of skin after the application of LTB4 and after tape-
stripping. Bar=20 μm.
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Supplemental Figure 4. IL-17A-expressing cells in dermal cell suspensions, measured by 
flow cytometry 48 hours after the application of LTB4. A representative experiment from 
n=3 healthy volunteers is shown. Percentages in the quadrants are within the live, CD45+ 
cell population.
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Supplemental tables
CD3 CD4 CD8 Foxp3 IL-17 RORγ elastase tryptase
t=0 26 ± 7 29 ± 10 39 ± 16 8 ± 2 45 ± 6 1 ± 0 1 ± 0 60 ± 6
t=8 33 ± 13 37 ± 15 33 ± 11 11 ± 3 58 ± 12 8 ± 1* 26 ± 15* 55 ± 6
t=24 33 ± 8 36 ± 9 30 ± 4 8 ± 2 236 ± 40* 143 ± 32* 295 ± 58* 64 ± 5
t=32 36 ± 7 61 ± 28 34 ± 8 16 ± 5 232 ± 30* 97 ± 21* 358 ± 42* 61 ± 5
t=48 185 ± 62 229 ± 62* 60 ± 10 36 ± 9 155 ± 35* 61 ± 14* 223 ± 59* 58 ± 4
t=72 198 ± 55* 198 ± 72* 60 ± 20 51 ± 12* 82 ± 16 24 ± 7* 117 ± 29* 64 ± 5
CD3 CD4 CD8  3 IL-17 RORγ elastase tryptase
t=0 35 ± 16 34 ± 9 26 ± 8 7 ± 2 51 ± 12 1 ± 0 1 ± 0 61 ± 5
t=16 262 ± 69* 230 ± 81* 86 ± 29* 37 ± 10* 168 ± 32* 72 ± 20* 231 ± 55* 61 ± 9
t=24 236 ± 64* 190 ± 55* 87 ± 20* 28 ± 8* 141 ± 38* 73 ± 26* 147 ± 49* 58 ± 6
t=48 231 ± 44* 302 ± 71* 87 ± 21* 50 ± 16* 73 ± 16 19 ± 10 77 ± 17* 64 ± 6
t=72 168 ± 46* 157 ± 42* 84 ± 25* 52 ± 17* 59 ± 11 8 ± 4 29 ± 10* 60 ± 8
Supplemental Table 1. Means (± SEM) at different time points after the application of LTB4.
Supplemental Table 2. Means (± SEM) at the different time points after tape stripping.
*P <0.01 as compared to t=0
*P <0.01 as compared to t=0.

 9
Cellular sources of IL-17 in psoriasis: 
a paradigm shift?
R.R.M.C. Keijsers, I. Joosten, P.E.J. van Erp, H.J.P.M. Koenen, P.C.M. van de 
Kerkhof
Accepted for publication in Exp Dermatol
152
Chapter 9
Abstract
Psoriasis is a common chronic inflammatory skin disease that results from interplay 
between the immune system and the epithelium. In light of the very successful anti-
cytokine therapies for psoriasis, the focus has been directed towards the adaptive 
immune system. Expression studies, genetic studies and treatments specifically 
targeting players of the IL-23/IL-17 pathway, point at an important role for IL-17 in 
the pathogenesis of psoriasis. IL-17 stimulates the keratinocytes to produce psoriasis-
associated molecules, eventually leading to chronic skin inflammation. 
The current opinion is that IL-17 is mainly produced by T cells, so-called T helper 
(Th) 17 cells, in psoriasis. However, evidence is accumulating that cells of the innate 
immune system, like neutrophils, mast cells, γδ T cells and innate lymphoid cells are 
the main source of IL-17 in psoriasis, rather than T cells. The paradigm in this field of 
research is shifting. With this viewpoint article we will address this novel concept by 
critically summarizing the current literature on this subject. 
In psoriatic arthritis and atherosclerosis, important conditions related to psoriasis, 
it was also found that the majority of IL-17 is associated with cells of the innate 
immune system. This new concept changes our view of IL-17. Blocking IL-17 with 
targeted treatments might be more far-reaching than previously thought; not only 
IL-17 production by T cells but also by innate immune cells is blocked. Furthermore, 
therapies specifically targeting IL-17 may not only improve psoriasis, but also 
comorbid disorders that is associated with the IL-17 pathway, hereby preventing 
serious complications on the long term.
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Introduction
Interleukin (IL)-17 is a proinflammatory cytokine that plays a key role in clearing 
extracellular pathogens, but is also known to be involved in various autoimmune and 
inflammatory conditions, such as psoriasis.1-5 Production of IL-17 is dependent on 
IL-23. IL-17 exerts its function in the skin by directly stimulating the keratinocytes to 
produce psoriasis-associated molecules, such as cytokines, ß-defensins, antimicrobial 
peptides (AMPs) and chemokines.6-11 
IL-17 is one of the key cytokines in the pathogenesis of psoriasis; Expression of IL-17 is 
elevated in lesional psoriatic skin as compared to nonlesional skin.12,13 Furthermore, 
genetic studies support an important role for IL-23, and thus for IL-23/IL-17 signaling 
in the pathogenesis of psoriasis.14 Ustekinumab a monoclonal antibody (mAb) 
targeting the shared p40 subunit of IL-12 and IL-23 is a well-established, frequently 
used and effective drug in the treatment of psoriasis.15 Moreover, recently developed 
mAbs directly targeting IL-17 (receptor) show very promising results in the treatment 
of psoriasis.16-18 
In psoriasis, the adaptive immune response is particularly associated with 
proinflammatory T cell subsets, such as T helper (Th) 1, Th17 and Th22 cells.19,20 
Currently, it is a widely held belief that Th17 cells are the main source of IL-17.21 
However, recent data point towards the fact that much of the IL-17 release during 
inflammation is actually derived from innate immune cells.22 Consequently, more 
and more studies are appearing addressing this issue in psoriasis and other IL-17 
mediated diseases. The current paradigm in this field of research is shifting. While 
different aspects of IL-17 in the pathogenesis and treatment of psoriasis have been 
highlighted in the last years, we feel that a critical overview on the actual cellular 
sources of IL-17 in psoriasis is lacking.
We here address this new concept in psoriasis by looking at the published data on 
the contribution of several T cell subsets and innate immune cells, like neutrophils, 
mast cells, γδ T cells and innate lymphoid cells (ILCs) to the production of IL-17. 
We performed an open search and critically summarized the current evidence on 
this subject in mice and humans, not only focusing on psoriasis but also on other 
IL-17 mediated chronic inflammatory diseases. Finally, in light of the new anti-IL-17 
treatments for psoriasis we propose a new concept for psoriasis and its comorbid 
diseases. 
γδ T cells are the primary source of IL-17 in murine skin
Psoriasis as such, does not exist as a naturally occurring disease in mice. Nevertheless, 
several immunological reconstitution approaches or xenotransplantation models 
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have shed light on the immunopathogenesis of psoriasis.23 However, it remains 
difficult to translate these results to the human situation. A frequently used 
mouse-model to study IL-17 in psoriasis-like skin inflammation, is the application 
of imiquimod (IMQ). IMQ is a TLR7/8 ligand and potent immune activator that is 
used as a treatment for condylomata acuminata, basal cell carcinomas and actinic 
keratoses. In patients with psoriasis, treatment with IMQ can exacerbate the skin 
disease.24 Topical application of IMQ on mouse back skin causes inflamed scaly skin 
lesions and induces a dermatitis that shows some similarities to human psoriasis, 
both macroscopically and histologically. Moreover, the induced dermatitis critically 
depends on the IL-23/IL-17 axis.25 The cells most frequently studied in this model with 
respect to IL-17 secretion comprise γδ T cells and ILCs. In murine skin γδ T cells are 
present in the epidermis, the so-called dendritic epidermal T cells (DETCs), as well as 
in the dermis. Human skin contains dermal γδ T cells, whereas direct equivalents of 
DETCs are absent. ILCs are emerging as important effectors in antigen-independent 
immune responses and lack the expression of lineage specific markers.26 Of special 
interest with respect to the production of IL-17 are group 3 ILCs, characterized by the 
expression of transcription factor RORγt. 
Using the application of IMQ as an in vivo model, it was found that not Th17 cells 
were the primary source of IL-17A in mice, but skin invading populations of γδ T 
cells and ILCs. Disease induction led to an upregulation of the number of dermal 
γδ T cells, whereas DETC numbers remained unaltered.27 Furthermore, skin 
pathology was diminished in Tcrd-/- (T cell receptor delta chain knock-out) mice 
treated with IMQ as opposed to Tcra-/- (T cell receptor alpha beta knock-out) and 
wild type mice, suggesting that dermal γδ T cells are major drivers in IMQ-induced 
skin inflammation.28 Interestingly, topical application of methotrexate alleviates the 
IMQ-induced psoriasiform phenotype and causes a decrease in the number of IL-
17A-producing dermal γδ T cells.29 Not much is known about other IL-17-producing 
immunocytes in this murine model for psoriasis.
Neutrophils and mast cells, but not T cells, are the main cell 
types expressing IL-17 in the human skin
In humans, it is unknown to what extent circulating Th17 cells contribute to skin 
inflammation in psoriasis. Moreover, it is even debated whether Th17 cells in 
peripheral blood of psoriatic patients are actually increased as compared to healthy 
controls,30-32 or not33,34 (summarized in Table 1). One study observed a significant 
correlation between the number of circulating Th17 cells and disease severity.31
Teunissen et al were one of the first to show that CD4+ T cell clones derived from 
psoriatic plaques expressed IL-17 mRNA upon stimulation with anti-CD3/CD28, 
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 PB = peripheral blood; PMA = phorbol-12-myristate 13-acetate
Table 1. Percentage of circulating/skin-derived Th17 cells within the CD4+ or total 
lymphocyte population in patients with psoriasis, measured by flow cytometry
Tissue Reference Stimulation method Phenotype Th17 
cells
Mean (± SEM)% of T cells 
producing IL-17
P 
value
Psoriatic patients Healthy 
controls
PB Kagami et 
al30
6 hours with PMA, 
ionomycine and 
Brefeldin A
CD4+IL-17+ 1.47 ± 0.74% 0.73 ± 
0.34%
<0.001
PB Zhang et 
al31
5 hours with PMA 
and ionomycine
CD3+CD4+IL-17+ 3.54 ± 2.05% 1.76 ± 
0.70%
<0.001
PB Torii et 
al32 
4 hours with PMA, 
ionomycine and 
Brefeldin A
CD4+IL-17+ 3.10 ± 1.14% 2.58 ± 
0.80%
<0.05
PB Kryczek et 
al33
Clonal expansion of 
single cells
CD3+IL-17+ 0.9% 0.7% >0.05
PB Lowes et 
al34
4 hours with PMA, 
ionomycine and 
Brefeldin A
CD3+IL-17+ 3.0% (within 
total lymphocyte 
population)
4.6% 0.4857
PB Lewis et 
al37
12 hours with 
Brefeldin A
CD4+CCR4+CCR6+ 
or CD4+IL23R+
11.2% Th17 cells. 
Of these Th17 
cells 0.168-3.50% 
produced IL-17.
- -
Skin Kryczek et 
al33
Clonal expansion of 
single cells
CD3+IL-17+ 6.8% 3.2% <0.05
Skin Lowes et 
al34
2 days of culture + 
4 hours with PMA, 
ionomycine and 
Brefeldin A
CD69+CD3+IL-17+ 6.2% (within 
total lymphocyte 
population)
0.5% 0.029
Skin Res et al36 6-7 days of culture 
+ 5 hours with 
PMA, ionomycine 
(the last 4 hours 
with Brefeldin A)
CD4+IL-17+ 5.94 ± 1.13% 5.87 ± 
1.83%
>0.05
Skin Lewis et 
al37
12 hours with 
Brefeldin A
CD4+CCR4+CCR6+ 
or CD4+IL23R+
57.6% Th17 cells. 
Of these Th17 
cells only 22.9-
26.9% produced 
IL-17.
- -
Skin Pene et 
al38
Clonal expansion of 
single cells in the 
presence of IL-2 
and anti-CD3/CD28 
mAbs
CD4+CCR6+ 29% Th17 cells. Of 
these Th17 cells 
only 27 ± 12.3% 
produced IL-17.
- -
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whereas in normal skin IL-17 mRNA was undetectable.35 This paved the way for 
other groups to study IL-17-producing T cells in the skin; it was found that T cells 
derived from skin biopsies contained discrete populations of Th17 cells in the 
dermis. It is questionable whether IL-17-producing T cell numbers in psoriatic 
skin are higher than,33,34 or are identical to the numbers found in normal skin.36 
Lewis et al isolated and clonally expanded CD4+ lymphocytes directly ex vivo from 
untreated psoriatic lesions and characterized Th17 cells as being CD4+CCR4+CCR6+ 
or CD4+IL23R+. Of the total isolated CD4+ population, more than 50% consisted 
of Th17 cells. Of these Th17 cells only 13.5-28.4% spontaneously produced IL-17. 
Unfortunately, corresponding information obtained from experiments in the healthy 
controls was lacking.37 From a broader perspective, it was found that within Th17 
mediated autoimmune-like diseases, CD4+CCR6+ Th17 cell numbers of patients 
with psoriasis were the highest upon clonal expansion (29% of the total CD4+ 
population). Around 30% of these Th17 cells actually produced IL-17.38 Of note, 
in none of the afore mentioned studies the IL-17-expressing subpopulation within 
the dermal T cell compartment surpassed the 10%, even after strong nonspecific 
T cell triggering in vitro (summarized in Table 1). However, low percentages of IL-
17-producing Th17 cells do not necessarily reflect low activity and in the in vitro 
situation the impact of local IL-17 production on the cutaneous microenvironment 
is unknown.
Besides proinflammatory CD4+ T helper cells, also anti-inflammatory CD4+ regulatory 
T (Treg) cells, including a subpopulation of memory Treg cells, have been associated 
with the production of IL-17 in psoriasis.39,40 Also CD8+ T cells have been associated 
with increased production of IL-17 in lesional psoriatic skin, especially CD8+ T cells 
that are localized within the epidermis.33,35,36,41
Of note, an important limitation of the above mentioned studies has been the 
dependence on techniques that drive the cells into a highly activated state by 
using artificial stimulation or culture methods. It has been shown that stimulation 
of skin derived T cells with PMA/ionomycine leads to more IL-17-producing T cells 
than directly ex vivo isolated skin derived T cells in the absence of any stimulation 
methods.37,42 Little data are available detecting Th17 cells directly ex vivo, or in vivo 
in humans. In the past, studies relied solely on the expression of IL-17 as a marker 
to immunohistochemically detect Th17 cells on paraffin embedded skin tissues.13,31 
Importantly, only very limited differences were found in the amount of skin derived 
IL-17-producing T cells derived from psoriatic patients versus healthy controls.32-34,36 
The question arises what the contribution is of such a small IL-17-producing T cell 
population to the development of psoriasis, and which other cell types are important 
producers of IL-17.
Using in vivo models for psoriasis-like skin inflammation we found substantial evidence 
that not T cells, but neutrophils and mast cells are the main cell types expressing IL-
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17. Immunohistochemical stainings were confirmed by performing flow cytometry 
on dermal cells that were directly isolated ex vivo. We were the first to show that 
neutrophils in the skin express the IL-17 associated transcription factor RORγt and 
contain IL-17 mRNA, implicating that neutrophils can make IL-17 themselves.43 This 
prompted us to summarize the literature of this novel concept in psoriasis.
By using immunohistochemistry, several other groups identified mast cells and 
neutrophils as the major cell types expressing IL-17 in vivo in psoriasis.36,44-46 In these 
studies IL-17-expressing T cells were only detected sporadically in lesional psoriatic 
skin. Th17 cells were reported to be absent in normal skin36 or to be equally as 
sporadically present in psoriatic versus normal skin (1.1 vs 0.5 cells per microscopic 
field).46 Virtually all mast cells expressed IL-17, as well in lesional psoriatic skin, non-
lesional psoriatic skin as in normal skin. The majority of the neutrophils expressed 
IL-17, especially within very active psoriatic lesions.36,45,46 Lin et al demonstrated 
that mast cells and neutrophils in psoriasis even have a mechanism to release IL-17. 
They are able to form extracellular traps (ETs) out of nuclear material as a manner to 
disarm and kill bacteria or fungi extracellularly.46-48 Besides the proposed function in 
host defense, ETs are also implicated in various autoimmune-like diseases.49,50
The IL-17 family has six members (IL-17A to F), of which IL-17A is the prototype 
family member. IL-17A, IL-17C and IL-17F are increased in psoriasis and act directly 
on keratinocytes, while IL-17B, IL-17D and IL-17E are most likely of less importance 
in the development of psoriasis.5,14 It was suggested that human mast cells do not 
contain IL-17A, but rather express IL-17F,51,52 which is a biologically less potent isoform 
as compared to the IL-17A homodimer or the IL-17A/F heterodimer.5,53 Although 
protein expression studies using immunohistochemistry so far could not discriminate 
between IL-17A and IL-17F, in human mast cell lines it was indeed confirmed that 
mast cells express IL-17F and not IL-17A mRNA upon stimulation.51
As discussed above, IL-17-producing dermal γδ T cells and ILCs have been extensively 
studied in murine models for psoriasis. However the role of these cells in human 
skin, and especially their role in IL-17 signaling is still poorly understood. There are 
a few studies pointing towards the existence of IL-17-producing γδ T cells in the 
human skin; Cai et al demonstrated that dermal γδ T cells in patients with psoriasis 
are greatly increased as compared to healthy controls. Approximately 15% of the γδ 
T cells derived from psoriatic dermis produced IL-17 upon stimulation with IL-23.28 
Laggner et al identified a novel human skin-homing Vγ9Vδ2 T cell subset that was 
significantly reduced in the circulation of psoriatic patients and that was significantly 
increased in the psoriatic skin, indicating redistribution of the cells from the blood to 
the skin compartment.54 Decreased numbers of circulating Vγ9Vδ2 T cells correlated 
with increased psoriasis severity and were restored upon successful anti-psoriatic 
treatment. A small percentage of activated circulating Vγ9Vδ2 T cells derived from 
healthy controls produced IL-17 and these cells were enriched within the CLA+ skin 
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homing population.54 However, direct and conclusive evidence for IL-17 production 
by human γδ T cells in psoriasis has yet to be found. 
Although there is accumulating evidence that group 3 ILCs are enriched in psoriasis, 
there is no evidence of IL-17 cytokine production from pure ILC populations in human 
skin.55-57
Predominant expression of IL-17 by innate immune cells in 
other chronic inflammatory diseases
Also in other diseases that are considered to be IL-17 mediated,58 it was found 
that besides T cells also other cell types were associated with the production IL-
17. In rheumatoid arthritis (RA), only a small fraction of the IL-17-expressing cells in 
synovial tissue were T cells. The vast majority of the IL-17-expressing synovial cells 
were mast cells, suggesting that innate immune pathways, and especially mast cells 
contribute substantially to the IL-17 response in RA.59,60 As the former results are 
based on protein expression using immunohistochemistry, Hueber et al showed in 
additional experiments that mast cells derived from umbilical cord blood are indeed 
able to release IL-17 upon in vitro culturing.59 Previous research already revealed that 
mast cells are implicated in the pathogenesis of RA.61 
Similar studies have been performed in spondylarthritis (SpA), another common 
chronic immune-mediated inflammatory arthritis, again detecting innate immune 
cells, including mast cells and neutrophils, as the predominant IL-17-expressing cell 
population at the site of inflammation. Interestingly, this IL-17 expression pattern 
was also seen in psoriatic arthritis, a non-cutaneous manifestation of psoriasis and 
a phenotypic subtype of SpA.62-64 Furthermore, in peripheral blood of patients with 
ankylosing spondylitits, the prototypical SpA, IL-17 secreting IL-23R+ γδ T cells were 
enriched as compared to healthy controls.65
In atherosclerosis, IL-17 protein was expressed by mast cells and neutrophils, but 
not by T cells. Similar as in psoriasis, mast cells in atherosclerosis expressed IL-17 at 
all stages of plaque formation including healthy vessel walls, while IL-17-expressing 
neutrophils were only found in complicated plaques.51
Conclusions and future implications
From this critical appraisal, we can safely conclude that IL-17-producing T cells 
represent in actual fact a minority of the IL-17-expressing cells in psoriasis in vivo. In 
contrast to the current believe, IL-17 is mainly expressed by mast cells and neutrophils 
in psoriatic skin (Fig. 1). Based on the findings that IL-17-expressing mast cells are 
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also present in normal tissue (normal skin, synovium and vessel wall), whereas 
neutrophils are only present at sites of inflammation, it is tempting to speculate 
that neutrophils more than mast cells, contribute disease expansion. Data on IL-17 
production by γδ T cells and ILCs in human are preliminary, which makes it difficult 
Figure 1. Proposed model for key players of IL-17 production in psoriasis. A combination 
of environmental and genetic factors determines susceptibility to the disease. Unknown 
triggers (yellow thunderbolt) can lead to stressed keratinocytes. Stressed keratinocytes 
initiate an innate immune response through the production of antimicrobial peptides 
(AMPs), ß-defensins, cytokines and chemokines. Chemokines attract neutrophils to the 
skin. Resident mast cells become activated immunologically or through ‘none immune’ 
mechanisms (exogenous stimuli).73 Neutrophils and mast cells produce IL-17 in the first 
phase of the inflammatory reaction. Furthermore, stressed keratinocytes release self-DNA, 
that in combination with AMPs, leads to the activation of dendritic cells (DCs). DCs migrate 
into the draining lymph nodes where they initiate differentiation of naïve CD4+ cells into 
Th17 cells, via the production of IL-23. These cells migrate to the skin and start producing 
IL-17, further promoted by the presence of proinflammatory cytokines such as IL-1ß. This 
adaptive immune response in combination with an ongoing innate immune response 
represents the second phase of the inflammatory reaction. IL-17 exerts its function by 
directly stimulating the keratinocytes to produce psoriasis-associated molecules, leading to 
keratinocyte hyperproliferation, amplification of the inflammatory reaction and eventually 
to a vicious circle of chronic skin inflammation. This model is partially based on a proposed 
disease model for psoriasis from Nestle et al.74
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to draw conclusions on this subject. IL-17 expression by innate immune cells was 
also found in other chronic inflammatory diseases, like RA, SpA and atherosclerosis. 
Now that IL-17 protein expression by mast cells and neutrophils is established, 
we feel that future research is necessary to confirm these results. It would be of 
great value to test for IL-17 transcriptomes and perform secretion experiments and 
functional assays to establish the actual role of IL-17 production by innate immune 
cells in psoriasis. Yet, we can no longer ignore that innate immune cells are important 
contributors to IL-17 signaling in psoriasis. Consequently, the effects of the new anti-
IL-17 targeted treatments may be more far-reaching than previously thought, as the 
adaptive as well as the innate arm of the immune system are covered. This might 
explain the remarkable effects of these treatments. 
Psoriasis is increasingly recognized as a disease with potential systemic effects due to 
a chronic inflammatory state.66,67 Patients are at a higher risk of developing associated 
conditions, with psoriatic arthritis68-70 and cardiovascular disease (CVD)71,72 being at 
the forefront. Interestingly, as outlined in the previous section of this review, both 
conditions are, like psoriasis, associated with IL-17-expressing neutrophils and mast 
cells. For CVD, it has already been demonstrated that some anti-psoriatic treatments 
improve cardiovascular inflammatory biomarkers and improve CVD outcomes.71 
Thus, therapies specifically targeting IL-17 or the IL-23/IL-17 pathway, may not only 
improve psoriasis, but also related conditions that are associated with this pathway. It 
is attractive to speculate that early targeted therapies prevent serious complications 
of systemic disease on the long term.
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Summary and discussion
Psoriasis is one of the most common chronic inflammatory skin diseases. Patients 
report a remarkably impaired quality of life.1,2 Hence, research to identify new 
treatment targets is important. Candidates for drug development reside within 
the immune system. One of the major advantages of the skin is that it is an easy 
accessible organ. Contrary to other organs, it is rather uncomplicated to collect tissue 
samples or biopsies and study the local immune system. The immunopathogenesis of 
psoriasis has always been of special interest in the field of dermatological research. 
However, with the introduction of biologics and small molecules, which specifically 
intervene in certain pathways of the immune system, this field exploded. The new 
drugs stood in marked contrast with the more aspecific immunosuppressive drugs 
used in the past. In this thesis, we especially focused on regulatory T cells (Treg) 
and interleukin(IL)-17-producing cells. These cells play an important role in the 
pathogenesis of psoriasis. Despite the fact that they are important (future) treatment 
targets, little is known about these cells in psoriasis.
Psoriasis is associated with production of proinflammatory cytokines, such as tumor 
necrosis factor (TNF) α, interferon (IFN) γ, IL-22 and IL-17.3,4 The development of IL-17- 
producing cells is mainly driven by IL-23. In the skin, IL-17 stimulates keratinocytes to 
produce psoriasis-associated molecules,5-7 leading to keratinocyte hyperproliferation, 
amplification of the inflammatory reaction, and eventually to psoriasis. Expression 
studies and genetic studies point towards an important role for IL-17 in psoriasis.8-10 
Furthermore, biologics specifically targeting players of the IL-23/IL-17 pathway are 
very effective in the treatment of psoriasis.11,12 Under normal circumstances, Treg 
produce immunosuppressive cytokines, such as IL-10, through which they are 
able to intervene in the cycle of inflammation.13,14 In psoriasis it appeared that the 
function of circulating Treg is hampered,15-17 and that these cells are able to produce 
proinflammatory cytokine IL-17.16 As outlined in the aims of this thesis, our goal was 
to further explore conversion of Treg into Th17 cells in vivo in psoriasis. However, 
along the way we had to adjust the focus of this thesis, because it appeared that not 
T cells, but cells of the innate immune system were the main producers of IL-17 in 
psoriasis, eventually leading towards new insights.
In this thesis, a number of issues is addressed. In order to gain a better understanding 
of Treg and their function in psoriasis, we conducted two studies using skin biopsies 
from patients. It is commonly accepted that the balance between Treg and effector 
T (Teff) cells may be important in controlling disease;18 sufficient numbers of Treg are 
necessary to maintain immune homeostasis.19,20 In chapter 2, we therefore looked at 
the balance of Treg vs. Teff cells in the margin zone of psoriasis lesions as an approach 
to describe Treg function in the different phases of the outgrowth of a psoriatic 
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plaque. In continuation of chapter 2, chapter 3 describes changes in the Treg/Teff 
cell balance during topical treatment with calcipotriol-betamethasone dipropionate 
(CBD) ointment and systemic treatment with adalimumab. 
Interestingly, it also appears that circulating Treg from patients with psoriasis have 
an instable phenotype. In comparison to Treg from healthy controls, they have an 
enhanced propensity to produce IL-17 upon stimulation in vitro.16 In chapter 4, we 
examined whether this phenomenon is specific for circulating Treg in psoriasis, or 
whether Treg from patients with atopic dermatitis (AD), another common chronic 
inflammatory skin disease, behave similarly. 
In chapter 5, we focused on the additional advances of the previously described 
huPBL-SCID-huSkin allograft model, and explored whether this model could 
potentially be used as a model to study psoriasis in mice. Chapter 6 and 7 provide an 
update on two frequently used in vivo models, where psoriasis-like skin inflammation 
is induced in healthy volunteers by the application of leukotriene B4 (LTB4) or by tape-
stripping. In chapter 8, these models appeared to be very useful in characterizing IL-
17-expressing adaptive and innate leukocytes. Finally, chapter 9 gives an overview 
of IL-17-expressing leukocytes in mice and humans, focusing on both psoriasis and 
other IL-17 mediated chronic inflammatory diseases. 
10.1  Balance between Treg and Teff cells in psoriasis
 
Summary
Proinflammatory immune responses are necessary to protect the body from intruders 
such as bacteria, viruses and fungi. However, sometimes this response is directed 
against healthy tissue. Therefore, the body is equipped with anti-inflammatory 
brake-mechanisms which are able to restore immune homeostasis. One of the cell 
populations mostly studied within this context are Treg. Dysfunction of these cells 
can lead to autoimmune and inflammatory diseases such as psoriasis.21 Besides 
dysfunction, also a lack of Treg can result in inflammation,19 as demonstrated by 
immunodysregulation, polyendocrinopathy, enteropathy, X linked (IPEX) syndrome, 
where a mutation in the FOXP3 gene causes severe autoimmune disease.22 Hence, 
the balance between Treg and Teff cells may be crucial in controlling disease. 
In chapter 2, we used the balance between Treg and Teff cells as a measure to 
study Treg function in the different phases of the outgrowth of a psoriatic plaque. 
The transition from symptomless to lesional skin served as a model to study the 
different phases of psoriatic plaque development. Skin biopsies were used to 
immunohistochemically detect Treg and Teff cells by the expression of Foxp3 and 
CD4, respectively. Foxp3/CD4 ratios were calculated in the centre, margin of a 
psoriatic plaque, perilesional skin and distant uninvolved skin, and subsequently 
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compared to skin of healthy volunteers. In the majority of the patients we observed 
a higher Foxp3/CD4 ratio in the symptomless skin at a distance from the psoriatic 
plaque compared with the perilesional and lesional skin. Furthermore, Foxp3/CD4 
ratios in the symptomless skin at a distance from the psoriatic plaque were even 
higher than in the skin of healthy volunteers. This may be suggestive for the presence 
of immune controlling mechanisms in the symptomless skin of psoriasis patients, 
where the tissue is actively trying to prevent expansion of disease. Upon certain 
triggers this mechanism may fail and new lesions can develop. Moreover, in lesional 
skin, the Treg/Teff cell balance seems to be shifted towards the presence of relatively 
more Teff cells. 
Along these lines of reasoning, we wondered in chapter 3 whether the Treg/Teff 
cell balance of a psoriatic plaque would be affected by certain treatments. Foxp3/
CD4 ratios were calculated before and after 8 weeks of successful treatment with 
CBD ointment, and before and after 1,5 and 16 weeks of successful treatment with 
adalimumab. It is known that treatment with anti-TNFα therapy leads to an up 
regulation of the number of circulating Treg.23,24 We found that, while both treatments 
led to a decrease in the number of cutaneous Treg and Teff cells, the Treg/Teff cell 
balance was differentially influenced; topical treatment with CBD ointment led to a 
decrease in the Foxp3/CD4 ratio after 8 weeks of treatment and systemic treatment 
with adalimumab led to an increase of this ratio after 16 weeks of treatment. 
Consequently, adalimumab treated skin differs in local immune status from CBD 
treated skin as far as the anti-inflammatory/inflammatory balance is concerned. 
It seems that patients successfully treated with adalimumab preserve relatively 
more Treg than Teff cells at the end of the treatment, as compared to patients that 
were successfully treated with CBD ointment. Therefore, it is attractive to speculate 
that adalimumab attributes to self-tolerance in the skin of psoriatic patients. This 
might be an additional mechanism that contributes to the mode of action, clinical 
improvement, and chance to relapse, of patients on adalimumab. 
Discussion and future recommendations
Of note, the Foxp3/CD4 ratio is a numerical balance, associated with effective Treg 
function, that is influenced by both arms; it reflects either a change in the number of 
Treg, Teff cells, or both. Consequently, the ratio should be interpreted as the outcome 
of both cell populations relative to each other. Importantly, in order to be able to 
draw any conclusions, it should be considered that the outcome of one isolated ratio 
is limited, and that this outcome should be interpreted in the context of other ratios. 
We decided to use the Treg/Teff cell ratio as a measure to at least give an indication 
of Treg function in vivo in psoriasis; sufficient numbers of Treg are necessary to 
restrain the local ongoing activation of Teff cells.19,20 However, strictly speaking, this 
ratio does not reflect actual Treg function. In order to asses Treg function in psoriasis, 
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other experiments are required, for example co-culture suppression assays.14 This 
encompasses the isolation of Treg (CD4+CD25high) and T responder cells (Tresp cells; 
CD4+CD25-) from peripheral blood or skin. Tresp are being stimulated with anti-CD3/
CD28-coated beads and Treg are brought into co-culture at varying Treg:Tresp ratios. 
The Tresp cell proliferation rate can be used to measure the suppressive capacity of 
Treg. While it is relatively straightforward to isolate Treg from peripheral blood, it 
remains challenging to obtain enough Treg from skin biopsies to be able to perform 
suppression assays. Consequently, studies performing these experiments with skin 
derived Treg cells are scarce.15 In this thesis, the Treg/Teff cell ratio enabled us to 
approach cutaneous Treg functioning in an alternative way. 
Another challenging issue in this field of research is the identification of Treg, since 
there is no unique Treg marker. In the world of flow cytometry, it is generally accepted 
that the combination of the following markers leads to the identification of Treg; CD4, 
CD25high, CD127
low
 and Foxp3 expression. Unfortunately, for immunohistochemistry 
the options are limited. A maximum of 3 markers can be used to detect Treg. In 
addition, the technique does not differentiate between high and low expression of 
a marker. To complicate matters even further, coexpression of CD4 and CD25 is not 
unique for Treg, as CD25 is also expressed on human conventional T cells (Tconv) 
upon activation. Likewise, it became evident that Foxp3 is expressed by activated T 
cells, albeit transiently and for a short period of time.25,26 This raises the possibility 
that any assessment of Treg cells may include recently activated Tconv in the Treg 
cell population, although we27 and others28 established that almost all Foxp3+ cells 
in psoriatic skin expressed CD4 and CD25. CD25-Foxp3+ cells were detected only 
sporadically, thereby increasing the chance that the Foxp3 cells we detected were 
indeed likely to be Treg.
This issue prompted other investigators to search for more specific Treg markers, as 
well as for markers which can identify human functional Treg. Numerous markers 
entered and/or left the stage: CTLA-4,29 ICOS,30 LAG-3,31 GARP,32,33 LAP,34 CD39,35-37 
CD49d,38 TNFR2,39,40 CD73,37 membrane bound TGFß,41 GITR28 and CD14742, to name 
a few. Unfortunately, while some of these markers detect functional subgroups of 
Treg, none of these markers is a unique Treg marker. Recently, much effort has been 
spent to distinguish thymus-derived natural Treg (nTreg) cells from those induced in 
the periphery (iTreg) and activated Tconv, by looking at the (de)methylation status 
of the FOXP3 locus. DNA methylation is an epigenetic modification which leads to 
silencing of genes in the promoter region trough interfering with transcription factor 
binding.43 It appears that specific sites in the FOXP3 promoter are demethylated in 
nTreg, and thus available for transcription factor binding, while this region remains 
methylated in iTreg or activated Tconv.44,45 
In this thesis, we particularly used Foxp3 as a marker in order to detect Treg. 
We did so despite some evident limitations. Yet, there are no better alternative 
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avenues to detect Treg by immunohistochemistry. It would therefore be helpful if 
future research would identify a single marker solely expressed by Treg, preferably 
identifying functional and activated Treg. Such an identification would unravel the 
identity mystery of Treg in the skin and stimulate further research on this topic. 
Furthermore, it would be interesting to investigate whether peripheral blood Treg/
Teff cell ratios correlate with local Treg/Teff cell ratios in the skin, for instance during 
local and/or systemic therapies. 
10.2  Stability of Treg in psoriasis versus atopic dermatitis
Summary
To complicate matters even further, recent insights reveal that the Treg phenotype 
is not as stable as previously considered. Upon stimulation, conversion of Treg into 
proinflammatory, IL-17-producing, Teff cells may occur.14,46,47 These instable Treg are 
characterised by coexpression of Foxp3 and RORγt, the key-transcription factors of 
Treg and T helper (Th) 17 cells, respectively.46 For the first time, our group showed 
that circulating Treg from psoriasis patients could easily differentiate into IL-17-
producing Treg in vitro.16 This Treg differentiation process was particularly boosted by 
IL-23, and was linked to high levels of RORγt combined with enhanced loss of Foxp3. 
The presence of IL-17-producing Foxp3 cells in the proinflammatory environment of 
a psoriatic dermis suggests that conversion of Treg into IL-17-producing cells might 
take place in vivo in humans. Consequently, this might lead to the perpetuation of an 
inflammatory condition. 
We wondered whether this Treg instability was a specific phenomenon observed 
in patients with psoriasis, or whether this also occurred under other chronic 
inflammatory circumstances, such as in atopic dermatitis (AD). Like psoriasis, AD 
is a very common inflammatory skin disease among the Western population. Yet 
in contrast with psoriasis, it is predominantly considered to be a Th2 cytokine (IL-
4, IL-5 and IL-13) mediated disease.48 Moreover, it is also closely associated with 
dysfunction of Treg,49 i.a. because AD is a prominent symptom in patients with IPEX-
syndrome, where mutations in the FOXP3 gene cause Treg deficiency.13 Based on our 
findings in psoriasis, the current literature,50 and the local inflammatory environment 
in AD, we hypothesized that Treg from patients with AD had an increased potential to 
differentiate into IL-4-producing cells rather than into IL-17- producing cells.
In order to investigate stability and cytokine producing potential of peripheral blood 
derived Treg and Tconv from patients with AD, ex vivo stimulation cultures were 
performed in chapter 4. While the cytokine producing capacity of Tconv was similar 
in both groups for IL-17, IL-4 and IFNγ, we found that Treg derived from patients 
with AD showed enhanced production of IL-4 as compared to healthy controls 
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(measured by flow cytometry). Differentiation of Treg into IL-4-producing cells was 
linked to loss of transcription factor Foxp3. Interestingly, IL-4-producing Treg also lost 
expression of transcription factor GATA-3. While GATA-3 is known as prototypic Th2 
driving transcription factor,51,52 it also exerts a critical function in regulating immune 
tolerance; it appears that GATA-3 is necessary for stable Foxp3 expression.53,54 
Our findings, combined with literature data, suggest that proinflammatory cytokines 
mediate conversion of Treg to Teff cells (reviewed55), not only in psoriasis, but also in 
other chronic inflammatory settings. It seems that cytokine production of unstable 
Treg is dependent of the disease, being either Th1, Th17 or Th2 mediated. In vivo, 
Treg to Teff cell conversion can potentially lead to enhancement of the inflammatory 
reaction. Together, these observations might provide mechanistic insights into the 
process that drives chronic autoimmune inflammation. 
Discussion and future recommendations
Nowadays, Treg instability seems to be a well-established phenomenon in vitro.55 
However, to the best of our knowledge, studies identifying these particular cells 
in vivo are rare. In the past, our group showed that IL-17+Foxp3+CD4+ cells were 
indeed present in the dermis of severe psoriasis patients.16 Recently, we learned that 
these cells are scarce in skin pathology, and can only be detected in a few patients. 
While in vitro more than 15% of the Treg in psoriasis produced IL-17 upon stimulation 
with IL-23, in vivo they are hard to find. This, then, begs the question of what the 
contribution of such a small cell population is to the development of a skin disease. 
Do we perhaps overlook these cells in vivo because the timing of the specimen taking 
is not right? Furthermore, there is a chance that we missed some converted Treg by 
using immunohistochemistry; Foxp3 expression of converted Treg may be so low that 
it became undetectable. 
It would be interesting to further examine the presence of unstable Treg in the skin 
by using an alternative and more sensitive method than immunohistochemistry, for 
example by performing flow cytometry directly on isolated Treg derived from skin 
biopsies. This method even enables the detection of markers that are being expressed 
low. Furthermore, it allows the use of more than 3 markers at the same time. In 
addition, one could stimulate skin derived Treg and look at the cytokine producing 
potential of these cells. However, as already mentioned in the first paragraph of this 
chapter, it remains a challenge to obtain enough Treg from skin biopsies to perform 
these experiments.
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10.3  IL-17-producing cells in psoriasis
Summary
In chapter 2, we used the balance between Treg and Teff cells to study Treg function 
in psoriasis. As a result of a growing interest in Treg with an unstable phenotype (as 
demonstrated in the previous paragraph), and in order to add a different dimension 
to the Treg/Teff cell balance, we searched for the presence of IL-17-producing Treg in 
the different phases of psoriatic plaque formation. Contrary to our expectations, we 
detected only a few T cells that expressed IL-17. The presence of IL-17-expressing Treg 
was even more scarce. Previously, it was reported that IL-17 expression in psoriasis 
was also associated with neutrophils and mast cells.56,57 Indeed, we were able to 
confirm these observations in our model of psoriatic plaque development. Mast 
cells were abundantly present and expressed IL-17 in lesional, non-lesional psoriatic 
skin, and even in the skin of healthy volunteers. Neutrophils were only present in 
active plaques marked by the presence of microabcesses of Munro, and the majority 
coexpressed IL-17. These findings set the avenue for further studies regarding IL-17 
expression by adaptive and innate immune cells in mice and in human. 
In chapter 5, we searched for additional advantages of the previously described 
human peripheral blood lymphocyte reconstitued severe combined immunodeficient 
(SCID) mouse human skin allograft model (huPBL-SCID-huSkin model).58,59 In this 
model, human skin is transplanted onto immunodeficient mice and subsequently 
allowed to heal. Following on, allogeneic human peripheral blood mononuclear cells 
(PBMC) are infused intra peritoneally to induce T cell mediated inflammation and 
microvessel destruction of the human skin. This model is of particular interest in 
studying human local skin inflammation in vivo. We expanded the current knowledge 
of this model, not only with new local human skin inflammatory markers including IL-
17, but also with information on systemic human T cell responses. In summary, skin 
inflammation in this model is characterized by aberrant epidermal differentiation 
(marked by deregulated expression of hBD2, Elafin, K10, K16 and Ki67), increased 
gene expression of human cytokines (IL1B, IL6 and IL8) and chemokines (CXCL1, 
CXCL10 and CCL5), and influx of IL-17-expressing cells. In this model, IL-17 was 
expressed by CD4+, CD8+ and Foxp3+ T cells, as well as mast cells. Local human skin 
inflammation was paralleled by systemic CD4 and CD8 T cell activation, proliferation 
and acquisition of homing markers. Finally, by analyzing the effect of systemic 
treatment with cyclospine-A and rapamycin on the newly identified parameters, we 
demonstrated that the huPBL-SCID-huSkin allograft model can be used as preclinical 
evaluation of novel immune-modulating agents. Based on our findings in combination 
with the known clinical and histological features of this model, we believe that the 
huPBL-SCID-huSkin allograft model is of potential interest to study the pathology of 
psoriasis at the level of skin and immune biology. 
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In humans, there is ongoing debate on which cell types are in fact the main 
producers of IL-17 in psoriasis. Moreover, evidence is lacking at which time point 
IL-17-expressing cells enter the stage during skin inflammation. Most in vivo studies 
in psoriasis provide us with static information of the disease at a time point when 
symptoms, and by implication immune cells, are already present. Ex vivo and in 
vitro studies may show a more dynamic picture, but often lack the complex disease 
environment and make use of artificial in vitro culture methods. Our goal was to 
investigate the presence of IL-17-expressing adaptive and innate immune cells, 
before and during early skin inflammation in vivo. We used two established models 
that induce skin inflammation in healthy volunteers, that both share mechanistic 
and histological features with psoriasis: the application of leukotriene B4 (LTB4)60-62 
and tape-stripping.63-65 In chapter 6 and 7, we provided an update on the dermal 
and epidermal changes induced by these models and explored whether these 
models could potentially be used to study adaptive and innate immune responses 
in psoriasis-like skin inflammation. Indeed, both arms of the immune system were 
induced by these models and IL-17+ cells were abundantly present. In chapter 8, we 
establish that most IL-17 expression is linked, not to T cells, but instead to cells of the 
innate immune system, to wit mast cells and neutrophils. Furthermore, neutrophils 
coexpressed the IL-17-associated transcription factor RORγt.66 Neutrophils in the 
epidermis even formed specialized structures to release IL-17, termed extracellular 
traps,67 while the formation of these structures was not observed in mast cells. 
Aside from degranulation and phagocytosis, the formation of extracellular traps by 
neutrophils, is a manner to disarm and kill bacteria extracellularly.67 We observed 
that the presence of mast cells remained steady during skin inflammation, while 
the presence of neutrophils was clearly dynamic in time. Our data, combined with 
previously published studies, as summarized in chapter 9, suggest that not T cells, 
but cells of the innate immune system, are the main source of IL-17 in psoriasis. 
Predominant expression of IL-17 by innate immune cells was also observed in other 
IL-17 mediated chronic inflammatory disorders such as rheumatoid arthritis,68,69 
spondylarthrithis including psoriatic arthritis70-72 and atherosclerosis.73 Based on the 
findings that IL-17-expressing mast cells are also present in normal tissue (normal 
skin, synovium and vessel wall), whereas neutrophils are only present at sites of 
inflammation (particularly in complicated psoriatic and atherosclerotic plaques), it 
is tempting to speculate that neutrophils contribute more to disease expansion than 
mast cells do. Consequently, blocking IL-17 with new targeted treatments might be 
more far-reaching than previously thought, since not only IL-17 production by T cells, 
but also by innate immune cells is blocked. In addition, these therapies may improve 
not only psoriasis, but also comorbid conditions associated with the IL-17 pathway, 
such as psoriatic arthritis.
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Discussion and future recommendations
With regard to IL-17 expression, there are some discrepancies between humans 
and mice. Using imiquimod (IMQ)-induced skin inflammation as a model to study 
psoriasis in mice, it was found that γδ T cells and a subgroup of innate lymphoid 
Figure 1. Proposed model for key players of IL-17 production in psoriasis (Figure is derived 
from chapter 9). A combination of environmental and genetic factors determines suscepti-
bility to the disease. Unknown triggers (yellow thunderbolt) can lead to stressed keratino-
cytes. Stressed keratinocytes initiate an innate immune response through the production of 
anti microbial peptides (AMPs), ß-defensins, cytokines and chemokines. Chemokines attract 
neutrophils to the skin. Resident mast cells become activated immunologically or through 
‘none immune’ mechanisms (exogenous stimuli).86 Neutrophils and mast cells produce IL-17 
in the first phase of the inflammatory reaction. Furthermore, stressed keratinocytes release 
self-DNA, that in combination with AMP, leads to the activation of dendritic cells (DCs). DCs 
migrate into the draining lymph nodes where they initiate differentiation of naïve CD4+ cells 
into Th17 cells, via the production of IL-23. These cells migrate to the skin and start produc-
ing IL-17, further promoted by the presence of proinflammatory cytokines such as IL-1ß. 
This adaptive immune response in combination with an ongoing innate immune response 
represents the second phase of the inflammatory reaction. IL-17 exerts its function by di-
rectly stimulating the keratinocytes to produce psoriasis-associated molecules, leading to 
keratinocyte hyperproliferation, amplification of the inflammatory reaction and eventually 
to a vicious circle of chronic skin inflammation. This model is partially based on a proposed 
disease model for psoriasis from Nestle et al. 3
178
Chapter 10
cells (ILCs) were the primary source of IL-17.74-76 In the huPBL-SCID-huSkin allograft 
model, we found abundant expression of IL-17 by T cells. However, in humans there 
is no direct evidence for production of IL-17 by γδ T cells and ILCs in psoriasis75,77-80 
and expression of IL-17 by T cells in human psoriatic skin is scarce. Even though mice 
are indispensible as a preclinical model for human disease and as evaluation tool 
of new treatments, there are some limitations to keep in mind when translating 
findings in mice to the human situation. First of all, there is no naturally occurring 
disorder in laboratory mice that mimics the complex phenotype of psoriasis. Hence, 
mouse models such as the IMQ-induced skin inflammation model81 and the huPBL-
SCID-huSkin allograft model,82 are an approach to mimic human psoriasis in an 
experimental set-up.83 Secondly, it worth considering the possibility that any given 
immunological response in a mouse may not occur in precisely the same way in 
humans.84 Examples in light of this thesis are; in mice Th17 cells also secrete IL-22, 
whereas in human subjects most IL-22 is secreted from a separate Th22 population.85 
In addition, human skin only contains γδ T cells in the dermis, whereas in murine 
skin γδ T cells are also present in the epidermis, so-called dendritic epidermal T cells 
(DETCs).75 
Most findings concerning IL-17-producing cells in vivo in psoriasis are based on 
protein expression studies, using immunohistochemistry. In chapter 8 we were able 
to confirm the findings of these studies, by using another experimental setup. IL-17 
expression by dermal immune cells was verified by performing flow cytometry on cell 
suspensions derived from skin biopsies. Although this method has to be optimized 
and data are preliminary, we found that the majority of the neutrophils and mast 
cells contained IL-17. Only a fraction of IL-17 was detected in T cells. Furthermore, we 
were the first to detect IL-17 mRNA transcripts in neutrophils in the skin, suggesting 
that neutrophils can make IL-17 themselves. Mast cells and T cells did not contain 
IL-17 transcripts in our experiments, however this may be due to the detection level 
of the essay. Future experiments are needed to ascertain IL-17 production, by i.a. 
neutrophils, mast cells and T cells in psoriatic skin. It would be of great value to 
perform secretion experiments and functional essays to establish actual release of 
IL-17 by innate immune cells in psoriasis. Furthermore, it would be interesting to 
explore whether IL-17 production by innate immune cells is, like T cells, dependent 
on IL-23, or whether other stimuli are needed. Yet, it can no longer be ignored that 
innate immune cells, and especially neutrophils, are important contributors to IL-17 
signaling in psoriasis.
Ultimately, in chapter 9 we proposed a new model for the pathogenesis of psoriasis 
(Fig. 1), implementing different key players of IL-17 production in psoriasis that were 
discussed in this thesis. 
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10.4  Final considerations
During the last decade, IL-17 emerged as one of the key players in the pathogenesis 
of psoriasis. While it was long thought that IL-17 was especially produced by T cells 
in psoriasis, it now seems that the paradigm in this field of research is shifting. 
Accumulating evidence points towards an important role for innate immune cells 
in IL-17 signaling. In this thesis, most evidence was found for IL-17 production by 
neutrophils. IL-17-expressing T cells represented a minority of the IL-17-expressing 
cells in our in vivo experiments. We were able to show that neutrophils contain the 
IL-17 protein and have the machinery to produce IL-17 themselves, marked by the 
presence of IL-17-associated transcription factor RORγt and IL-17 mRNA transcripts. 
Consequently, blocking IL-17, may not only affect the adaptive but also the innate 
immune system, perhaps explaining the remarkable effects of these new drugs12 in 
the treatment of psoriasis. Future experiments are needed to evaluate the exact role 
of different immune cell subsets in the production and excretion of IL-17.
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Samenvatting
Psoriasis is een vaak voorkomende chronische ontstekingsziekte van de huid die wordt 
veroorzaakt door een combinatie van genetische factoren en omgevingsfactoren. 
Psoriasis vulgaris, waar in dit proefschrift de nadruk op ligt, wordt gekenmerkt door 
de aanwezigheid van scherp begrensde, rode, schilferende plaques. Deze plaques zijn 
vaak aanwezig op voorkeursplaatsen zoals de ellebogen, de knieën, de hoofdhuid en 
de stuit. Naast de huid kunnen de nagels en gewrichten zijn aangedaan. Bovendien 
hebben patiënten met psoriasis een verhoogde kans op het krijgen van onder 
andere hart- en vaatziekten en metabool syndroom. Op microscopisch niveau wordt 
psoriasis gekenmerkt door veranderingen in de epidermis (opperhuid) en dermis 
(lederhuid). De epidermis wordt gekarakteriseerd door acanthose (verbreding 
van de epidermis), verlengde retelijsten en parakeratose (abnormale verhoorning 
waarbij nog kernen in de hoornlaag aanwezig zijn). Zeer typerend voor psoriasis is de 
opeenstapeling van neutrofielen in het stratum corneum/hoornlaag (microabces van 
Munro) en hoog in het stratum spinosum (microabces van Kogoj) van de epidermis. 
In de dermis bevindt zich een gemengd cellulair infiltraat, waarvan het grootste deel 
bestaat uit T-cellen. In de dermale papillen zijn prominente opstijgende capillairen 
zichtbaar.
De afgelopen jaren is er in toenemende mate wetenschappelijke interesse voor 
interleukine-17 (IL-17). Dit cytokine speelt niet alleen een belangrijke rol in het 
klaren van extracellulaire micro-organismen, maar wordt ook geassocieerd met 
verschillende inflammatoire en auto-immuunaandoeningen, waaronder psoriasis. 
Genetische studies laten zien dat IL-17 van essentieel belang is in het ontstaan van 
psoriasis. Bovendien zijn bepaalde ‘biologics’, medicijnen specifiek gericht tegen 
IL-23 of IL-17, zeer effectief in de behandeling van dit ziektebeeld. Lang werden 
T-cellen gezien als de belangrijkste bron van IL-17, zogenaamde T-helper 17 (Th17) 
cellen. Hier lijkt echter verandering in te komen. Ook neutrofielen en mestcellen 
worden in toenemende mate gerelateerd aan de productie van IL-17. De productie 
van IL-17 is onder meer afhankelijk van IL-23. In de huid zet IL-17 de keratinocyten 
(opperhuidcellen) aan tot het produceren van allerlei, met psoriasis geassocieerde, 
moleculen. Verhoogde deling van de keratinocyten in combinatie met een 
aanhoudende ontstekingsreactie leidt uiteindelijk tot psoriasis. 
Normaal gesproken beschermt de huid het menselijk lichaam tegen invloeden 
van buitenaf. Naast een fysieke en chemische barrière bevat de huid een ander 
afweersysteem, namelijk het lokale immuunsysteem. In het geval van een potentiële 
dreiging is samenwerking tussen keratinocyten, antigeen-presenterende cellen en 
dermale immuuncellen van cruciaal belang om de schadelijke stoffen te herkennen 
en elimineren. Een uit de hand gelopen immuunrespons kan echter leiden tot 
chronische ontsteking zoals psoriasis. Om dit proces een halt toe te roepen, is het 
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immuunsysteem uitgerust met een aantal regulatiemechanismen. Verschillende 
soorten cellen zijn gespecialiseerd in het onderdrukken van immuunresponsen. 
Het meest bekend zijn regulatoire T-cellen (Treg). Deze cellen verminderen 
weefselschade door immuunreacties van onder andere pro-inflammatoire effector 
T-cellen (Teff cellen), zoals Th17 cellen, af te remmen. Treg worden gekenmerkt 
door expressie van onder andere transcriptiefactor Foxp3. Uit onderzoek is naar 
voren gekomen dat Treg van psoriasispatiënten minder goed functioneren. Onder 
normale omstandigheden produceren Treg immuno-suppressieve cytokines, zoals 
IL-10. Het is echter gebleken dat Treg van patiënten met psoriasis een verhoogde 
neiging hebben tot het produceren van IL-17 in vitro. Het tegelijkertijd aanwezig zijn 
van zowel Treg als Th17 eigenschappen in één cel was voor ons aanleiding tot het 
bestuderen van deze conversie in vivo. Hiervoor hebben wij gebruik gemaakt van 
verschillende dynamische modellen in zowel gezonde proefpersonen als patiënten 
met psoriasis. Toen het onderzoek vorderde, bleek echter dat niet T-cellen maar 
cellen van het aangeboren immuunsysteem zoals neutrofielen en mestcellen de 
belangrijkste bron van IL-17 in psoriasis waren. De focus van dit proefschrift werd 
daarom verlegd, hetgeen tot nieuwe inzichten leidde. 
Treg zijn in staat om het ontstekingsproces te controleren en te zorgen voor 
immuunhomeostase. Disfunctie van, of gebrek aan, Treg kan leiden tot auto-
immuniteit en chronische ontsteking. De balans tussen het aantal Treg en het aantal 
Teff cellen lijkt dus van cruciaal belang voor het ontstaan van ziekte. Een maat voor 
deze balans, en daarmee de functie van Treg, is de zogenaamde Foxp3/CD4-ratio. 
In hoofdstuk 2 hebben we onderzocht of deze ratio samenhangt met de verschillende 
fasen van ontwikkeling van het ontstekingsproces in psoriasis. Daarnaast hadden 
wij als doel IL-17 producerende cellen in psoriasis te typeren. Bij patiënten met 
psoriasis werden vier huidbiopten afgenomen, van respectievelijk het centrum 
van de laesie, de rand van de laesie, de perilaesionale huid en de normale huid 
op afstand van de laesie. De aanwezigheid van het aantal Treg en Teff cellen in de 
biopten werd aangetoond met behulp van immunohistochemie. In de meerderheid 
van de patiënten werd een hogere Foxp3/CD4-ratio aangetroffen in de gezonde 
huid op afstand van de laesie vergeleken met de perilaesionale en de laesionale 
huid. De gemiddelde Foxp3/CD4-ratio in de gezonde huid op afstand van de laesie 
was zelfs hoger dan de gemiddelde Foxp3/CD4-ratio in de huid van gezonde 
vrijwilligers. Relatief hoge Foxp3/CD4-ratio’s in de gezonde huid op afstand van de 
psoriasis laesie zouden mogelijk kunnen wijzen op de aanwezigheid van actieve 
controlemechanismen van het immuunsysteem. Deze controlemechanismen 
zouden het ontstaan of de uitbreiding van psoriasis tegen kunnen te gaan. Bepaalde 
triggers kunnen ervoor zorgen dat deze mechanismen falen, waardoor er nieuwe 
laesies kunnen ontstaan. Karakterisatie van IL-17+ cellen in psoriasis toonde aan dat 
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dit cytokine met name geassocieerd wordt met mestcellen en neutrofielen en in 
mindere mate met T-cellen. 
Hoofdstuk 3 beschrijft het effect van behandeling op de balans tussen Treg en Teff 
cellen in psoriasis. Patiënten werden ofwel lokaal behandeld met betamethason-
dipropionaat/calcipotriol (BDC)-zalf, een veel gebruikte combinatiebehandeling uit 
de eerste lijn, ofwel systemisch met adalimumab, een tumor necrosis factor α (TNFα)-
remmer. Alleen patiënten die goed reageerden op behandeling werden geïncludeerd. 
Uit eerdere studies is gebleken dat anti-TNFα therapie leidt tot een toename van het 
aantal Treg in het bloed. Er zijn echter nog geen studies verricht naar het effect van 
deze behandeling op het aantal Treg in de huid. Met behulp van immunohistochemie 
werden Foxp3/CD4-ratio’s berekend voor én na 8 weken behandeling met BDC-
zalf, en voor, na 1,5 en na 16 weken behandeling met adalimumab. Voor beide 
behandelingen werd een afname van zowel het aantal Treg als het aantal Teff cellen 
vastgesteld. Interessant is dat de balans tussen Treg en Teff cellen wordt beïnvloed 
wordt door het type behandeling. Behandeling met BDC-zalf resulteerde namelijk in 
een afname van de Foxp3/CD4-ratio, terwijl behandeling met adalimumab leidde tot 
een toename van deze ratio. Het lijkt er dus op dat behandeling met adalimumab 
leidt tot een andere samenstelling van het immuunsysteem in de huid aangaande de 
anti-inflammatoire/inflammatoire balans dan behandeling met BDC-zalf. Patiënten 
succesvol behandeld met adalimumab behouden relatief meer Treg dan Teff cellen 
vergeleken met patiënten succesvol behandeld met BDC-zalf. De gegevens uit deze 
studie suggereren dat behandeling met adalimumab bijdraagt aan het herstel van 
de immuunbalans in de huid. Dit herstel zou een nieuw mechanisme kunnen zijn dat 
bijdraagt aan het uiteindelijke werkingsmechanisme en het effect van adalimumab.   
Niet alleen de balans tussen Treg en Teff cellen, maar ook de functie van Treg kan 
van invloed zijn op (het ontstaan van) een ziekte. Zoals eerder al aan bod kwam in 
deze samenvatting, lijkt het erop dat Treg van psoriasispatiënten niet op de juiste 
wijze functioneren. Ze hebben onder andere een verhoogde neiging om IL-17 te 
produceren in vitro. Het fenotype van deze cellen wordt gekenmerkt door een lage 
expressie van Foxp3 en een hoge expressie van RORγt, de transcriptiefactor voor Th17 
cellen. Stimulatie met IL-23 versterkt deze conversie. Wanneer we deze bevindingen 
koppelen aan de in vivo situatie, zou dit betekenen dat conversie van Treg in IL-17 
producerende cellen een potentiële bijdrage kan leveren aan het verergeren van de 
ontstekingsreactie. Anti-inflammatoire cellen vallen immers weg. Pro-inflammatoire 
cellen komen daarvoor in de plaats.
Conversie van Treg in een pro-inflammatoir celtype is inmiddels een veel beschreven 
fenomeen, dat onder andere voorkomt bij ziektebeelden zoals multipele sclerose 
(MS), artritis, de ziekte van Crohn en colitis ulcerosa. Op het gebied van huidziekten 
zijn deze instabiele Treg alleen beschreven voor psoriasis. In hoofdstuk 4 hebben 
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wij onderzocht of instabiele Treg specifiek zijn voor psoriasis, of dat deze cellen ook 
voorkomen bij andere chronisch inflammatoire huidaandoeningen, zoals atopisch 
eczeem. Daarnaast hadden wij als doel het fenotype van deze cellen bij patiënten met 
atopisch eczeem in kaart te brengen. In tegenstelling tot psoriasis spelen bij eczeem 
T-helper 2 (Th2) cellen een belangrijke rol in het ontstaan van de ziekte. Th2 cellen 
worden gekenmerkt door de productie van onder andere IL-4, IL-5 en IL-13. Ook 
eczeem wordt geassocieerd met disfunctionerende Treg. Atopisch eczeem is namelijk 
een prominent symptoom bij patiënten met het IPEX-syndroom (immuundysregulatie, 
polyendocrinopathie, auto-immuun enteropathie, X-gebonden syndroom). Bij dit 
syndroom veroorzaakt een mutatie in het FOXP3-gen disfunctioneren van Treg. Om 
de functie van Treg te kunnen onderzoeken, werd bloed afgenomen van patiënten 
met atopisch eczeem en van gezonde vrijwilligers. De Treg werden uit het bloed 
geïsoleerd en vervolgens in vitro gestimuleerd en gekweekt. Treg afkomstig van 
patiënten met atopisch eczeem vertoonden significant meer productie van IL-4 dan 
Treg afkomstig van gezonde controles, gemeten met behulp van flowcytometrie. 
Differentiatie van Treg naar IL-4 producerende cellen ging gepaard met verlies van 
Foxp3 expressie. Tevens werd er verlies van GATA-3 expressie waargenomen in de 
IL-4 producerende Treg. GATA-3 staat niet alleen bekend als transcriptiefactor van 
Th2 cellen, maar heeft ook een immuun-regulerende functie. Het blijkt namelijk 
dat GATA-3 nodig is voor stabiele expressie van Foxp3. Bovenstaande bevindingen 
suggereren dat een pro-inflammatoire omgeving conversie van Treg in een pro-
inflammatoir celtype in de hand kan werken. Het lijkt erop dat de cytokineproductie 
door instabiele Treg afhankelijk is van het lokale milieu dat bij de ziekte hoort. In het 
geval van psoriasis, een Th17 gemedieerde ziekte, leidt dit tot IL-17 producerende 
Treg, terwijl in atopisch eczeem, een Th2 gemedieerde ziekte, Treg IL-4 produceren.  
In de volgende hoofdstukken richtten we ons op IL-17 en de productie van IL-17 door 
verschillende celtypen in psoriasis. In hoofdstuk 2 stelden we reeds vast dat IL-17 
voornamelijk voorkomt in mestcellen en neutrofielen, en in mindere mate in T-cellen. 
Mestcellen brengen IL-17 tot expressie in zowel gezonde huid als in laesies, terwijl 
neutrofielen alleen IL-17 lijken te produceren in actieve psoriasis laesies. Om IL-17 
producerende cellen in psoriasis verder in kaart te brengen, maakten wij gebruik van 
verschillende dynamische modellen in gehumaniseerde muis en mens.
In hoofdstuk 5 zijn we op zoek gegaan naar nieuwe mogelijkheden binnen het 
inmiddels bekende ‘human peripheral blood lymphocyte reconsituted severe 
combined immunodeficient mouse human skin (huPBL-SCID-huSkin) allograft model’. 
In dit model wordt humane huid getransplanteerd op muizen zonder immuunsysteem. 
Vervolgens worden intraperitoneaal humane allogene mononucleaire cellen 
afkomstig uit het bloed ingespoten. Dit model is met name geschikt voor het in 
vivo bestuderen van T-cel gemedieerde ontstekingsreacties in de humane huid. Wij 
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hebben het bestaande model uitgebreid met nieuwe markers voor inflammatie van 
de huid, zoals IL-17, en met systemische parameters. Samenvattend wordt dit model 
gekarakteriseerd door een gestoorde epidermale differentiatie (aangetoond door een 
afwijkende expressie van hBD2, Elafin, K10, K16 en Ki67), verhoogde gen-expressie 
van menselijke cytokines (IL1B, IL6 en IL8) en chemokines (CXCL1, CXCL10 en CCL5) 
en een influx van cellen die IL-17 tot expressie brengen. IL-17 werd met name tot 
expressie gebracht in CD4+, CD8+ en Foxp3+ T-cellen, en in mestcellen. Het lokale 
ontstekingsproces ging gepaard met systemische activatie en proliferatie van CD4+ 
en CD8+ T-cellen. Uit behandeling van muizen met cyclosporine-A en rapamycine 
blijkt dat het huPBL-SCID-huSkin allograft model geschikt is als preklinisch evaluatie-
instrument van nieuwe immuun-modulerende geneesmiddelen. Gebaseerd op de 
voorgaande bevindingen in combinatie met de al bekende gegevens over dit model, 
zijn wij van mening dat dit model potentieel interessant is voor het bestuderen van 
de pathogenese van psoriasis. 
Er is in toenemende mate discussie over de vraag welke cellen in de mens 
daadwerkelijk de belangrijkste bron zijn van IL-17 in psoriasis. Bovendien is 
onduidelijk wanneer de verschillende IL-17 producerende cellen een rol spelen in 
het ontstekingsproces van de huid. De meeste in vivo studies, zoals deze ook in 
hoofdstuk 2 zijn verricht, laten een statisch beeld zien van een ziekte op één tijdstip, 
wanneer de symptomen en dus ook het ontstekingsinfiltraat reeds aanwezig zijn. Ex 
vivo en in vitro studies lijken meer geschikt voor het onderzoeken van dynamische 
processen. Echter, vaak ontbreekt de complexe omgeving van een ziekte en wordt 
er gebruik gemaakt van artificiële kweekmethoden. Het doel van ons onderzoek 
was het in kaart brengen van de verschillende IL-17+ aangeboren en verworven 
immuuncellen, vóór en tijdens ontsteking van de huid. Hiervoor maakten wij 
gebruik van twee veel gebruikte in vivo modellen, die beide zowel mechanistisch 
als histopathologisch overeenkomsten vertonen met psoriasis, namelijk de applicatie 
van leukotriene B4 (LTB4) en tape-strippen. Hoofdstuk 6 en hoofdstuk 7 bieden een 
verdieping van deze inmiddels veelgebruikte in vivo modellen voor inflammatie van 
de huid. Daarnaast hebben wij onderzocht of deze modellen geschikt waren voor 
het bestuderen van zowel het aangeboren als het verworven immuunsysteem in 
een psoriasisachtige ontsteking van de huid. De modellen leidden inderdaad tot 
een inductie van beide armen van het immuunsysteem. Bovendien waren IL-17+ 
cellen rijkelijk aanwezig. In hoofdstuk 8 tonen wij aan dat IL-17 expressie met name 
gevonden wordt in cellen van het aangeboren immuunsysteem, zoals mestcellen 
en neutrofielen, en maar zelden in T-cellen. Bovendien brengen neutrofielen ook 
RORγt tot expressie, de transcriptiefactor die nodig is voor de productie van IL-17. 
Daarnaast zijn neutrofielen in de epidermis in staat gespecialiseerde structuren 
te vormen waarmee zij IL-17 uit kunnen stoten uit de cel. Deze zogenaamde 
‘extracellular traps’ zijn evenals phagocytose en degranulatie bedoeld om bacteriën 
194
Chapter 11
te doden. Mestcellen zijn daarentegen niet in staat deze structuren te vormen. 
Ook brengen zij niet transcriptiefactor RORγt tot expressie. Zowel vóór als tijdens 
de ontstekingsfase bleef de aanwezigheid van mestcellen in de huid gelijk, terwijl 
de aanwezigheid van neutrofielen in de huid een meer dynamisch beloop liet zien. 
Deze dynamiek kwam overigens overeen met de dynamiek van IL-17+ cellen in de 
huid. De bevindingen van dit onderzoek waren aanleiding tot het verrichten van een 
uitgebreide literatuurstudie naar de verschillende celtypen die geassocieerd worden 
met de productie van IL-17 in muis en mens, zowel in psoriasis als in andere IL-17 
gemedieerde chronisch inflammatoire aandoeningen.
In hoofdstuk 9 worden de resultaten van deze literatuurstudie beschreven. Er zijn 
maar weinig in vivo studies die laten zien dat T-cellen daadwerkelijk IL-17 produceren 
in psoriasis. Onze huidige gedachtegang lijkt met name gebaseerd op IL-17 productie 
door T-cellen in in vitro experimenten onder uiterst ideale omstandigheden. Zelfs dan 
produceert maar een klein percentage van het aantal T-cellen IL-17. Er zijn meerdere 
in vivo studies die bevestigen dat IL-17 met name tot expressie komt in cellen van 
het aangeboren immuunsysteem. Dit fenomeen wordt niet alleen waargenomen 
in psoriasis, maar ook in andere IL-17 gemedieerde en met psoriasis geassocieerde 
ziektebeelden, zoals reumatoïde artritis, spondylartritis (inclusief artritis psoriatica) 
en atherosclerose. Het lijkt interessant dat IL-17 producerende mestcellen zowel 
in normale huid als in psoriasis laesies voorkomen, terwijl neutrofielen alleen in 
gecompliceerde laesies (zowel psoriasis als atherosclerotische laesies) voorkomen. 
Dit voorkomen zou kunnen betekenen dat neutrofielen een belangrijkere rol spelen 
dan mestcellen in IL-17 gemedieerde ziekte-uitbreiding. Het blokkeren van IL-17 
productie met nieuwe geavanceerde ‘biologics’ zou dus voor een breder effect 
kunnen zorgen dan voorheen gedacht. Deze middelen blokkeren niet alleen IL-
17 productie van het verworven immuunsysteem, maar ook van het aangeboren 
immuunsysteem. Dit breder effect zou een mogelijke verklaring kunnen zijn voor het 
feit dat deze behandelingen veelbelovende resultaten laten zien. In potentie zouden 
deze behandelingen ook kunnen aangrijpen op IL-17 gemedieerde comorbiditeiten 
die gepaard kunnen gaan met psoriasis, zoals artritis psoriatica.  
Slotoverwegingen
De afgelopen decennia is in toenemende mate gebleken dat IL-17 een belangrijke 
rol speelt in het ontstaan van psoriasis. Hoewel er lang werd gedacht dat IL-17 
met name werd geproduceerd werd door T cellen in psoriasis, lijkt er momenteel 
een verschuiving in denken plaats te vinden. Er is in toenemende mate bewijs dat 
ook cellen van het aangeboren immuunsysteem, zoals mestcellen en neutrofielen, 
een belangrijke rol spelen in IL-17 signalering. In dit proefschrift werd het meeste 
bewijs gevonden voor IL-17 productie door neutrofielen in psoriasis. In onze in vivo 
experimenten waren T-cellen die IL-17 tot expressie brachten ruim in de minderheid. 
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Wij stelden niet alleen vast dat neutrofielen het eiwit IL-17 tot expressie brengen, 
maar ook dat neutrofielen beschikken over de machinerie om IL-17 te maken. 
Neutrofielen brengen namelijk RORγt, de transcriptiefactor die wordt geassocieerd 
met productie van IL-17, tot expressie. Bovendien bevatten neutrofielen IL-17 mRNA, 
hetgeen betekent dat het DNA dat codeert voor het eiwit daadwerkelijk in dezelfde 
cel wordt afgelezen en dat IL-17 niet uit de omgeving wordt opgenomen in de cel. 
In theorie zouden ‘biologics’ die specifiek aangrijpen op IL-17 dus een veel breder 
effect kunnen uitoefenen dan voorheen gedacht. Niet alleen de productie van IL-
17 door het verworven immuunsysteem, maar ook de productie van IL-17 door het 
aangeboren immuunsysteem wordt hiermee geblokkeerd. Toekomstig onderzoek 
zal moeten uitwijzen wat de exacte rol is van de verschillende immuuncellen in de 
productie en excretie van IL-17 in psoriasis.
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Dankwoord
Zo ... genoeg serieuze stof nu! Dit is het leuke gedeelte. De tijd is aangebroken om 
uitgebreid te bedanken. Want zonder de hulp van velen was dit proefschrift er niet 
geweest.
Allereerst wil ik prof. dr. dr. Peter van de Kerkhof bedanken voor het vertrouwen dat 
hij in mij heeft gesteld. Vier jaar geleden begon het allemaal. Als groentje kwam ik uit 
de collegebanken en mocht ik, in afwachting van een promotieplek, als ANIOS komen 
werken op de afdeling Dermatologie. En die promotieplek, die kwam er uiteindelijk. 
Het werd een inhoudelijk interessant project met veel mogelijkheden, kansen en 
uitdagingen; zowel op dermatologisch als immunologisch vlak. Beste professor, ik 
bewonder uw positivisme. Wanneer ik het even niet meer zag zitten, wist u mij altijd 
op te beuren en kon ik er weer met frisse moed tegenaan. Daarnaast was uw alles 
overkoepelende blik onmisbaar in de totstandkoming van dit proefschrift. Ook wil ik 
hier graag dr. Piet van Erp bedanken. Piet, bij jou kon ik altijd laagdrempelig binnen 
lopen. Dat is precies wat een promovendus nodig heeft! We hebben samen een 
mooie tijd beleefd met interessante congressen naar Barcelona, Verona en, als kers 
op de taart, Miami. Altijd was je erbij wanneer ik een paper mocht presenteren, zelfs 
om 7 uur in de ochtend en ver na etenstijd in de avond. Bedankt voor je geduld en 
je support!
Zeker zo belangrijk voor de totstandkoming van dit proefschrift zijn prof. dr. Irma 
Joosten en dr. Hans Koenen. Irma en Hans, jullie introduceerden mij in de wereld 
van de immunologie. Bedankt voor jullie begeleiding in een project waarin ik 
op immunologisch vlak flinke stappen moest maken en heel veel geleerd heb. 
Immunologie is mijn tweede passie geworden. Jullie kritische blik heeft dit 
proefschrift naar een hoger niveau getild. Bedankt, bovendien, voor jullie begrip 
wanneer ik in mijn enthousiasme weer eens 6 passen sneller wilde dan mogelijk was. 
Irma, door jouw tips en tricks ben ik een betere schrijver geworden. Hier kan ik de 
rest van mijn loopbaan op terugvallen. Hans, bedankt voor al je geduld en hulp bij 
het analyseren van flow-data. Gelukkig hebben we ook hard kunnen lachen en zijn 
heel wat vakantieverhalen de revue gepasseerd. 
Veel dank ben ik verschuldigd aan mijn naaste collega’s. Een fijne werkomgeving is 
inspirerend en zorgt naast het werk voor een flinke dosis plezier. Anke en Karlijn, 
samen zijn wij begonnen aan ons onderzoek. Samen zijn we de opleiding ingegaan. 
En alle drie ronden we deze maanden onze proefschriften af met een verdediging. 
Wij zijn een goed team! Ik ben super blij dat jullie vandaag mijn paranimfen zijn. 
Lieve Ankert, we hebben heel wat tijd doorgebracht met het nemen van biopten 
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bij vrijwilligers en het doen van kleuringen op het lab. Wij zijn uitstekend op elkaar 
ingespeeld geraakt. Het was altijd gezellig samenwerken en sjonge … wat hebben 
wij gelachen. Lieve Karly, wie had ooit gedacht dat wij het als coassistenten op de 
afdeling Dermatologie nog eens tot dermatologen zouden schoppen? Ik heb grote 
bewondering voor jouw discipline! En dan natuurlijk de rest van de (ex)-klinisch 
onderzoekers: Lisa, Anne, Renée, Malou, Denise, Maartje, Jorre, Jeffrey, Sabine, 
Inge, Kim, Paula, Esther en Marisol. Bedankt voor de mooie en gezellige tijd in de 
kamer(s) van innovatie, maar ook daarbuiten. Ik koester goede herinneringen aan 
onze borrels en de legendarische stapavonden. Hopelijk houden we deze erin! Mijn 
speciale dank gaat uit naar Margit, Juul en Annet. Samen met Anke en Karlijn hebben 
wij een mooie vriendschap opgebouwd, waarbij we lief en leed met elkaar gedeeld 
hebben. Heel veel succes met de laatste loodjes van jullie promoties!
Tevens wil ik mijn collega’s van het Lab Medische Immunologie (LMI) bedanken. 
Esther F., we hebben heel wat uren samen in het lab doorgebracht. Wij kunnen met 
gemak uren volkletsen en ondertussen pipetteren. Het is dan ook enorm jammer 
dat onze samenwerking nu al ten einde komt. Hopelijk kunnen we toch nog eens 
af en toe een bakkie doen, ook al vertoef ik niet meer in het lab. Ik ben blij dat 
jij op deze dag mijn paranimf bent. Esther van R., Bram en Marina: bedankt voor 
jullie technische ondersteuning. Ik heb veel van jullie geleerd en kon altijd op jullie 
rekenen. Daartegenover stond dat júllie altijd konden rekenen op mijn klunzige acties 
op het lab! Dear PhDs, especially Xuehui, Elena and Vivian; even though I was not 
much around, I could always count on your help whenever necessary. A big thanks 
for that!
Beste Roelie, als analist op het lab van de dermatologie heb jij mij de fijne kneepjes van 
de immunohistochemie bijgeleerd. Bedankt voor je tijd en doorzettingsvermogen, ook 
als je af en toe dacht “er is een reden dat artsen niet op het lab werken”. Geniet van je 
pensioen! Elkie, ook al hebben we maar kort samengewerkt, jou wil ik bedanken voor 
de ondersteuning die je mij op het lab hebt gegeven gedurende het laatste jaar van 
mijn promotie. Graag wil ik bovendien de andere collega’s van het lab Dermatologie 
bedanken. Ondanks dat er geen sprake was van een directe samenwerking, hebben 
jullie mij in de afgelopen jaren heel wat keren op weg geholpen, bijvoorbeeld 
wanneer ik weer eens niet wist hoe een bepaald apparaat werkte of wanneer ik iets 
niet kon vinden. Aangezien ik één van de weinige klinisch onderzoekers op het lab 
was, was ik vaak op jullie aangewezen. Bedankt voor jullie hulp en gezelligheid. In het 
bijzonder wil ik Ellen bedankten. Het was fijn dat ik af en toe met jou kon sparren. 
Als enige immunologisch-georiënteerde klinisch onderzoeker, kon ik daarvoor niet bij 
mijn directe collega’s terecht. De congressen naar Barcelona en Edinburgh waren erg 
gezellig. Ik bewonder jouw drive en wens je heel veel succes met je carrière!
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Huib, bedankt voor je hulp bij het gebruiken van de confocaal microscoop. Jouw 
instructies hebben uiteindelijk tot hele mooie afbeeldingen geleid. Het resultaat is te 
zien op de omslag van dit proefschrift!
Matthijs, zonder jou zou dit mooie proefschrift er vandaag niet liggen. Bedankt voor 
het lay-outen en de goede ideeën. Het resultaat mag er zijn!
Als arts-assistent ‘pas net’ in opleiding wil ik verder mijn nieuwe collega’s en de staf 
bedanken. Bedankt voor jullie interesse in mijn onderzoek. Na de verdediging zal ik 
voorlopig geen presentaties meer geven over neutrofielen en T-cellen. Beloofd!
Voor een groot deel van mijn onderzoek ben ik afhankelijk geweest van proefpersonen 
die vrijwillig biopten wilden afstaan. Via deze weg wil ik iedereen bedanken die heeft 
geparticipeerd in mijn onderzoek. Marisol, jij hebt mij geholpen bij het zoeken naar 
geschikte proefpersonen en je stond altijd klaar voor verpleegkundige ondersteuning. 
Bedankt!
Lieve verpleging, bedankt voor jullie hulp en flexibiliteit als er tussendoor weer eens 
tien buisjes bloed bij een proefpersoon moesten worden afgenomen.
Gelukkig bestaat het leven niet alleen uit promoveren en was er genoeg afleiding te 
vinden bij vrienden. Lieve vriendinnetjes, Stephie, Manon, Floor en Maartje, dit jaar 
is het alweer 10 jaar geleden dat wij elkaar hebben leren kennen. En ook al zijn de 
‘Grey’s-Anatomy’-avondjes vervangen door borrels en bezoekjes door het hele land, 
het is nog net zo gezellig. Bedankt voor jullie belangstelling in mijn proefschrift. En 
wat betreft de promoties: one down, two to go. Succes Manon en Floor! En dan zijn 
er nog de vrienden van cogroep 103, Jorik, Femke, Iris, Stephie, Amelieke, Bas en 
Frank inclusief aanhang, bedankt voor de gezellige tennislessen, fietstochten, bier-
avondjes, spellen-avondjes, uitjes en weekendjes weg. Amelieke en Jorik, ik denk dat 
ons ‘promovendus-clubje’ hierbij is opgeheven? Jammer dat we nu alle drie in een 
ander ziekenhuis werken. Succes met jullie verdedigingen. Natuurlijk kunnen ook de 
geschiedenis-dudes/-girls, oud-huisgenoten en vrienden van Chris niet in dit rijtje 
ontbreken. Het is fijn om af en toe onder volk te vertoeven dat het niet alleen over 
patiënten heeft ;). 
Mijn allergrootste dank gaat uit naar mijn familie. Mams en paps, bedankt voor 
alle liefde die jullie mij gegeven hebben. Door jullie heb ik een zorgeloze jeugd 
gehad, vol kansen, en zie waar het toe geleid heeft: een proefschrift. Bedankt 
ook voor de gezellige weekenden thuis, het luisterende oor, de fijne gesprekken 
en de mooie vakanties. Dat er nog vele mogen volgen: America, here we come! 
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Jammer dat Nieuwstadt niet naast Nijmegen ligt, maar daar laten we ons niet door 
tegenhouden! Lieve Simone, schwestie, met jou kan ik alles delen. Ook al lijken we 
soms verschillend, wij begrijpen elkaar precies. Ik ben blij dat je in de buurt woont en 
we regelmatig kunnen gaan tennissen, eten, bank-hangen of dat ik gewoon even kan 
langskomen voor een knuffel. Ik ben trots op je, je bent een bikkel en een master van 
een organisator. En dan de pater familias, opa. Wat leuk dat je er vandaag bij bent. Jij 
bent altijd geïnteresseerd geweest in mijn proefschrift, waarvoor ik veel bewondering 
heb. Je hebt zelfs nog een aantal artikelen in het Engels gelezen. Wie had gedacht 
dat jouw kleindochter ooit nog eens, net zoals jij, op een laboratorium zou werken? 
Ten slotte wil ik mijn schoonouders en -broer, Josine, Bèr en Stijn, bedanken voor 
een warm tweede thuis. Chris en ik genieten van de gezellige avondjes, van de 
kookkunsten van Josine en de filosofische gesprekken.
Als allerlaatste en allerbelangrijkste wil ik mijn man bedanken, Chris. De afgelopen 
vier jaar stonden voor ons beiden in het teken van onze promoties. Hoe bijzonder is 
het dat wij vandaag allebei ons proefschrift mogen verdedigen? Ondanks dat onze 
vakgebieden erg verschillend zijn, ben jij mijn grootste steun geweest. Jij was er om 
me op te peppen, om het succes te delen, maar ook om me te helpen als ik even 
niet uit het Engels kwam. Ik bewonder jouw ijzeren discipline. De reden dat ik hier 
vandaag sta ligt deels bij jou. Jij hebt mij gestimuleerd om door te werken en de vaart 
erin te houden. Samen zorgden we voor ontspanning door te reizen, te wielrennen, 
muziek te maken, met vrienden af te spreken en familie te bezoeken. Jij maakt mij 
ultiem gelukkig. Met een bruiloft en twee promoties was 2014 ons jaar. Ik hoop dat 
nog veel mooie jaren mogen volgen!
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antibody
atopic dermatitis
antigen presenting cell
antimicrobial peptide
LTB4 receptor-1
bovine serum albumin
body surface area
calcipotriol-betamethasone dipropionate
chemokine C-C Motif Ligand
C-C chemokine receptor
cluster of differentiation
cutaneous lymphocyte-associated antigen
cyclosporine-A
cardiovascular disease
CXC chemokine ligand
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dendritic cell
dermal dendritic cell
dendritic epidermal T cell
deoxyribonucleic acid
ethylene diaminetetraacetic acid
extracellular trap
fluorescence activated cell sorting
forkhead box P3 
genome-wide association scan
human ß-defensin-2
haematoxilin and eosin
human immunodeficiency virus
human leukocyte antigen
horseradish peroxidase
hematopoietic stem cell
human peripheral blood lymphocyte reconstituted severe combined 
immunodeficient mouse human skin allograft
human peripheral blood mononuclear cell
inflammatory bowel disease 
inflammatory dendritic skin cell
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AMP
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IFN
IHC
IL
ILC
IL-23R
IMQ
i.p.
IPEX
iTreg
K16
Ki-67
LCE
LL-37
LTB4
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MPO
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nTreg
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PBS
PCR
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PPP
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qPCR
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interleukin
innate lymphoid cells
interleukin-23 receptor
imiquimod
intra peritoneally
immune dysregulation, polyendocrinopathy, entheropathy, X-linked
keratin-10
keratin-16
cellular marker for proliferation
late cornified envelope
cathelicidin
leukotriene B4 
monoclonal antibody 
mast cell extracellular trap
myeloperoxidase
multiple sclerosis
neutrophils extracellular trap
natural killer
non-steroidal anti-inflammatory drugs
naturally occurring regulatory T cell
psoriasis area and severity index
peripheral blood
peripheral blood mononuclear cell 
phosphate buffered saline
polymerase chain reaction
plasmacytoid dendritic cell
phorbol-12-myristate 13-acetate
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psoriasis susceptibility locus
quantitative real time PCR
rheumatoid arthritis 
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retinoid-related orphan receptor 
region of interest
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TGF
TNF
Treg
Tresp
SCID
SEM
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transforming growth factor 
tumor necrosis factor
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